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Mouse models of Huntington’s Disease (HD) are often used for testing potential 
therapeutic compounds. These experiments require substantial investments in time and 
resources, and have yet to produce any intervention that has made a significant impact 
on disease progression in the clinic. In evaluating potential therapeutics, there is an 
unmet need for a rapid, highly quantitative measure of disease progression in the HD 
mouse model brain. Such an assay would help make preclinical trials more efficient. To 
address this need, I have developed a novel technique for measuring the progression of 
transcriptional dysregulation, a phenotype with substantial similarities between mouse 
models and patients. Specifically, utilizing mice that drive GFP expression under the 
control of one such dysregulated gene (Drd2), I have improved on previous protocols for 
the isolation and characterization of adult neurons by flow cytometry. Drd2 is a well-
studied marker of a particularly vulnerable population in HD patients, the indirect 
medium spiny neurons of the striatum. Using this technique, I have demonstrated the 
ability to accurately and rapidly quantitate Drd2 transcript levels, as measured by Drd2 
GFP (D2GFP) fluorescence, in several strains of HD model mice. This D2GFP loss is 
particularly robust, with sufficient power to allow subtle, statistically significant 
alterations to be observed with very small cohorts. Furthermore, the introduction of this 
D2GFP transgene does not alter the classic HD pathology in these mice. Finally, I show 
that D2GFP dysregulation can be either induced or ameliorated genetically by delivering 
transgenes via adeno associated viral vectors, and that a small molecule with only 
subtle transcriptional effects (cystamine) fails to rescue D2GFP loss. I hope that this 
system can be of great utility in the validation of effective therapeutic interventions for 
HD. 
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CHAPTER 1 – HUNTINGTIN FUNCTION AND MALFUNCTION 
 
Introduction 
 Huntington’s Disease (HD) is a progressive, fatal neurodegenerative disorder, 
characterized by motor, cognitive, behavioral, and psychological dysfunction. Affecting 
approximately 1 in 10,000 people worldwide, HD is caused by an expansion within a 
poly(CAG) tract in exon 1 of the huntingtin (HTT) gene. Age of onset is roughly inversely 
correlated with the length of the CAG tract (1-3). Disease occurs with 100% penetrance 
when 40 or more CAG repeats are present (2). Pathology in HD is characterized by 
progressive neurodegeneration, particularly within the striatum (caudate and putamen). 
The massive loss of neurons in this region, normally responsible (amongst many things) 
for facilitation of volitional movement, is believed to lead to the characteristic motor 
dysfunctions of HD, such as uncontrolled limb and trunk movements, difficulty 
maintaining gaze, and general lack of balance and coordination (4). Neuronal loss or 
dysfunction also leads to cognitive problems, behavioral abnormalities, and 
psychological dysfunction, some of which are reported before motor abnormalities are 
noticeable. Importantly, some patients present with a more rigid, Parkinsonian form of 
the disease, most typicaly when age of onset is under 20 (so called juvenile onset 
cases). These children generally have large repeats, ranging from over 50 repeats up to 
180 repeats, the highest observed value in an early juvenile patient (5). The distinctive 
features of juvenile HD cause many investigators to think of it as a discrete subform of 
the disease that may involve distinctive pathological processes. Although 20 years have 
passed since the discovery of the causative gene, there is no disease modifying 
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treatment for HD. Treatments providing temporary symptom relief are the only 
interventions currently available to patients. Significant strides have been made in 
understanding the gene and its dysfunction when mutated, but the complexities of the 
cellular pathology observed in HD make it clear that curing HD will not be a simple task. 
 
Wild Type Huntingtin Function and Evolution 
Encoded by a gene spanning 67 exons over 170 kbp of the genome at 
Chromosome 4p16.3, huntingtin (HTT) is a 350 kDa protein of ~3140 residues; the 
length is approximate, due to a coding CAG trinucleotide polymorphism in exon 1 
causing a polyglutamine (polyQ) tract of varying length near the protein’s N-terminus. 
The protein can tolerate a wide variance of lengths in this polyQ tract, typically falling 
between 6 and 33. At 36 or more repeats, the huntingtin protein acquires toxic 
properties which become increasingly more severe with increases in repeat length (1).   
While the lion’s share of research in the field is focused, justifiably, on the toxic 
isoform with 36 or more Q’s (here called mutant HTT or mHTT), understanding the 
disease process and the consequences of targeted therapeutics requires intimate 
knowledge of the wild type isoform (wtHTT). 
HTT expression is ubiquitous, but most highly expressed in the brain and testis 
(6,7). It has no known paralogs, but clear orthologs of HTT are present in all 
deuterostomes and some protostomes, including Drosophila, and in general it is highly 
conserved in animals (8). HTT has few characterized domains; its large size and 
presence at membranes of many organelles has precluded detailed structural analysis 
(9). However, it has some highly conserved features. The polyQ repeat in exon 1 varies 
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in length in chordates, but amongst sequenced animals is longest in humans, and its 
length tends to correlate with greater organismal complexity and phylogenic similarity to 
primates (10). A polyproline (polyP) repeat follows the polyQ repeat only in mammals, 
including marsupials. The function of the polyP and polyQ repeats are not clearly 
defined, as development, behavior, and neuropathology are largely normal in mice bred 
missing one or the other region (11,12), and it was even reported that homozygous 
removal of the polyQ region lengthens lifespan (13).  
N-terminal to the polyQ tract is a 17-residue region commonly termed N17. It has 
strong conservation in deuterostomes, particularly in chordates, where only residue 4 
changes (either L or M) and all others are identical (10). A tremendous amount is known 
about the N17 region and will be discussed more in the following sections, particularly in 
regards to posttranslational modifications. For now, I will simply say that N17 forms an 
amphipathic α-helix that is involved in membrane binding (14), and its rapid evolution 
and minimal sequence variation, particularly in vertebrates, implies a crucial functional 
role for this domain. 
The three regions previously discussed (N17, polyQ, and polyP) all reside in 
exon 1, within the first 100 residues. However, HTT has more than 3000 residues. As a 
testament to the mystery of HTT’s structure, the only documented, conserved domains 
downstream of exon 1 are HEAT repeats, protein-protein interaction domains whose 
name in part derives from HTT itself (the “H” in HEAT). HEAT domains consist of 
repeated helix-turn-helix motifs, each of which forms a hairpin with two hydrophobic 
faces, but assembled together form a largely soluble superhelix with a hydrophobic core 
(15). There are four such HEAT domains in HTT, three of which are capable of auto-
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interaction or cross-interaction. This leads to one model in which HTT’s N-terminus is 
membrane bound, while the protein folds on itself as HEAT domains interact in 
antiparallel arrangement (16), allowing dimerization. This is supported by evidence of 
HTT being observed as either a monomer or dimer in tissue culture and native brain 
samples (9,15). Potential facilitation of dimerization notwithstanding, these HEAT 
repeats are most commonly associated with protein-protein interactions in general, and 
given HTT’s diverse set of interaction partners, they are the main reason HTT is 
commonly referred to as a scaffolding protein (17). 
In spite of its large transcript size and 66 introns, regulation of HTT at the 
transcript level is minimal. There is an upstream open reading frame, an alternative 3’ 
untranslated region, and several miRNA target sites (18-20), but none have been 
strongly implicated in normal HTT function or disease pathology, nor is there any well 
studied alternative splicing of the transcript. Post-translational modifications, on the 
other hand, have significant effects on HTT’s turnover, localization, and interactions. 
There are many locations along the protein that are subject to covalent 
modifications; most are concentrated within the rapidly evolving N-terminal 600 residue 
region. Such modifications include phosphorylation, ubiquitination, SUMOylation, 
acetylation, palmitoylation, and protease cleavage (reviewed in (1,21)), although 
proteolysis only happens with regularity in mHTT (2,9). Ubiquitination and SUMOylation 
of lysines within N17 likely control HTT’s turnover (3,22-24). Meanwhile, serine and 
threonine residues within N17 are sites of phosphorylation. Here, more phosphorylation 
is generally neuroprotective in the mHTT context, promoting mHTT turnover (reviewed 
in (25)), but basal phosphorylation is lower in mHTT than in wtHTT (4,26,27), and 
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wtHTT N-terminal phosphorylation is lowest in those cell types that are most vulnerable 
in HD (striatal and cortical neurons). Outside of the N17 region, proteolysis sites and 
serine phosphorylation (pS) events are common. Serine 421 has been particularly well 
studied. Reduced basal pS421 correlates with sensitivity to mHTT toxicity (5,28), and is 
particularly important for vesicle transport (to be discussed later). 
HTT is known to be associated with many organelles and membranes, and 
palmitoylation, particularly at cysteine 214, appears crucial in this regard. Mutation of 
this cysteine residue can induce aggregation even in wtHTT, and can increase 
aggregation of mHTT, amplifying toxicity. Similarly to protective phosphoserine and 
phosphothreoninie sites, basal C214 palmitoylation is higher in wtHTT than mHTT 
(1,29). Proteolysis of wtHTT is not well studied. Native protein preparations of wtHTT 
include monomers and dimers with very limited proteolytic products; only one cleavage 
product of ~180 kDa is observed in such preparations (6,7,9). Nevertheless, caspase 3 
cleavage can occur on wtHTT in certain disease conditions, as excitotoxic stimulus 
(excess Ca2+ influx from hyperactive ionotropic glutamate receptors) results in cleavage 
of HTT in neurons, while cells expressing extra wtHTT are protected from this stimulus 
(8,30). 
Many of these covalent modifications influence HTT’s localization and interaction 
partners. It can be found associated with the cytoskeletion, playing a role in microtubule 
transport of vesicles and organelles through p150glued and HAP1 of the dynactin 
complex (9,31). It also has a well-studied role in transcriptional control. The N17 region 
acts as a nuclear export signal, keeping it primarily in the cytosol or associated with 
cytosolic organelles (10,14,32), but HTT can directly act on chromatin or transcriptional 
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machinery (11,12,33). It is known to interact with many transcription factors, including 
Sp1, CBP, and REST/NRSF, the latter of which is sequestered outside the nucleus, 
which increases transcription of BDNF and other neuronal genes (13,34). On a more 
global level, unbiased mass spectrometry revealed interaction partners involved in the 
14-3-3 network, chaperones, mitochondrial function, synaptic function, calcium 
signaling, and the actin cytoskeleton, among others (10,17). In addition, it has been 
found tightly associated with the mitochondria, the ER, and the plasma membrane 
(14,32,35,36).  
Despite this variety of crucial neuronal functions aided by HTT association, not 
many specific protein-protein interactions are known to depend solely on HTT, and most 
are unaltered by a polyQ expansion (15,17). This may help explain why neurons can 
survive decades with a polyQ expansion in HTT. Additionally, while its knockout is 
embryonic lethal (due to a role in nutrient transfer from extraembryonic tissue) 
(16,37,38), it is more dispensable within adult mice. Chimaeras of mice with mixtures of 
Htt(+/+) and Htt(-/-) cells can survive for months or longer, depending on chimaeric 
makeup (9,15,39). This is not universal in mouse tissues, because while some 
peripheral and brain tissues can contain large numbers of healthy Htt(-/-) cells, such 
cells are scarce in the cortex, striatum, palladium, thalamus, and the cerebellar purkinje 
layer. Nevertheless, this demonstrates that Htt is not necessary for neuronal survival, 
and tolerance of Htt loss is not murine-specific, as short hairpin RNA-mediated 
knockdown of HTT in adult primates is not toxic (17,40,41).  
Based on its promiscuous interaction partners but ultimate dispensability in most 
cells, HTT likely has no specific, indispensable function in most adult cells that cannot 
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be at least partly replaced by redundant scaffolds. However, its conservation, rapid N-
terminal evolution, and embryonic necessity suggest it has been adapted by vertebrates 
(and mammals in particular) to the development of extraembryonic tissues and complex 
nervous system patterning while maintaining a role in neuronal homeostasis. Overall, it 
is clear that neuronal and organismal health and development relies on HTT. 
Nevertheless, apart from the polyQ expansion conferring a toxic gain of function that is 
relatively subtle and highly context dependent, the embryonic survival and slow, subtle 
degeneration in mHTT-expressing neurons establish that mHTT behaves very similarly 
overall to wtHTT. 
 
mHTT Aggregates: Toxic, or Byproduct? 
After HTT was cloned and mHTT expressed in mice (a variety of which are 
illustrated in brief in Figure 1, and explored in detail in Chapter 3) to generate the first 
genetic animal model (18-20,42), its subcellular localization was investigated. This led 
to the discovery that mHTT-expressing cells contain inclusions, small (~1 µm) 
aggregates that stain strongly for mHTT and are found in either the cytosol or nucleus, 
depending on the model. They were also seen in HD patient samples (43) and became 
one of the hallmarks of neuropathology.  
 As reviewed by Yamada et al. (44), there are at least nine disorders involving a 
coding polyglutamine expansion: Huntington’s Disease, spinal and bulbar muscular 
atrophy (SBMA, also known as Kennedy’s Disease), dentatorubral-pallidoluysian 
atrophy (DRPLA), and spinocerebellar ataxia (SCA) 1, 2, 3, 6, 7, and 17. There is no 
overarching pattern to their linkage or even the function of the proteins involved. This 
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results in vastly different protein contexts in which the polyQ tracts are embedded, 
which likely leads to the different regional susceptibilities involved. The SCA diseases 
tend to cause degeneration in the cerebellum and brainstem, but with variable 
pathologies, including basal ganglia involvement (striatum and globus pallidus) in SCA1, 
SCA3, and SCA17. DRPLA strongly affects the globus pallidus and other forebrain 
subcortical structures, while SBMA is primarily a disease of lower motor neuronal and 
spinal motor nuclei loss. All of the known polyQ diseases are neurodegenerative (which 
may be a result of the postmitotic nature of neurons lacking the ability to remove 
damaged proteins through dilution upon division), and they all demonstrate neuronal 
intranuclear inclusions and eventual neuronal death as a result of the gain of toxic 
function imparted by the polyQ expansion.  
However, it is worth mentioning that SBMA presents a unique case. Because 
androgen binding is required for intranuclear translocation of the protein involved 
(androgen receptor), it only causes disease in males, and is rapidly cleared upon 
administration of anti-androgen therapies or castration (45,46). The rapid clearance of 
polyQ SBMA when not sequestered in the nucleus provides another example (apart 
from HD) in which nuclear accumulation of a polyQ protein appears under conditions of 
proteotoxic stress. As will be discussed in Chapter 5, though, a mouse model of HD with 
poor nuclear retention still causes neuropathology (47), suggesting that nuclear 
translocation is not a requirement for polyQ proteotoxicity. 
Like wtHTT, mHTT is largely cytosolic (48), but N-terminal mHTT, either the 
result of cleavage or due to the expression of an N-terminal fragment of mHTT, can 
form inclusions in the cell soma or nucleus (49-51). These inclusions are presumed to 
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be rich in β-sheet amyloid, as they bind thioflavin T and congo red, and the CD spectra 
of isolated polyQ amyloid is demonstrably β-sheet rich (52). mHTT aggregation is 
currently thought to begin by seeding of small oligomers, facilitated by the amphipathic 
helical N17 region and which can be modulated by posttranslational modifications in the 
region. Once there is a local increase in the concentration of polyQ regions in close 
apposition, the structure reorganizes to a more regular β-sheet amyloid (53,54). In 
support of this, congo red, which binds amyloid and mHTT inclusions in patient samples 
(55), was shown to inhibit the formation of mature amyloid fibrils (56). Many groups 
theorized that these inclusions were the source of mHTT toxicity; for example, it was 
tested whether in vivo treatment of HD model mice with congo red could prevent 
toxicity, but the data was inconclusive, as one group showed improvement of weight, 
survival, and aggregate formation, while a second failed to show any of those 
improvements (57,58). These, and other studies, caused the field to re-think the 
relationship between inclusions and HD. 
In an elegant imaging study, it was demonstrated that, in PC12 cells transfected 
with an exon 1 fragment containing 47Q, inclusion formation correlates with survival, 
rather than toxicity. Instead, soluble mHTT levels are a stronger predictor of death (59). 
Meanwhile, in mouse models of HD and in two other polyQ disease models, aggregates 
either fail to correlate with neuron death or actually correlate with survival (60-62). 
Perhaps most compelling is an N-terminal mouse model known as shortstop (Ss). Ss 
mice were the result of an unintended truncation in exon 2 during integration of a full-
length YAC construct of mHTT, resulting in the expression of a short N-terminal protein 
reminiscent of that in the highly toxic R6/2 line, albeit with some of exon 2 present. Like 
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R6/2 mice, inclusions are pervasive in neurons, but this line exhibits no behavioral or 
neuropathological defects (63). Later work showed that Ss constructs in vitro don’t form 
soluble oligomers and more readily interact with the chaperone Hsp70, suggesting that 
oligomers, now thought to be the toxic species, are not a kinetically favorable state for 
Ss constructs. Other N-terminal mHTT constructs known for toxicity readily form 
oligomers (64). Yeast models provide additional insight into the regulation of 
aggregation kinetics, as they suggest there are distinct classes of genes either 
facilitating small oligomer formation or the transition from oligomers to inclusions. 
Knockouts in the former pathway were protective, while loss of those in the latter 
enhanced the 103Q construct’s toxicity (65).  
All told, there is strong evidence that inclusions appear in the presence of 
neurotoxic species in patients and most mouse models, but there is stronger evidence 
that this is little more than the correlative, and that such inclusions may be protective or 
benign. One might think of the inclusions as the cell’s landfill. If there is garbage (mHTT) 
in the cell, it is better that it ends up in the landfill (inclusions) rather than littering the 
streets (cytosol and nucleus). If an intervention is altering the size of the landfill / 
inclusion, this makes it crucial to distinguish whether the trash is being disposed of (for 
example, by autophagy), which would be healthy, or whether the garbage now isn’t 
getting to the landfill in the first place (remaining as oligomers), increasing toxicity.  
 
Insights into Oligomer Toxicity for mHTT and Other Proteins 
There are many aggregation-prone proteins, both disease-associated and 
artificial, which shed further light on the relationship between oligomers, aggregates, 
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and toxicity. Studying the kinetics of aggregation in artificial conditions can provide 
detailed mechanisms of self-association, but these experiments are normally done in 
the absence of the cellular milieu, let alone the specific environment encountered by the 
natural protein in a cell type prone to particular sensitivity (e.g. the striatum in HD). 
Additionally, protein context provides a great deal of control over the pathways to 
aggregation. All that being said, Bemporad and Chiti (66) have proposed three 
simplified pathways towards aggregation, based on studies of a number of such 
proteins in a variety of in vitro and in vivo model systems. The first involves native-like 
proteins that self-associate into higher order multimers without gross misfolding, only 
slowly acquiring β-sheet-rich amyloid structure as they form more regular, higher order 
structures. In the second, proteins either partially or completely misfold and rapidly form 
small oligomers, hiding exposed hydrophobic regions from solution. These oligomers 
then slowly become the nucleation sites for more stable amyloid structures. Finally, the 
third pathway involves monomer nucleation, where rare misfolding events drive a 
partially-denatured monomeric protein (poor in exposed hydrophobic regions) into a 
very stable β-sheet-rich nucleation site, which then rapidly catalyzes both the misfolding 
and association of other monomers into a mature amyloid. 
Such state changes likely are concentration-dependent, as tissue samples 
containing Alzheimer’s Disease (AD)-associated amyloid β (Aβ) plaques show 
oligomeric species in a halo around the organized amyloid structures (67). These higher 
molecular weight oligomers may be transient in nature (68), and become more stable 
the larger they get (69). Intriguingly, the kinetics of these varied pathways might be 
modulated chemically, as small molecules were shown to drive toxic oligomers into 
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either larger disordered aggregates, highly structured fibrils, or even dissociated 
monomers, all of which were less toxic in tissue culture than the original oligomeric 
species (70). 
 The particular toxicity of oligomers has been demonstrated in many models of 
aggregation-prone proteins. Rapidly-formed early amorphous aggregates of two model 
proteins, the SH3 domain of PI3K and the N-terminal region of bacterial HypF, are much 
more toxic to mouse fibroblasts than are mature amyloid fibrils when applied to tissue 
culture media (71). For the HypF protein fragment, its toxicity likely involves Ca2+ influx 
alterations (72), a source of toxicity in mHTT-expressing cells as well. In the case of 
mHTT, oligomers were seen to associate with Hsp70 in an ATP- and Hsp40-dependent 
manner in vitro. Furthermore, in cells expressing toxic mHTT exon 1 fragments, 
overexpression of both Hsp40 and Hsp70 reduced toxicity, increasing the presence of 
non-toxic oligomers while reducing both toxic oligomers and aggregates. However, the 
group also found a reduced rate of luciferase refolding by Hsp40 and Hsp70 when 
mHTT oligomers are present, demonstrating a potential mechanism for protein 
homeostasis deficits in mHTT-expressing neurons (73).  
Such artificial constructs can be neurotoxic to animals. When oligomers of Aβ or 
α-synuclein (an aggregation-prone protein implicated in protein homeostasis defects in 
Parkinson’s Disease) generated in vitro were delivered to the rat brain, toxicity and 
cognitive problems were observed. In contrast, injection of either monomers of Aβ or of 
α-synuclein mutants that were prone to rapid amyloid formation had no effect. (74,75). 
Furthermore, these studies implicating oligomers (but not monomers or mature amyloid) 
in neurotoxicity are not limited to proteins generated in vitro. At a correlative level, a 
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common mouse model of AD demonstrates cognitive decline at an age when 
intracellular Aβ staining is apparent but before more structured plaques or tangles form 
(76). Furthermore, when such an Aβ oligomer (~56 kDa) found in another AD mouse 
model was purified, it could induce memory deficits when delivered to the rat brain (77). 
None of these studies investigate the cell-type specificity of oligomer sensitivity, 
but one group generated interesting data to this end in HD models (78). Starting with an 
Exon 1 mHTT fragment, they generated amyloid fibrils at either 4°C (cold) or 37°C 
(warm), which had different structural properties. The cold fibrils were more heat labile 
(producing monomeric species at room temperature over time), rich in loops and turns, 
and had more surface-exposed glutamines. In contrast, the warm fibrils were more 
heat-stable, had numerous intermolecular β-sheets, and more buried glutamine 
residues. Only the unstable, cold fibrils were toxic when bath-applied to tissue culture 
cells. mHTT aggregates purified from the R6/2 HD mouse model brain were similarly 
analyzed, and remarkably, the aggregates from the striatum were more similar in 
biophysical and toxicity profiles to the cold fibrils, while cerebellar mHTT had the 
characteristics of the warm amyloid. This does not provide a mechanism for the different 
kinds of aggregation seen, but it is clear that different cell types drive aggregation down 
different pathways. Perhaps posttranslational modifications like phosphorylation or 
ubiquitination, which are differentially regulated in various brain structures, control these 
kinetics in some way. 
 
Sequestration of Proteins in Inclusions 
The study of oligomer seeding and amyloid inclusion formation in vitro has 
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helped better define the polyQ-driven kinetics of N-terminal mHTT aggregation, but in 
vivo, these inclusions can have quite complex structures and are not simple amyloid 
fibrils. The core of such inclusions is largely made of N-terminal mHTT fragments as 
well as other small proteins including ubiquitin and Hsp40 (79). Ubiquitination of 
inclusions is not necessary for their formation, though, as both model mice and juvenile 
cases demonstrate mHTT+ inclusions that stain negative for ubiquitin (43,80,81). The 
surface of these aggregates, once established, contains full-length wtHTT and mHTT, 
and also Hsp70, dynamin, the proteasome, and others (79). These more surface-
oriented proteins are susceptible to protease digestion, while the core proteins are not. 
 Many believe that some of the molecular pathology is the result of proteins being 
titrated out of solution in the cell, caught in these aggregates. Proteins found in 
aggregates include mTOR, p53, Mdm2, Hsp70, caspases, and nuclear pore proteins 
(82,83). mHTT also aberrantly interacts with many transcription factors (reviewed in 
(84)) resulting in transcriptional profile alterations that have wide-ranging effects (to be 
discussed later). However, bound transcription factors were not found in macroscopic 
aggregates (85) and soluble monomers found in the nucleus can suppress transcription 
(86), so sequestration in an aggregate is not required for mHTT to disrupt a transcription 
factor’s function. 
 
mHTT, Misfolded Proteins, and Chaperones in HD 
As mentioned above, mHTT is a target for chaperones, proteins that aid in the 
proper folding or degradation of misfolded proteins. The presence of heat shock 
proteins (Hsps) and ubiquitin in insoluble inclusions demonstrates that cells are 
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attempting to refold or mediate degradation of mHTT (82,87), and there is a wealth of 
data on mHTT’s effects on chaperone pathways and vice-versa (Figure 2).  
 The interaction of Hsps and inclusion bodies seems to be polyQ and age-
dependent. Hsps are mainly found on the periphery of inclusion bodies (79), and are 
only found there in older HD model mice (88). Hsp70 may play an active role in 
facilitating the degradation of mHTT under normal HD conditions, as its knockout 
significantly worsens symptoms of HD mice and increases the size of inclusions (89), 
though it is possible that these effects are indirect through dysregulation of proteostasis. 
On the other hand, Hsp90 seems to protect mHTT from proteasomal degradation, and 
its knockdown reduces mHTT levels (90). Basal levels of Hsps may contribute to the 
specific toxicity of medium spiny neurons (MSNs) in the striatum, as Hsp70 is 
particularly highly expressed in the cerebellum, a tissue with little to no neuropathology 
in HD (91).  
Drosophila models have been especially instructive for the relationship between 
Hsp70 proteins, ubiquitination, and neurodegeneration. PolyQ-expanded androgen 
receptor (AR), HTT, and MJD1 (the fly homolog for the gene mutated in Machado-
Joseph Disease) all cause degeneration of the retina when expressed in the fly eye (92-
94). When Hsp70 is overexpressed in the context of many of these polyQ proteins, 
degeneration is suppressed, while its deletion or dominant negative expression 
exacerbate the degenerative phenotype. Hsp70 does not function alone in this regard, 
as the cochaperones HIP and CHIP facilitate ubiquitination of polyQ substrates (94,95). 
Interestingly, CHIP, an E3 ubiquitin ligase functioning through Hsp70, appears to 
depend on the protein context for its activity. CHIP overexpression can suppress toxicity 
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of polyQ mHTT, but not that of a protein only consisting of an HA-tagged polyQ tract of 
identical length (94). Furthermore, the ubiquitination of polyQ proteins by Hsp70-aided 
processes also depends on SUMOylation (92). This may be particularly relevant to HD 
because SUMO, a similar protein to ubiquitin, was recently found to be conjugated to 
mHTT by Rhes in human cells. Rhes is a striatal-specific protein, and its SUMOylation 
of mHTT is competitive with pro-survival ubiquitination (96). 
 Given the interesting data on mHTT’s interaction with Hsps (particularly Hsp70), 
many groups have tested whether the overexpression of Hsps is protective in 
mammalian HD models. Tissue culture cells overexpressing Hsc70, Hsp40, and Hsp84 
are protected from a polyQ construct (88,97), but mice were not so easily treated by 
single-gene overexpression. Unlike data seen in flies, even a massive congenital 
overexpression of Hsp70 only modestly rescued the weight loss phenotype of R6/2 
mice, without affecting neuropathology (98,99). It’s possible that in adult neurons, 
multiple Hsps need to be overexpressed if a significant alteration of mHTT aggregation 
kinetics is to be seen. To that end, overexpression of a constitutively active Hsf1, a 
positive regulator of many Hsps, was tried in R6/2 mice. Though this transgene did not 
express well in the CNS, the mice survived longer and showed reduced inclusion body 
formation in skeletal muscle (100), indicating that modulating levels of Hsps may be a 
viable strategy in HD. 
However, a note of caution is warranted regarding modulation of proteostasis for 
a therapeutic option. It is plausible that steady state increases in a person’s proteostasis 
capacity could promote tumorigenesis, as it is well known that many oncoproteins are 
clients of Hsp90 or other chaperones (101). While tumors are commonly seen to 
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overexpress chaperone proteins, I am unaware of whether pharmacologic upregulation 
of chaperone activity has been shown to induce tumorigenesis. However, it is worth 
mentioning that polyQ disease patients (including both manifest and premanifest HD) 
have roughly half the rate of cancer, after correcting for age and other factors, as family 
members without the polyQ expansion (102). It is therefore worth investigating whether 
mHTT’s disruptive effect on proteostasis is preventing chaperone pathways from 
facilitating hypertrophy and uncontrolled cell division. If this were true, rescue of this 
pathway may also lead to normalization, or even a further elevation, of cancer incidence 
rates, though this is purely speculative. 
 The classical chaperones Hsp40, 70, and 90 are not the only members of the 
protein folding machinery known to interact with and modify mHTT toxicity. The 
chaperonin TRiC is a large ~1 MDa complex that actively refolds proteins through 
sequestration within a cavity, providing an optimal entropic folding environment (103). It 
may work by exposing client proteins to a highly hydrophilic environment, essentially 
preventing cargo from “bumping into” other proteins or lipids and allowing secondary 
and tertiary folding to take place in seclusion. Initially, client protein interaction takes 
place through the apical lid subunit that tends to bind hydrophobic, disordered proteins. 
Its interaction with mHTT was established when overexpression of TRiC subunits in 
yeast prevented N-terminal mHTT constructs from aggregating (104). Interestingly, this 
only occurred when all 8 subunits were expressed, indicating that this may require an 
intact complex. Further work, though, showed that the apical domain alone can 
suppress aggregation and toxicity (105,106), even when applied exogenously to the cell 
culture media. Clearly the apical domain alone would have a very different function than 
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an intact TRiC, and it is possible that apical domains of TRiC subunits simply suppress 
toxicity by interacting with mHTT in such a way that it alters aggregation kinetics rather 
than actively refolds it.  
All told, chaperones and chaperonins are responsible for maintaining protein 
folding homeostasis, and there is sufficient evidence that not only is protein folding 
deranged in mHTT-expressing cells, but that toxicity can be ameliorated by artificially 
increasing the cell’s capacity to deal with misfolded proteins. 
 
Pleiotropic Transcriptional Profile Changes in mHTT-Expressing Cells 
Shortly after the cloning of the causative gene, postmortem HD patient brain 
samples were analyzed for levels of neurotransmitter receptors to investigate the cause 
of the complex motor and psychiatric symptoms displayed by patients. Several 
receptors expressed on the vulnerable MSNs demonstrated robust reductions, 
particularly dopamine receptors D1 and D2 (107,108). Intracellular markers of these 
neurons were also reduced, namely substance P and enkephalin (109). Even 
interneurons, spared from cell death, are nonetheless subject to dysregulation in the 
form of reduced neuronal NOS and somatostatin levels (110). These receptor or antigen 
reductions were determined to be not simply total tissue loss, but the result of reduced 
transcripts on a cell-by-cell basis. 
Reduced transcript levels of receptors led to studies on the mechanism of 
transcriptional dysregulation in HD (Figure 3). Many groups have established aberrant 
interactions between mHTT and the transcription factors CBP, TBP, p53, NCoR, and 
Sp1, in addition to some of the core transcriptional machinery (84,111). Additionally, the 
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transcriptional repressor of neuronal genes REST/NRSF, normally sequestered in the 
cytosol by a complex including wtHTT, cannot efficiently form a complex with mHTT. 
Due to mHTT’s reduced ability to bind HAP1, another component of the REST/NRSF 
sequestration complex, REST/NRSF now enters the nucleus more freely, reducing the 
levels of its target neuronal transcripts (112,113).  
Given the large number of transcription factors affected by HTT polyQ expansion, 
global transcriptional profiles are highly informative. In patient tissues studied by array-
based transcriptional profiling, many categories of genes are significantly dysregulated. 
These include synaptic transmission, neurogenesis, ATP synthesis, CNS development, 
and Ca2+ transport, among others (114), and similar alterations are present in blood and 
skeletal muscle samples from patients (115,116). Studies in mouse models gave similar 
results, indicating that this is a shared and consistent feature of mammalian mHTT 
expression (117-119). REST/NRSF targets are of particular interest, based on two lines 
of study. First, it was determined that those genes that have strongest downregulation in 
HD brain are most highly enriched for being targets of REST/NRSF, suggesting that of 
all of the transcription factors with altered activity in mHTT-expressing neurons, 
REST/NRSF plays a particularly central role (Reviewed in (120)). Second, a particularly 
crucial gene for striatal health is BDNF, which encodes a neurotrophic factor mainly 
produced in the cortex and trafficked by afferent projections to the striatum (121). There 
are four alternative promoters for BDNF, and it is promoter II that is responsible for most 
of the physiological BDNF present in the striatum. REST/NRSF controls transcription 
from this promoter, resulting in significantly reduced levels of this transcript in HD mice 
and cell models. (Reviewed in (122)). REST/NRSF-mediated suppression of BDNF and 
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other transcripts is observed in mice and patient samples (34). Loss of wtHTT 
recapitulated some of these effects in embryonic stem cells, and surprisingly, the 
transcriptional profiles of HD model mice and patient samples are remarkably similar to 
that of a heterozygous knockout BDNF mouse (119).  
Dysregulated REST/NRSF targets (BDNF in particular) are not the only disease-
relevant dysregulated genes. As an additional example, PGC1α (gene name 
PPARGC1A), a central regulator of mitochondrial biogenesis, activity, and structure, is 
itself dysregulated in HD. Given striatal cells’ particular vulnerability to perturbations of 
electron transport chain (ETC) function (to be discussed later in the chapter), this may 
go a long way to explaining striatal vulnerability in HD. mHTT is found at the 
PPARGC1A promoter (123), and its protein levels are reduced in striatal but not cortical 
samples from HD mice (124). In addition, its loss in wild type animals results in striatal 
lesions, while its loss in HD mice exacerbates symptoms (123,125). Mitochondrial 
energetic problems in HD are manifold, and will be discussed in more detail later, but 
reduced levels of PGC1α only worsen energetic demands on already fragile MSNs.  
 
Taking Out the Trash: Autophagy and mHTT 
 For all the focus on transcription and translation in modern molecular biology, it’s 
easy to forget that in general, for every protein produced, another is degraded. In 
protein folding disorders like HD with impaired degradation of a misfolded toxic protein, 
this process is clearly deranged, if only subtly.  
 Proteins are largely degraded by either the proteasome, which typically requires 
interaction with ubiquitinated substrates that are brought to the proteasome by 
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chaperones, or by the lysosome / autophagosome processes when the protein in 
question is too large or aggregated to be fed into the proteasome. It is well known that 
mHTT is often ubiquitinated, particularly in inclusions, and that chaperones also are 
readily found in association with it (43,79). There is also evidence that impairment of the 
proteasome worsens mHTT toxicity (126,127); this may be of limited direct relevance, 
though, as the proteasome is relatively poor at degrading polyQ proteins. The 
eukaryotic proteasome’s three protease activities cut after hydrophobic, basic, and 
acidic residues, but glutamine fits none of these criteria, and is thus resistant to 
proteasome-mediated proteolysis (128).  
 Autophagy, on the other hand, is more amenable to not only degrading 
polyglutamine-bearing proteins, but at engulfing and disposing of insoluble inclusion 
bodies (Figure 3). Cells expressing mHTT seem to detect this protein homeostasis 
threat and increase autophagy signals, particularly cathepsins (129), and impairment of 
proteasome function increases autophagy-mediated degradation of mHTT fragments 
(130). Increased autophagy through starvation or dietary restriction also reduces the 
toxic effects of mHTT (130,131). 
HTT, being often membrane-associated, is found on autophagosomes (wtHTT, 
full-length mHTT, and N-terminal mHTT are all seen there) (32,132). Targeting to the 
autophagosome is carefully regulated by acetylation at K444. This residue is acetylated 
by CBP and deacetylated by HDAC1, and mutating this residue, preventing acetylation, 
increases mHTT levels and toxicity in vitro and in vivo (133). This effect is dependent on 
macroautophagy (as it is LC3-dependent), which is one of two autophagy pathways 
relevant to mHTT degradation, the other being chaperone-mediated autophagy. 
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Macroautophagy plays an important role in removal of toxic mHTT, as LC3 knockdown 
increases the presence of mHTT aggregates. However, macroautophagy is reduced in 
general in mHTT-expressing cells, while chaperone-mediated autophagy seems to try to 
compensate, as it increases in such cells. This phenomenon may partly explain the late 
onset nature of the disease, as this LAMP-2 and Hsc70-dependent chaperone-mediated 
autophagy pathway becomes less effective in aged HdhQ111 mice (134). Lastly, an 
essential regulator of autophagy, ATG7, houses a SNP that reduces the age of onset in 
patients (135), giving autophagy additional credibility as a potential therapeutic target. 
 
mHTT and Mitochondria: Altered Activity, Morphology, and Permeability 
 Mitochondrial function has long been a crucial player in HD pathology (Figure 4), 
and may be more important to striatal neurons than those of other parts of the brain 
such as the cortex and cerebellum. Some of the first evidence for this was the 
demonstration that systemic treatment with 3-nitropropionate (3-NP), a specific 
mitochondrial Complex II (succinate dehydrogenase) inhibitor, induces neurotoxicity that 
is reminiscent of HD in terms of its cell-type specificity (136). Intraperitoneal injection of 
the drug induces striatal lesions (cell death and gliosis) due to death of MSNs but, 
similarly to brains of HD patients and genetic animal models, the cholinergic 
interneurons are spared. This made 3-NP treatment a simple, rapid animal and cell 
model of HD, and its continued study demonstrated further similarities in mitochondrial 
dysfunction to cells expressing mHTT. 
 3-NP’s inhibition of the ETC has many interesting effects, most of which seem to 
damage MSNs disproportionally. Its overall effects on mitochondrial energetics and ATP 
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production play a role, as treatment results in depolarization of MSNs but not HD-
resistant interneurons (137). Energetics don’t tell the whole story though, as the effects 
of 3-NP can be ameliorated without rescuing succinate dehydrogenase. 3-NP-treated 
samples generate reactive oxygen species (ROS) and produce DNA oxidative damage 
(138). Antioxidants and free radical scavengers protect striata from lesions and protein 
carbonylation (139), so the striatal specificity of 3-NP seems to rely in some part on 
ROS generation. 3-NP also appears to induce toxicity via sensitization of mitochondrial 
permability, as inhibitors of the permeability transition pore (PTP) prevent damage in 
culture (140,141). The effects of disruption of the ETC can were also examined 
genetically when a restriction enzyme (PstI) was directed to the mitochondria in 
transgenic mice, producing a condition of chronic mtDNA damage and reducing ETC 
activity under careful transcriptional control. In this study, as is the case with 3-NP 
treatment, MSNs of the striatum are particularly sensitive to mtDNA damage / ETC 
reduced activity. Additionally, the mitochondria specifically were hypersensitive to 
challenge with Ca2+ (142), a response that will be covered in more detail in the next 
section.   
 Once the HTT gene was cloned and mouse and cell models of mHTT expression 
were more prominent, studying the interplay between mitochondrial function and mHTT 
was possible. Based on the 3-NP studies and its demonstrated ability to selectively 
damage MSNs in an HD-like pattern, patient and cell samples were tested for 
mitochondrial activity. Striatum from late-stage patients demonstrates reduced activity of 
multiple complexes of the ETC, and DNA oxidation is also increased (143-145). The 
cortex and cerebellum are relatively spared in this regard, suggesting a mechanism of 
 28 
those tissues’ relative protection from mHTT. Furthermore, ATP levels (reported as the 
ATP/ADP ratio) were reduced in lymphoblastoid cell lines generated from patients 
(146). Two points are notable from this study. First, there was exquisite CAG-length-
dependence, as the correlation between high repeat length and low ATP/ADP ratio was 
strikingly strong, and second, there was even a reduction in ATP/ADP ratio in cells 
expressing HTT with high-wild-type repeats (30-35), a range not known to produce 
neuropathology.  
 Mouse models of HD show similar ETC abnormalities. Striatal slices in culture 
from mice expressing an N-terminal transgene have half of the respiratory capacity of 
their wild type littermates, though interestingly, this effect was rescued by perfusion with 
succinate, indicating that in spite of 3-NP’s ability to mimic HD, it may not specifically be 
succinate dehydrogenase that is the defective enzyme in HD striatal cells limiting their 
respiratory capacity (147). R6/2 mice, expressing a particularly lethal mHTT transgene, 
have elevated striatal DNA oxidation and glutathione levels (148,149), and mHTT 
primes their mitochondria to depolarize more readily upon exposure to 3-NP (137,150). 
Their sensitivity could be compounded by impaired mtDNA repair, a phenomenon 
shared between R6/2 mice and 3-NP-treated mice (138). ETC defects are not limited to 
mouse neurons in the brain, as immortalized striatal precursors from knockin mice 
behave similarly to patient-derived lymphoblasts by demonstrating reduced ATP/ADP 
ratios (151). 
 Many studies have also demonstrated that mitochondrial morphology and 
movement are altered in HD samples, and not only is this not a simple byproduct of 
toxicity, but its prevention can ameliorate toxicity. Initially, it was demonstrated that 
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increased fragmentation and reduced movement are observed in cells expressing 
mHTT (152), possibly relating to aberrant trafficking to the mitochondria of mHTT (153). 
Further studies have revealed aberrant morphology of mitochondria in HD patient 
lymphoblastoid cells, myoblasts, and fibroblasts (154,155), effects that are more severe 
in homozygote samples than heterozygotes. Altered mitochondrial morphology is highly 
dependent on a subset of genes involved in fission and fusion of the mitochondrial 
reticulum, and Drp1 has been studied in some detail in this regard. Drp1, a 
mitochondrial GTPase enzyme, positively regulates mitochondrial fission (156). Drp1 
levels are increased in mid- to late-stage HD patient striata (157,158), and its GTPase 
activity is increased upon interaction with mHTT (159,160). Phosphorylation of Drp1 
suppresses its activity, while both the increased basal levels of calcineurin seen in HD 
(a phosphatase of Drp1 among many targets) and impairment of its phosphorylation by 
staurosporine increase its activity and result mitochondrial fragmentation (161). This can 
be rescued by dominant negative (DN) Drp1 expression (156), and in fact, DN Drp1 in a 
C. elegans polyQ model partially rescues its movement defect (162).   
 
Excitotoxins and Striatal Vulnerability 
 The specificity of neurodegeneration in HD (selectively killing the GABAergic 
MSNs of the striatum while cholinergic interneurons are spared) is striking. In trying to 
explain this pattern, a popular hypothesis is that mHTT-expressing MSNs are 
particularly sensitive to the glutamatergic inputs from the cortex. Glutamate normally 
activates many receptors, among which are ionotropic NMDA receptors and 
metabotropic mGluR receptors, which lead either directly or indirectly to increases of 
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intracellular Ca2+ (Figure 4). An excellent review on calcium’s role in neurodegeneration 
(163) summarizes it thusly: as Ca2+ levels rise in the neuron (from both NMDA receptor 
influx and from Ca2+ escaping the ER by way of hyperactive IP3 receptors), three things 
happen. First, calcium-mediated proteases (e.g. calpains) are activated, degrading 
substrates that can include cytoskeletal components and neurotransmitter receptors. 
Second, levels of reactive oxygen species rise via perturbations of oxidative 
phosphorylation. Third, mitochondrial permeability is induced, flooding the cytosol with 
proapoptotic factors such as cycochrome C. mHTT appears to prime mitochondria for 
this toxic insult, as mitochondria from HD mouse models (both brain and muscle), 
patient lymphoblastoid cells, and knockin mouse striatal precursors all permeabilize in 
response to lower levels of Ca2+ than is seen in wild type samples (164-167). In all of 
these cases, mitochondrial permeability transition pore (mPTP) opening not only 
releases proapoptotic factors but also depolarizes mitochondria, hampering ATP 
production, and allows glutathione and calcium to escape, exacerbating damage from 
ROS and cytosolic Ca2+ levels. 
The observation that NMDA receptor agonists, many of which are analogs of 
glutamate, can cause toxicity when administered at highly supraphysiological 
concentrations (termed “excitotoxicity”) (168) led to a great deal of research on how 
normal excitatory stimuli cause apoptosis when present in excess. One such 
excitotoxin, kainic acid, specifically lesions the striatum when administered intracranially 
(169). Kainic acid is not an endogenous metabolite, unlike quinolinic acid (QA), an 
excitotoxin that is a product of tryptophan metabolism. When administered intrastriatally 
to rats, QA’s effects, much like those of 3-NP, are strikingly similar to HD (albeit 
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occurring acutely rather than over weeks to years) in that the MSNs are destroyed 
rapidly but cholinergic interneurons are spared (170,171). This effect is not rodent 
specific, having been demonstrated in primate brains and additionally establishing that 
NMDA receptor activation mediates the toxicity, as an antagonist prevented the damage 
(172). At this point, it was commonly proposed that much of HD pathology stems either 
a) from endogenous excitotoxic metabolites like QA leading to degeneration of mHTT-
expressing neurons, or b) because mHTT-expressing neurons are hypersensitive to 
normal glutamate inputs from the cortex. 
There is intriguing recent data to suspect the former (endogenous tryptophan 
metabolites like QA) plays a role. Typically studied by delivery of synthetic QA to the 
brain, as it is an endogenous metabolite, it has been investigated in animal models 
whether modulation of steady state tryptophan metabolism may play a role in HD. In fly 
HD models, administration of 3-hydroxykynurenine (3-HK), a precursor of excitotoxic 
QA, enhances neurodegeneration, while deletion of the enzyme just upstream of 3-HK, 
kynurenine monooxygenase (KMO), rescues the effect (173). Furthermore, some 
benefit to survival and reduction in inflammatory microglial activation were seen in R6/2 
mice treated with a specific KMO inhibitor (174). 
 Much of the HD / excitotoxicity subfield has focused on calcium currents from 
NMDA receptors (NMDARs). They can be found at the synapse or on the extrasynaptic 
plasma membrane, where their activation evokes different responses (175), and are 
heterotetramers composed of two NR1 and two NR2 subunits. NR2 comes in two main 
subtypes, NR2A and NR2B, and aside from different developmental functions, they 
appear to elicit different responses to the presence of mHTT. NR2B-containing 
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NMDARs, both synaptic and extrasynaptic, have higher Ca2+ currents in cells 
expressing mHTT when challenged with chemical agonists or synaptic glutamate 
(176,177). This may be a minor effect on cellular health compared to the sensitized 
mPTP on mitochondria of mHTT-expressing cells (165,178), but increased NR2B levels 
compound neurodegeneration (179) and are normally found in tissues that are more 
vulnerable to mHTT (177). 
If increased Ca2+ currents are not responsible for excitotoxicity (165), how does 
NR2B play a role? Subcellular localization and posttranslational modifications of NR2B 
seem important to the specific response to agonists evoked by their NMDARs. Many 
studies suggest it is extrasynaptic NMDARs that mediate much of the toxicity from 
agonism. Synaptic / extrasynaptic localization is regulated by both cleavage of the C-
terminus by calpain and dephosphorylation by the phosphatase STEP, which both 
reduce its synaptic presence (180). This may alter the balance of downstream CREB-
mediated transcription pathways, which are activated by synaptic NR2B NMDARs but 
inhibited by the extrasynaptic ones. (181). Extrasynaptic NR2B-containing NMDARs are 
more common in HD mice, possibly in part because both STEP and calpain levels are 
increased in mHTT-expressing animals (180,182). 
Given the relationship between mHTT and NMDAR activity and locations, many 
HD model mouse strains have been tested for their response to excitotoxic stimulus, 
generally via intrastriatal injection of kainic acid or quinolinic acid. The particulars of 
each strain’s response to such stresses is discussed in more detail in Chapter 3 (and 
summarized in list form by Graham et al. 2009 (183)), but a basic trend is apparent, and 
the correlation involves mHTT aggregation. As was previously discussed, it is still 
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unclear what role aggregates play in disease, and it is likely that visible aggregates 
have little to no role in disease other than as a histological byproduct of polyglutamine 
stress. However, over many studies, it seems that the appearance of aggregates (but 
not necessarily visible behavioral symptoms) correlates with a transition from mouse 
models being hypersensitive to excitotoxicity to being resistant to such insults. While 
cells with mHTT aggregates are not necessarily as healthy as cells only expressing 
wtHTT, it seems clear that aggregation is a sign of a cellular attempt to cope with such 
stress. Both visible aggregation and survival of cells expressing polyQ proteins are 
influenced by chaperone proteins like Hsp40, Hsp70, and Hsp90, and mice challenged 
with the mitochondrial toxin 3-NP suffer less damage when overexpressing Hsp70 
(184). Given that a) 3-NP and other electron transport chain inhibitors generate 
prodigious oxidative stress (138), b) excitotoxins largely kill cells through the Ca2+ influx 
from NMDA receptors (172), c) neuronal death from both ETC poisoning and excitotoxic 
stress can be reduced significantly by inhibiting mitochondrial permeability (140,165), 
and d) cells and mice that are better capable of promoting aggregation of mHTT survive 
longer in general (63,64), one can imagine the following path to resistance to 
excitotoxicity.  
--Initially, expression of mHTT causes reorganization of NMDAR location, 
activity, and NR2B/NR2A ratios. This puts neurons under steady state Ca2+ elevation, or 
at least puts them at risk to mitochondrial permeability transition due to mHTT’s effect 
on its sensitivity. Under these conditions (elevated Ca2+ and/or mPTP opening 
sensitivity), mHTT-expressing neurons are subject to oxidative stress.  
--Increased oxidative stress leads to general protein homeostasis defects (185), 
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and over time, Hsps are recruited, promoting aggregation of mHTT along the way. This 
could be aided by a steady-state increase of pro-survival Akt signaling (which can 
induce HSF1) (186), since NMDAR-dependent Akt activation has been demonstrated in 
cultured knockin mHTT-expressing cells (187). 
--When such neurons are later subject to excitotoxicity, they are better equipped 
to handle acute mitochondrial oxidative stress. Hence, they are resistant to 
excitotoxicity. wtHTT-expressing cells, on the other hand, have no such steady-state 
elevation in acute oxidative stress response and are normally vulnerable. Meanwhile, 
cells with mHTT but which are incapable of generating aggregates instead have 
tremendous amounts of toxic oligomers, which prime mitochondria to permeability under 
lower Ca2+ levels, hence rendering them hypersensitive to excitotoxicity. 
Excitotoxicity, despite being an artificial condition, can also inform us about 
mHTT modifications that may be relevant to steady state conditions. We know that 
increased levels of non-toxic HTT render cells resistant to excitotoxicity (30,63,188), 
which in the context of excitotoxins’ mitochondrial-mediated toxicity, lends importance to 
the fact that many proteins involved in mitochondrial function bind with HTT (17). I use 
the phrase “non-toxic HTT”, because in this case, I also mean mHTT that does not 
cause toxicity, evidenced by caspase-6-resistant (C6R) mHTT (a strain carrying a 
version of mHTT that is resistant to caspase-6 cleavage, limiting the production of N-
terminal fragments) and the previously-mentioned Shortstop (Ss) strain, both of which 
have an expanded polyQ tract but neither of which induces neurodegeneration in vivo or 
in vitro (188,189). Because C6R mHTT has reduced production of toxic N-terminal 
fragments while Ss mHTT appears to aggregate too readily for toxic oligomers to 
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occupy a significant population (64), it seems all the more apparent that mHTT fragment 
oligomers, but not full length mHTT or aggregated mHTT, are what render mitochondria 
hypersensitive to Ca2+ fluctuations. Such Ca2+ fluctuations likely occur in the absence of 
excitotoxicity and are carried out by corticostriatal glutamatergic inputs, because 
decortication relieves some neurodegeneration in R6/2 mice (190).  
Excitotoxic stimulation also informs us about the steady state phosphorylation 
dynamics of certain disease-relevant residues within HTT. One such residue, serine 421 
(S421) has been studied in detail and its phosphorylation influences vesicle transport 
(discussed in the next section). S421 phosphorylation is reduced after excitotoxic 
stimulation, and is also seen in YAC128 transgenic mice (191,192). The likely culprits 
are the phosphatases calcineurin and PP1, which have altered activity in mHTT-
expressing cells. Calcineurin levels and activity are elevated, directly or indirectly, by 
mHTT (193). Meanwhile, PP1 is inhibited by activity at the dopamine D1 receptor, 
whose levels drop over time in HD patients and model mice (192). As phosphorylated 
S421 is well known to reduce mHTT toxicity (31,194-196), it is clear that excitotoxic 
stimuli are also acting direcly on HTT (rather than solely on mitochondrial permeability) 
to contribute to neurodegeneration. 
 
BDNF Transport Alterations and Striatal Vulnerability 
 While we see that phosphorylation of mHTT S421 rescues cells from 
excitotoxicity, it also modulates a vesicle trafficking defect seen in HD cortical neurons 
(31) (Figure 5). These vesicles are carried by the dynactin / microtubule network via a 
complex involving HTT, HAP1, and p150glued. This requires HTT S421 phosphorylation 
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for proper directional movement along the microtubule network (195). A major cargo 
delivered by these vesicles is BDNF. Striatal degeneration is seen in Bdnf knockout 
mice, while its overexpression reduces neuropathology in YAC128 HD model mice 
(121,197). Its altered transcript levels clearly play a role in pathology, but even if 
transcribed properly, it must be efficiently delivered to the striatum from its site of 
production in the cortex. Calcineurin-regulated dephosphorylation of phosphoS421 is an 
attractive target, and inhibition of calcineurin by FK506 rescues phosphoS421 levels 
and BDNF vesicle transport in vitro (198). Delivery of exogenous BDNF may go a long 
way towards therapy in HD, and it has been demonstrated beneficial in model mice with 
many delivery modes (197,199-201). 
 
Summary 
 The above chapter is not an exhaustive list of the dysfunctions induced by mHTT 
in neurons, yet it is clear that even if reduction of mHTT levels through knockdown 
approaches are not yet viable and produce complex risks of their own, there are many 
pathways mediating part of toxicity that are potential targets for therapeutic intervention. 
I do not believe that any one pathway has particular importance or deserves priority, 
and there is a need to test any and all approaches quickly and conclusively. In the 
following chapter, I will explore what therapeutic options have been and are being tried 
in animals and patients, while Chapter 3 will discuss in detail the mouse models of HD 





Figure 1: Gene structure of common mouse models of HD. There are many genetic 
mouse models of HD. Their detailed phenotypic characteristics will be covered in 
Chapter 3, but in general, they can be divided into 3 categories. Those with the most 
striking pathology and lethality are the Exon 1 and N-terminal transgenics (R6/2 and 
N171-82Q are most common). Full-length transgenic strains use human mHTT as a 
transgene under endogenous human transcriptional control. YAC128 has been used 
most commonly in this group. Knockin strains can be subdivided into those with human 
DNA in exon 1 (HdhQ111 is a prominent example; CAG140 is also known as HdhQ140) 
versus those with pure mouse mHtt and only an expanded CAG tract knocked in to the 
endogenous locus, such as CHL2 (also known as HdhQ150). Additional endogenous 
Htt alleles are listed as a reminder that the transgenic strains have both Htt alleles 
present and unaltered, while the knockin strains have 1 (if mHtt is heterozygous) or 0 (if 
mHtt is homozygous). 
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     
    
    
     



















Figure 2: Disposal of mHTT. Cells can safely dispose of mHTT through one of four 
routes. Inclusion bodies represent a relatively safe place for mHTT. Non-toxic isoforms 
of mHTT (like Shortstop) bind Hsp70 and Hsp40 readily and do not form toxic oligomer 
species, and Hsp70/40 overexpression suppresses toxic oligomer formation. However, 
non-toxic mHTT isoforms still form inclusion bodies, so either Hsp70/40 facilitate 
oligomer sequestration into inclusion bodies, or they prevent toxic oligomerization, 
allowing mHTT to join inclusion bodies through alternate pathways. The proteasome 
can also degrade mHTT after Hsp70-aided ubiquitination and IKK-mediated 
phosphorylation, while SUMOylation by RHES opposes it. Autophagy can also be 
employed to destroy mHTT. Acetylated mHTT (regulated by CBP and HDAC1) is a 
target for LC3-mediated macroautophagy, while Hsc70 promotes passage of mHTT 
through Lamp2a channels for chaperone-mediated autophagy. These routes of disposal 
 40 
are clearly insufficient as cells age, but experiments demonstrating enhanced toxicity 






Figure 3: Transcriptional dysregulation by mHTT. Many classes of genes are 
dysregulated by mHTT. Genes such as DRD1 have reduced transcription due to 
sequestration of transcription factor Sp1 by nuclear N-terminal mHTT. BDNF levels are 
repressed by REST/NRSF, which is normally excluded from the nucleus by a complex 
including wtHTT and HAP1. mHTT also directly represses PGC1α (gene name 
PPARGC1A) expression, a process normally induced by wtHTT. However, the 
presence of protein folding stress and oxidative stress also cause Hsp90 to release 















































Figure 4: Glutamate Receptors Cause Calcium-mediated Toxicity in HD. Glutamate 
activates two classes of receptors, leading to toxicity due to hypersensitive 
mitochondrial permeability transition pores (mPTPs). mGluRs activate PLCγ, causing 
IP3 to allow IP3 receptors on the ER (hypersensitized by mHTT) to release Ca2+ into the 
cytosol. Meanwhile, extrasynaptic NMDARs open to glutamate, allowing Ca2+ into the 
cytosol. This increase of Ca2+ leads to many toxic pathways. Calpain activity increases, 
causing among other things increased extrasynaptic NMDAR presence. The 
phosphatase calcineurin is also activated, reducing pS421 levels on HTT which 











































causing mitochondrial fission that hampers ATP production. More directly, Ca2+ causes 
opening of the mPTP, which has three effects. First, mitochondrial potential drops, 
reducing ATP production. Second, reactive oxygen species (ROS) production spikes. 





Figure 5: Toxicity at the Synapse. mHTT impairs transport down the axon towards the 
synapse. Mitochondria are not efficiently trafficked, impairing energetics at the synapse. 
BDNF also is not efficiently transported, so postsynaptic TrkB receptors less efficiently 
activate prosurvival MAPK and Akt pathways. Additionally, mHTT results in fewer 
synaptic NMDARs, so prosurvival CREB activity (specifically the result of synaptic Ca2+ 
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CHAPTER 2 – ASSESSING HD PROGRESS AND CANDIDATE THERAPIES 
 
Introduction 
There are no validated neuroprotective therapies for Huntington’s Disease, but if 
the previous chapter is any indication, we understand a great deal about the pathways 
leading to neuropathology. For the last 10 years, it has been fairly well known that 
rescuing mitochondrial energetics, reducing corticostriatal glutamate signaling, 
scavenging free radicals, normalizing protein homeostasis, or reversing transcriptional 
dysregulation at a single-transcript (e.g. BDNF) or global level could eventually be 
viable options for therapeutic intervention. The crux of the issue, now, is not just 
continuing to identify new targets, but also sifting through the potential interventions, 
whether drug or otherwise, and evaluating their efficacy in patients. The slow course of 
the disease may be preferable for patients when contrasted with a rapid, deadly 
neurodegenerative disorder like Amyotrophic Lateral Sclerosis. However, the slow and 
steady nature of HD also makes conclusive determination of a candidate therapeutic’s 
ability to alter disease progression very difficult. In this chapter, I will discuss therapeutic 
development for HD. This will include a review of how disease progression is tracked in 
patients, what interventions have been attempted (and suggestions for why most have 
failed), and what novel therapeutics may be around the corner. 
 
Diagnosing HD and Measuring its Progress 
 HD patients present a classical set of symptoms, the combination of which is not 
often confused with other disorders, particularly when a parent or grandparent has 
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diagnosed HD (with some exceptions). HD’s progressive nature also makes it possible 
to quantify the degree to which the disease is impairing neural pathways or social 
functions. The Unified Huntington’s Disease Rating Scale (UHDRS) was developed in 
the mid 1990’s to attempt to standardize diagnostic parameters across many sites and 
as performed by different investigators (1). With an eye on clinical trial facilitation, it 
places an emphasis on those symptoms which advance most rapidly but all of which 
can ideally be evaluated within a 30 minute period. The UHDRS divides symptoms into 
four categories: 
1) Motor symptoms, including oculomotor, dysarthria, chorea, dystonia, gait, and 
posture. Among the dystonia motor tests, timed finger tapping has become a 
popular evaluation for both its quantitative nature and the fact that it is often 
observed as mildly altered in premanifest patients. 
2) Cognitive symptoms, including phonetic verbal fluency, symbol digit modalities, 
and the Stroop word test. Facial emotion recognition is not classically included in 
the UHDRS, but it is also commonly tested (2). 
3) Behavioral Assessment, organized into subscales of mood (Does the subject 
often feel sad?), behavior (Is the subject often impatient or demanding?), 
psychosis (Has the subject been experiencing delusions or hallucinations?), and 
obsessiveness (Does the subject have recurrent and persistent ideas or 
images?). 
4) Functional capacity, asked largely in the form of a yes/no questionnaire and 
including questions that cover a wide range of functional impediment, from the 
subtle (“Could the subject supervise children without help?”) to the highly 
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disruptive (“Could the subject use the toilet without help?”). 
Nearly every HD Phase II or III clinical trial since the mid-1990’s has used this or a 
subsection of this as a primary endpoint, often Motor Score or Total Functional 
Capacity, as worsening in these categories is highly associated with patients’ quality of 
life decline. While it is clear that improvement in these real-life behavioral derangements 
is the overall goal for patients, many of these are by their very nature subjective and 
variable. A patient may be more likely to be depressed if a family member died, or more 
irritable after an argument with his or her spouse, or have better chorea depending on 
the time of day. Efforts can be made to normalize and reduce variability in these, but it 
is well appreciated that other measurement tools, not subject to day-to-day randomness 
or bias, can augment the evaluation of disease progression. This is not just essential for 
drug rescue measurements, but for giving accurate assessments of whether a patient’s 
acute worsening is likely a “bad day” at the test, or a sign that a change in his or her 
medical care is in order. 
 The field has made advancements in disease progress measurement in two main 
areas: brain volumetric or activity imaging, and peripheral biomarker discovery. Imaging 
is the area with the most precision at the moment, though its high cost and the 
challenges of standardizing techniques center-to-center remain to be solved. Soon after 
postmortem tissue evaluation detected loss in neurotransmitter receptor levels, Positron 
Emission Tomography (PET) was used in living patients. Using specific ligands for 
dopamine D1 and D2 receptors, it was determined that binding of these ligands sharply 
decreases in patients (3). Furthermore, D2 receptor signal loss was found to agree 
almost perfectly with postmortem tissue analysis in a specific way: 35.5 CAG repeats 
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represent a clinical threshold of sorts, wherein any increase of repeats past 35.5 
presents a proportionally increased rate of cell loss, pathological grade advancement, 
and D2 receptor binding loss (4,5). In other words, a patient with 48 repeats (12.5 over 
the threshold) at age 60 will have lost roughly twice as many neurons and twice as 
much D2 binding as a 60 year old patient with 42 repeats (6.5 over the threshold). 
 Given what we know about the specificity of degeneration, it is no surprise that 
progression can be followed by MRI volumetric measurements. There is a wealth of 
knowledge in this regard, and many studies have been focused on presymptomatic 
individuals (to be discussed in more detail later), but in general, the common sites for 
measureable changes are the striatum (both caudate nucleus and putamen), globus 
pallidus, nucleus accumbens, and cortical white matter (6,7). This regional degeneration 
is not uniform patient-to-patient, particularly in the cortex, and this regional variation is 
likely to underlie and explain at least a proportion of symptom variability from patient to 
patient. Through careful postmortem stereology, it was determined that patients with 
strong motor symptoms consistently demonstrate more cell loss in the primary motor 
cortex, whereas cell loss in the anterior cingulate cortex was strongly associated with 
mood dysfunction (8). Such information could help stratify patients in clinical trials to 
improve the power of trials that use volumetric MRI as an endpoint. Volumetric analysis 
is not the only use of MRI technology with practical applications to HD. Another useful 
technology is functional MRI, which measures the uptake of glucose molecules 
radiolabeled to emit positrons, which are visible to MRI. As neurons take up glucose in 
proportion to their rate of action potential firing, such images can be taken during tasks 
to measure brain activity (or lack thereof). In one such study, caudate and putamen 
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activities were seen to rapidly decline in HD patients, with slower declines seen in many 
cortical structures (9).  
 MRI is powerful, but due to its high cost and the necessity of bringing patients to 
the testing centers, peripheral biomarkers of disease progression are sorely needed. 
There is some progress in this regard, as blood can be collected easily and HD patient 
samples have already demonstrated differences in a subset of transcripts (10) as well 
as creatine kinase levels (11). Gene-positive individuals have also demonstrated 
increases in oxidative damage markers, namely 8-OHdG DNA (12) and lipid 
peroxidation (13). The former may not have robust utility (14), but lipid peroxidation 
correlated well with patients’ UHDRS motor scores and independence scales. 
Remarkably, mHTT itself can be measured in patient leukocytes, using a highly 
quantitative fluorescence assay (15). This may be particularly useful if an attempt is 
made to knock down HTT levels systemically using oligonucleotide therapeutic 
approaches. Muscle biopsies have also been analyzed by transcriptomics, and there 
are at least 100 transcripts showing strong changes between patients and controls (16). 
More studies are needed to arrive at a workable group of tests to assess progression 
with minimal invasiveness, but the progress so far is encouraging.  
 
Pathology Before Phenoconversion: Premanifest HD 
 As demonstrated by MRI and postmortem studies, significant tissue damage and 
neuronal loss is apparent even early in manifest disease. However, the HD community 
is in the unique position of being able to conclusively identify individuals who, assuming 
no accidents occur, will eventually get the disease. Of course, many individuals at risk 
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for HD (those with an affected parent) choose not to be genotyped, an understandable 
decision given the future implications that such a genetic diagnosis carries. 
Nevertheless, populations of such genotyped individuals allow for a wealth of research 
into the dysfunctions prior to visible symptoms. Just as importantly, clinicians can use 
premanifest populations for the development of neuroprotective therapeutics with the 
hope of forestalling or preventing pathology altogether. As an aside, nomenclature in 
these studies is not uniform when referring to individuals with the mutation but who do 
not yet have conclusively-diagnosed HD. So, despite their subtle differences in the 
medical literature, for clarity, “presymptomatic”, “asymptomatic”, “prodromal”, and 
“premanifest” will all be referred to as premanifest when discussing the below studies. 
 All of the above diagnostic tools have been brought to bear to monitor the 
progression of neuropathology in premanifest populations, revealing some interesting 
clues to the disease process. Several early studies using PET ligands for dopamine 
receptor D2 demonstrate loss of signal in premanifest patients (5,17-19). This loss of 
signal may be attributable to the loss of caudate and putamen volume in premanifest 
patients (20), but it likely isn’t that simple. The transcription factor Sp1 is partly 
responsible for control of dopamine receptor D2 (DRD2) transcription, and its binding to 
the transcriptional coactivator TAFII130 is weaker in both manifest and premanifest 
brain tissue samples (21), so transcriptional dysregulation is likely also occurring very 
early in pathology. The presence of blood mRNA biomarker elevations in premanifest 
patient samples supports this (10). 
 Structurally, many of the alterations observed in manifest HD are present in a 
lesser form in premanifest HD. Studies have demonstrated reductions in the volumes of 
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the whole brain, striatum, cortical white matter, and globus pallidus, with an expected 
increase in the size of lateral ventricles (20,22-26). Most of these changes are 
progressive, and tracking these changes longitudinally within a patient will allow 
clinicians to have a better idea of whether their interventions are having a beneficial 
effect on halting pathology. However, even measurements taken in single visits for 
premanifest patients are informative. It was demonstrated that both 18F-FDG uptake and 
the ratio of striatal to total brain volume can be used to augment standard predictive 
measures (CAG repeat length and age) to more accurately predict the age of onset for 
patients (25,27). This may allow patients to better plan for future medical care. 
Additionally, it can help clinicians to further stratify premanifest patients in clinical trials 
into those who are, or are not, expected to phenoconvert (progress from premanifest to 
manifest) during the trial or follow up period.  
 Brain activity and structural alterations in the premanifest period may come as no 
surprise, as a late onset, slowly-progressive disease like HD is not going to demonstrate 
its characteristic degenerative pattern overnight. However, there are also many 
behavioral symptoms that appear in patients not yet diagnosed with HD. This may seem 
counterintuitive, but it’s worth remembering that an HD diagnosis does not necessitate 
just any neurological or neuropsychological impairment often present in HD patients. It 
requires that the neurologist can be certain that this patient has HD, based on the 
presence of many HD-like behavioral, psychological, and motor manifestations (as laid 
out in the UHDRS). This array of symptoms is clearly not going to appear all at once. 
With this in mind, the behavioral alterations present in premanifest individuals have 
some patterns. Almost by definition, total functional capacity scores are rarely worsened 
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in premanifest patients, but motor, cognitive, and behavioral alterations are commonly 
observed and worsen as patients approach the expected age of onset (20,28). These 
commonly include bradykinesia (specifically, finger tapping impairment), impaired circle 
drawing, poor performance at smell tests, and failures of emotion recognition (22,26,29-
31). Detailed analyses demonstrate that word learning and smell tests begin to decline 
~15 years before diagnosis, while motor scores like tapping don’t decline until ~10 years 
before diagnosis (32). This seems to add detail to the pattern of cortical white matter 
degeneration apparent in premanifest patients. Not surprisingly, these behavioral 
changes are often subtle, yet it still appears that volumetric changes of premanifest 
patients are more quantitative and statistically significant than most UHDRS tests (22). 
Some metrics may be more useful than others, though, and tapping, being highly 
quantitative in nature, might be the best candidate, as it correlates well with striatal and 
cortical volumetric changes (30).  
 Such tools to measure premanifest disease progression are of great use to 
clinicians in trials, but they are still highly variable in this population. This is hardly a 
criticism, as clinicians don’t have the advantage of age-matched, inbred populations 
used in preclinical trials. Nevertheless, many clinical trials likely fail simply due to small 
sample size, and this is an even greater issue when assessing the power of the subtle 
premanifest changes. Various studies using volumetric imaging or behavioral 
alterations, even those of a highly quantitative nature, still estimate sample sizes of 
approximately 100-350 premanifest individuals would be needed to reliably detect a 
disease-altering effect of 20-50%, which would be a substantial alteration (23,26,33). 
Such clinical trials are often difficult to organize for a rare disorder, particularly one 
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whose premanifest population often chooses not to be tested. Therefore, this places 
particular emphasis on the efficient culling of ineffective candidate therapeutics in the 
preclinical setting.  
There is good news, though. In spite of the difficulties in organizing and funding 
trials that often take a minimum of 1-2 years for confident “go / no go” assessment, 
there is a tremendous potential market for an HD treatment. Estimates for the market for 
such a treatment (34), in the US alone, may conservatively assume a patient population 
of 30,000 with diagnosed HD, and another 170,000 individuals who may elect to take 
the drug because they are at risk or have a related disorder. In the case of this 
population, and assuming a conservative estimate of $15 per day for drug costs, the 
potential market exceeds $1 billion per year even before accounting for increased 
survival, such as was seen for patients with chronic myelogenous leukemia taking 
Gleevec. Combined with the similarities between the cellular and molecular 
pathogenesis of HD and many more common neurodegenerative diseases, it is easy to 
see why there is not only a medical need for a treatment, but a commercial motivation 
for one as well. 
 
The Current Therapeutic Landscape: Small Molecules, Small Effects 
 Therapeutics for HD (and for neurodegenerative diseases in general) are 
generally classified into either symptom management or disease modifying drugs, the 
latter of which can be further differentiated into neuroprotective (preventing neurons 
from being damaged) or neurorestorative (either promoting the regrowth of neurons or 
strengthening the pathways crippled by the absence of the degenerated connections). 
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The neuroprotective vs. neurorestorative distinctions are important in the context of 
patient populations. Premanifest indivituals can benefit from both neuroprotection and 
neurorestoration, but manifest HD patients have already suffered enough degeneration 
that behavioral impairment is present. This makes neuroprotection somewhat irrelevant 
and prone to failure. At this point, there are no approved disease-modifying therapeutics 
for patients. Symptom management has improved, but thus far, no drugs given to 
patients extend life expectancy.  
 After diagnosis, patient therapies are highly individualized. They often include 
antichoreics, of which tetrabenazine (TBZ) has become the most popular choice and is 
the only FDA approved drug for HD chorea. However, it has some unfortunate side 
effects, commonly including depression, drowsiness, fatigue, and parkinsonism (35-37). 
A depressive effect is not surprising from a drug with a dopamine depleting function 
(TBZ inhibits VMAT2, the transporter that loads dopamine into presynaptic vesicles) 
(38,39), but given that depression is already a common psychiatric symptom for HD 
patients, an alternative antichoreic without these side effects would be preferred. 
Pridopidine is a putative dopamine stabilizer that may serve such a purpose, as a 
relatively small clinical trial in HD patients demonstrated trends toward improvement of 
both voluntary and involuntary movement (40). Importantly, it had no significant side 
effects, and larger clinical trials are onging. Other symptom management interventions 
include SSRIs for depression, atypical neuroleptics for psychosis, and benzodiazepines 
for anxiety (41,42). Non-pharmaceutical therapies are also crucial for patient care, 
particularly as patients lose independence in late stage disease (43). This includes 
physical therapy, occupational therapy, speech therapy (including swallowing training), 
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and even simple exercise, all of which can improve quality of life in all of the disease 
stages. 
Symptom management is necessary and helpful, but there are also many 
potential disease-modifying therapeutics already in the clinical pipeline. Those that have 
made the most progress concern the pathway that was perhaps earliest connected to 
HD, that of mitochondrial dysfunction. Creatine and coenzyme Q10 (CoQ10) both 
restore mitochondrial function as antioxidants and also aid energy production through 
oxidative phosphorylation, and are furthest along in clinical trials. Creatine is well 
tolerated in doses up to 10 g/day but showed no benefit to symptoms after up to 2 years 
of treatment (44-46) other than a reduction of serum 8-OHdG levels (47). However, 
there is reason to believe that higher dosing may be required, as the mouse trials on 
which these were founded supplemented the mouse chow with as much as 2% 
creatine. This would correspond to ~25 g for a patient that eats 1.25 kg/day. Hence, 
there are two ongoing large clinical trials with higher doses of creatine, one in manifest 
HD (CREST-E), and another in premanifest HD (Pre-CREST) both of which dose up to 
30 or 40 g/day of creatine. 
CoQ10 has a similar history. Early clinical trials demonstrated no benefit (48,49), 
but the dose was on the low side (600 mg/day). Upon successful dose escalation trials 
to demonstrate peak tolerability at 2400 mg/day without adverse events (50), two trials 
are ongoing at this higher dose. As with creatine, one targets manifest HD (2CARE) and 
another premanifest HD (PREQUEL), the latter of which is mainly assessing safety and 
tolerability at this point. Creatine and CoQ10 are also among the few items in clinical 
trials available as over the counter supplements, another being highly unsaturated fatty 
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acids. A clinical trial has been completed with only a trend towards benefit in the 
UHDRS motor scale and total functional capacity (P=0.08 for each), but most 
interestingly, there seemed to be not just a halting of progression but an improvement 
(51). This may warrant more testing as a potential neurorestorative therapy. 
Cystamine and its redox partner cysteamine (upon administration, they rapidly 
interconvert) are another pair of antioxidants with strong interest from the HD clinical 
community. Like creatine and CoQ10, they are present in tissues already and represent 
little risk in high doses, having been given at up to 20 g/day (52). Originally thought to 
function through transglutaminase inhibition but now found to primarily protect neurons 
as an antioxidant, cysteamine is fairly effective in mouse trials (10-20% enhanced 
lifespan, reduced weight loss and motor phenotypes, and less striatal degeneration) 
(53-55), and a Phase II clinical trial is ongoing in France (CYST-HD).  
Given that mHTT’s toxicity is mediated at least partially (if not entirely) by altered 
protein folding, efforts to facilitate its refolding or degradation are ongoing. As discussed 
in Chapter 1, the upregulation of heat shock proteins has therapeutic potential. While no 
specific HD trials have been completed, low doses of the Hsp90 inhibitors geldanamycin 
or 17-AAG have been tested in many cell and animal models of polyQ diseases with 
promising results (56,57). They have been shown to both alter Hsp90 client protein 
proteasomal targeting and to disrupt Hsp90 / HSF1 binding, which releases HSF1 to the 
nucleus for induction of Hsps like Hsp70 and Hsp40 (58-60). 17-AAG doesn’t cross the 
blood brain barrier efficiently, but other Hsp90 inhibitors with similar mechanisms of 
action are in the pipeline. Ganetespib, currently in clinical trials for some cancers, is 
more lipophilic and less toxic than 17-AAG (61). Additionally, a novel Hsp90-inhibiting 
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compound called AT13387 has very long lasting effects, and an interesting (if somewhat 
disconcerting) side effect of blurred vision with light flashes may be indicative of CNS 
penetrance (62,63). 
Other disease-modifying therapeutics are not as far along or have been 
demonstrated ineffective. Autophagy augmentation through mTOR inhibition has 
promise, but may require more specificity of action. For example, a rapamycin analog 
everolimus has good pharmacokinetics, but was ineffective in R6/2 mice (64). This may 
be because mTOR has two main downstream pathways, and rapamycin analogs target 
mTORC1 but not mTORC2, the latter of which has more efficacy at reducing 
aggregated mHTT proteins in cells (65). Minocycline was enthusiastically studied 10 
years ago and reduces cytochrome C release from mitochondria in HD models (66,67). 
In mice, the results were conflicting (68-70), and a futility trial in HD patients 
demonstrated no efficacy and suggested halting its study for HD (71). A DNA-binding 
compound mithramycin seems to rescue histone H3K9 hypermethylation and rescues 
pathology in R6/2 mice (72), but has not made it to clinical trials, possibly because it has 
demonstrated transcription factor Sp1 inhibition (73), so there may be worry of 
worsening an already present phenotype. 
The pleiotropic effects of mHTT on transcriptional profiles, primarily 
downregulation of neuroprotective genes, have led to investigation of histone 
deacetylase (HDAC) inhibitors, which might globally relieve this transcriptional 
repression. Many have therapeutic potential in mouse models (Reviewed in (74)). 
Sodium phenylbutyrate is one such HDAC inhibitor of interest in HD. It has minimal 
adverse effects, and a 16-week safety and tolerability trial in HD has been completed, 
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with the results yet to be published (PHEND-HD). The potential of HDAC inhibitors to 
reverse the global transcriptional dysregulation seen in HD is tempered by the fact that 
they would be quite likely to have significant adverse effects in patients if treated at high 
doses, as has been demonstrated in mice alongside neuroprotective benefit (75-77). 
Because there are many different histone deacetylases, a targeted pharmaceutical 
approach may be warranted. With that in mind, Gillian Bates’ group is making strides to 
identify the particular HDACs whose modulation is most likely to have therapeutic 
impact (78-80), with the hope that specific inhibitors to those HDACs could be 
developed with reduced adverse effects and improved efficacy. 
Neurotransmitter modulation aimed at neuroprotection has also been attempted, 
with little success so far. Memantine, an NMDAR antagonist, demonstrated a trend 
towards motor rescue, but the trial was small (81). Riluzole, a glutamate antagonist with 
a somewhat unknown mechanism of action, has been tested numerous times in 
animals, with demonstrated protection against mitochondrial toxins and excitotoxicity 
(82-84). However, its trial was halted in patients due to liver enzyme elevation, despite a 
benefit for patients in total chorea score and UHDRS motor score (85).  
Based on these and other clinical and preclinical studies, there is clearly no 
shortage of targets in deranged HD pathways for small molecule therapeutics. At this 
point, the motivation at the bench needs to be generating compounds with safe toxicity 
profiles that effectively target these pathways, and using available models to more 
efficiently weed out ineffective drugs or subtherapeutic dosing regimes. The latter is 
perhaps hardest to predict from preclinical trials, given the differences in 
pharmacokinetic properties between rodents and humans (and primates are simply too 
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expensive to be a standard in-between step). Alternative strategies using cell, gene, or 
oligonucleotide therapeutics are younger in their development, but as they are more 
targeted than most small molecules (e.g. delivery of a growth factor rather than a drug 
that could upregulate many genes, including the desired growth factor), they may 
provide better predictability in the transition from bench to bedside. 
 
Cell Grafting for Tissue Replacement or Trophic Factor Supplementation 
 One of the main impediments of small molecule therapeutics is the blood brain 
barrier (BBB), a specialized membrane surrounding blood vessels in the CNS that gives 
an extra layer of protection from the likes of blood borne pathogens and hyperactive 
immune insults, among others. However, this also limits the passage of potential 
therapeutic small molecules. Without a doubt, patients would tolerate continuous 
intracranial dosage if such an intervention promised significant improvements in 
longevity and quality of life compared to current treatment options. Nevertheless, 
cerebral pump implantation and maintenance is fraught with risks of infection. To avoid 
this problem, cell and gene therapies that only require single dose implantations to 
bypass the BBB are being rigorously investigated. 
 Cell implantation first began as a simple neuronal replacement strategy with the 
hope that implanted fetal neuronal precursor cells would differentiate into neurons and 
become useful parts of the corticostriatal network, restoring motor control to patients. 
Several small patient cohorts have been tested, with varying degrees of success (86-
91). While cell growth is often shown and proper nigrostriatal dopaminergic connections 
can occasionally be seen, in general the results are only an occasional benefit to the 
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patients’ motor scores or total functional capacity. Immunosuppression is often needed, 
which can lead to infections. It may be possible to get around this using modern induced 
pluripotent stem cell (iPSC) technology, where it has been demonstrated that patient 
fibroblasts can not only be reprogrammed into transplantable MSN-like cells (92), but 
that the cells can be genetically corrected beforehand (93). In such grafts in patients, 
though, rejection is likely not the cause for failure. As reviewed in Cicchetti et al., 2011 
(94), which discusses the fetal grafting clinical history in HD and Parkinson’s Disease, 
the likely result of such failures is the death of the engrafted cells, probably as a result 
of poor trophic support. This makes sense in the context of the hampered delivery of 
neurotrophic factors from cortex to striatum that plays a well-established role in HD 
neuropathology. 
Hence, for HD and other neurodegenerative diseases, the delivery of such 
growth factors by way of transduced cells has been rigorously investigated. Many such 
growth factors may be therapeutic in HD; in 3-NP-treated rats, fibroblasts expressing 
the factors BDNF, neurotrophin-3 (NT-3), neurturin (NTN), or GDNF all suppressed 
neurotoxicity (95). BDNF has perhaps been the best studied in this context, as it has 
demonstrated protective efficacy in toxin and genetic models, and using cell delivery 
methods including mesenchymal stem cells, fibroblasts, and bone-marrow stem cells 
(96-103). Among these varied studies, two are of particular interest. Astrocytes often 
become activated in HD patients and animal models, as demonstrated by increased 
presence in the tissue and elevated GFAP expression. These astrocytes, when altered 
to express BDNF under the control of the GFAP promoter, can be cultured and 
transplanted, and there is evidence suggesting that BDNF expression from these cells 
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may selectively increase when neurotoxic stress is present (98,99).  
BDNF has incontrovertible therapeutic potential, primarily by activating several 
pro-survival kinase pathways (including Akt and MAPK), and has relevance in many 
neurodegenerative diseases (104). However, despite the recent development of 
effective small molecule agonists for the BDNF receptor (105), the directed implantation 
of BDNF-secreting cells into a confined area may be safer in the long run. This is due to 
evidence that brain-wide hyperactivity of BDNF activity has been associated with a 
number of disorders including epilepsy, addiction, chronic pain, and depression (106).  
Other neurotrophic factors have been delivered by transduced secreting cell 
implantation, including GDNF (107-109), Neurturin (110), and CNTF (111-113). The 
CNTF studies are particularly interesting in that they were xenografts, but the cells 
survived in vivo by being encapsulated in a semipermeable membrane that renders 
them immunoisolated. However, this also prevents the cells from growing, which is safe 
in the context of undesirable hypertrophy but also necessitates a large amount of 
engrafted material for sufficient dosage. In the Phase I clinical trial (113), some 
electrophysiological improvements were seen in patients for whom the implanted 
capsules released the largest amount of CNTF, but cell survival was poor in more than 
half of the patients’ capsules, stressing the need for improving both implanted cell 
survival and neurotrophic factor production. 
 
Gene Therapy Delivery of Growth Factors 
Implantation of transduced, engrafted cells is not necessary for long-lasting 
growth factor supplementation. Gene therapy approaches (transduction of patient cells 
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in vivo) are also beginning to be investigated for neurodegenerative diseases. Viral 
vectors for accomplishing this task are varied, but mainly are limited to vectors based on 
adenovirus, lentivirus, or adeno-associated virus (AAV), as these three can transduce 
postmitotic neurons. Adenovirus has fallen out of fashion due to high immunogenicity, 
but preclinical studies for all three have been effective. AAV and adenovirus have 
delivered a combination of Bdnf and noggin (Nog) in R6/2 transgenic mice and rat toxin 
models (114,115). These studies were notable because the combination of neurotrophic 
factors actually induced neurogenesis. While this carries with it the risk for uncontrolled 
cell growth, it also offers the potential for neurorestoration in manifest patients whose 
striata have already suffered significant deterioration. AAV-delivered Gdnf is also 
therapeutic in 3-NP-treated rats and N171-82Q transgenic mice (116,117), but neurturin 
(Nrtn) has perhaps the most immediate potential due to the clinical trial safety data in 
the PD field. AAV-delivered neurturin therapy, known as CERE-120, was tested in 6-
OHDA treated rats (6-OHDA destroys dopaminergic nigrostriatal neurons, causing PD-
like symptoms) and produced substantial therapeutic rescue with evidence of Nrtn 
expression out to at least 1 year post-transduction (118). Clinical trials were initiated, 
with enough modest success to warrant protocol alterations and further clinical 
investigation (119-121). Given the protective evidence of neurturin-secreting engrafted 
fibroblasts (95,110) and demonstrated protection for AAV-Nrtn in toxin rat models of HD 
(122), the HD field will be anxiously watching CERE-120 progress, and if promising, its 
evaluation in HD could initiate before the end of the decade. 
HD gene therapy treatment need not be limited to endogenous growth factors, 
and the immune privileged state of the CNS may in fact be the perfect place for 
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expression of novel molecular therapeutics with minimal risk of inflammation due to the 
presence of foreign epitopes. Intracellular antibodies, single-chain non-secreted 
antibody fragments known as intrabodies, have significant potential. They can be 
directed to specific portions of the mHTT protein (123), and after delivery by AAV or 
lentivirus, have demonstrated significant neuroprotective potential (124,125) likely by 
hastening mHTT turnover. In the context of mHTT’s toxic oligomers but likely benign 
inclusions, demonstration that mHTT is actually degraded after intrabody treatment 
rather than simply showing reduction of inclusion size is the most promising part of this 
avenue. In that vein, using polyQ-binding peptides with Hsc70-recognition domains to 
directly drag mHTT to autophagosomes for chaperone-mediated autophagy is also 
promising, and reduces pathology in transgenic mice (126). 
 
Prevention Rather than Rescue: Knockdown Approaches for HD 
Growth factors, intrabodies, and peptides may have therapeutic potential by 
aiding the degradation of mHTT or reversing some of its downstream toxic pathways, 
but recent advances in RNAi therapeutics may soon make it possible to prevent mHTT’s 
production in the first place. Making use of endogenous microRNA (miRNA) 
transcriptional regulation pathways, artificial short hairpin RNAs (shRNAs) or genetically 
modified miRNAs altered to target different sites have been investigated for safety and 
efficacy. Safety has a specific focus for such approaches in HD. The mutation in mHTT 
is relatively subtle, so RNAi-based therapeutics against the HTT transcript don’t always 
differentiate between mutant and wild type alleles, depending on the target site. We 
know that wtHTT is essential, but heterozygous knockout mice have only subtle 
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phenotypes (127). Thus, it may be necessary to only transiently reduce mHTT transcript 
levels and allow neurons the chance to “hit the reset button” on proteotoxic stress (128). 
Limiting the effects on wtHTT and evaluating the safety of partial wtHTT knockdown 
have been just as much a focus of the HD RNAi therapeutic field as demonstrating 
therapeutic efficacy.  
AAV-delivered shRNA constructs have been evaluated in transgenic murine HD 
models. The first such published study showed a strong ability to reduce mHTT RNA, 
protein, and inclusion levels, and to improve transcriptional dysregulation and 
behavioral dysfunction (129). However, of the two constructs tested, both were equally 
effective at reducing mHTT RNA and proteins, but one of the two was highly toxic and 
actually exacerbated transcriptional profile alterations. This was likely the result of off 
target effects, a risk for any RNAi therapeutic as they often depend on the 6-base seed 
sequence to mediate most of their target specificity, and such 6-base sequences in 
shRNAs can be toxic if promiscuous (130). Nevertheless, careful evaluation of off target 
risks can yield safe knockdown vectors, which have been evaluated and proven 
tolerable in primates (131,132) and effective in murine HD models (133-135).  
Harnessing the miRNA pathway is only one way nucleic acids can suppress 
mHTT levels, the other being chemically-modified oligonucleotides (oligos). Most 
promising is a chemically-modified oligo versus human HTT that specifically reduces 
human mHTT levels by >50% in transgenic mouse models, and was somewhat effective 
in rhesus after intrathecal injection. Most remarkably, the protein reduction was 
maintained for up to 3 months in mice from a single 2-week-long intracranial infusion 
(136). This surprising longevity is the result of the modified nucleic acid chemistry. Its 
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cell penetrance was sufficient when the oligo was simply provided in a saline 
suspension. Additionally, altered oligonucleotide chemistry facilitated binding, cellular 
uptake, and nuclease resistance. This was achieved by using phosphorothioate rather 
than phosphodiester bonds between bases, as well as a base structure including 2’-O-
methoxyethyl nucleosides on the outermost 5 bases rather than standard 
deoxynucleotides. Unlike small RNAs that use the RNAi pathway to reduce transcript 
levels, it requires no interaction with the RISC complex, instead relying on RNase H 
degrading the RNA portion of the RNA-DNA hybrid. That the modified DNA oligo is not 
degraded in the process allows it to be recycled, enhances longevity without diluting its 
knockdown capabilities, and avoids potential unintended modulation of the RNAi 
pathway by not serving as a substrate.  
The above study was allele-specific only insofar as it was species specific. For 
true allele-specificity, one can potentially take advantage of common patient single 
nucleotide polymorphisms (SNPs). There is evidence that only 2 SNP-targeting oligos 
are needed to differentially target mHTT in 2/3 of patients (137). Potent oligos have 
been targeted to SNP-bearing sequences in HTT (138), and humanized mouse models 
are being used to test them in a preclinical setting (139). Nevertheless, it is worth noting 
that the presence of a SNP in a transcript does not necessarily mean that location 
would make a good target site for an oligo, as local secondary structure and RNA 
binding proteins in the region might modify an oligo’s binding strength. Indeed, in the 
above studies, only four such SNP targets were found to provide both significant allele 
specificity and sufficient knockdown strength. The CAG repeat itself may also serve as 
an effective target for RNaseH mediated degradation of mHTT transcripts, which would 
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by definition be allele-specific (140). However, there are many other mRNAs that 
include CAG repeats of significant length. This makes the evaluation of potential off 
target effects particularly important for this approach. 
 
Summary 
 As a field, there is much known about the pathogenic processes in HD and the 
possible treatments for them. The clinical and preclinical research communities have 
tremendous tools for both administering these potential treatments and, more 
importantly, assessing their efficacy with minimal invasiveness. Nevertheless, the lack 
of an effective disease modifying therapeutic for HD in spite of the hundreds of drugs 
tested in models by this point tells us two things. Firstly, the clinical trials likely need to 
be longer with better sensitivity and power to detect a reduction in symptoms, both 
behavioral and neuropathological. Secondly, preclinical models must improve in 
identifying when a therapeutic intervention has little to no potential in the clinic. The next 
chapter will discuss mouse models of HD, the symptoms that can be measured in these 
models, and how they can be better leveraged for determination of a candidate 
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CHAPTER 3 – MOUSE MODELS OF HUNTINGTON’S DISEASE 
 
Introduction 
All of the therapeutic options discussed in Chapter 2 have made the most 
progress towards the clinic by demonstrating neuroprotection and behavioral rescue in 
mouse models of HD. However, not all models are created equal, and it is important to 
realize the differences between the models and their expected phenotypes before 
attempting to demonstrate that a given intervention will show therapeutic benefit. Some 
strains display neuropathology from birth and early mortality, while others progress so 
slowly that visible phenotypes are not seen until the mice are very old, and do not 
present with morbidity. The age of onset of a number of frequently utilized behavioral 
and biological measures of pathology for HD mouse models are summarized in Figure 
1.  
The first transgenic models of HD in mice were developed in 1996 (1) by 
introducing a fragment of a juvenile HD patient’s HTT gene into the mouse genome. 
Although these strains (R6/2 and R6/1) were initially designed to study repeat 
expansion, these strains displayed motor and metabolic symptoms, including tremors, 
lack of coordination (rotarod balance difficulty), and excessive weight loss, leading to 
death at a very early age (~12-14 weeks in the R6/2 line). The rapid and reproducible 
progression of HD-like symptomology in R6/2 mice has made this line a mainstay of HD 
research. However, the limitations of R6/2, the absence of a full length mutant HTT 
protein and the extremely rapid progression of disease, led to the development of quite 
a number of other animal models, each with their own unique genetic and phenotypic 
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characteristics summarized in Table 2. 
 Mouse models of HD can be grouped into three categories, based on the genetic 
basis of their creation. N-terminal transgenic animals are those carrying a small 5’ 
portion of huntingtin, either human or chimeric human/mouse, at random in their 
genome. These animals tend to have the earliest onset of motor symptoms and 
diminished lifespan (1-5), thought to be because mHTT pathology is greatly enhanced 
by its proteolytic processing into N-terminal fragments (6,7); these mouse models are 
probably a short cut to this particularly toxic state. 
Transgenic models expressing full-length mHTT mice also exist, containing 
random insertions of the full-length human HTT gene with an expanded CAG repeat in 
the form of either YAC or BAC DNA (8-10). One interesting observation of the two most 
commonly used models in this category is the unexpected age of onset difference (~6 
months in YAC128 mice and as early as 8 weeks in BACHD mice) despite the shorter 
repeat length of BACHD mice (97 vs. 128).  
Several strains in which a pathological length CAG repeat is introduced into the 
mouse huntingtin (Htt) gene have also been created (so called knock-in strains) (11-17). 
The best studied long repeat models (140 and 150 repeats) have motor symptom onset 
within 6 months, but the shorter models have little or no observable motor dysfunction 
for the first year of life, and no decrease in lifespan has been reported in any knock-in 
models. This may properly model the late adult onset of human HD but does not 
replicate the impaired quality of life and inevitable mortality.  
As many models have been brought into use, significant differences among the 
models have emerged. It is important to note, however, that many cross-model studies 
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underline significant pathological and molecular similarities in the different genetic 
models in spite of their inevitable differences (18-28). 
 
Behavioral Symptoms in HD Model Mice 
 HD in patients is characterized by motor, cognitive and behavioral symptoms, 
and assays testing these broad categories are used to measure progression of 
pathology in HD mice. Motor phenotypes have been tested in a number of HD model 
mice, including limb clasping upon tail suspension, basal activity level, gait 
abnormalities, balance beam traversing time, swimming speed, suspended horizontal 
beam turning, and latency to remain on a fixed-speed or accelerating rotarod. The 
rotarod, in particular, has proven to be a robust measurement of balance and 
coordination deficits for which nearly every HD model mouse has demonstrated a 
deficiency, and is the metric for which the most data exists on motor dysfunction. N-
terminal transgenic mice consistently display an early onset of severe motor symptoms. 
R6/2 mice swim poorly by 5 weeks of age, and show beam walking and rotarod 
deficiencies by 6 weeks, both of which progressively worsen with age (1,2). R6/1 mice 
experience clear rotarod deficiency at 18 weeks (1-5) with an earlier (13 week) onset of 
failure to turn around on a suspended horizontal rod (6,7,29), while N171-82Q mice 
display a subtle but progressive rotarod phenotype at 3 months (4,8-10). 
Full-length transgenic models display delayed motor symptoms compared to N-
terminal transgenics; YAC72 mice do not display a significant rotarod phenotype until 16 
months (11-17,30), while YAC128 mice decline starting at 6-7 months (10,18-28,31). 
BACHD transgenics do show a significant reduction in rotarod latency as early as 4 
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weeks of age, but they do not precipitously decline in performance until 28 weeks; this 
is in contrast to R6/2 rotarod performance, which rapidly declines once a difference is 
measured (2,32). 
 Knockin mice do not always display the characteristic motor phenotype seen in 
transgenic models, despite some strains carrying as many CAG repeats as R6/2 mice 
(~150) and having twice the gene dose as most transgenic strains (behavioral 
experiments carried out in knockin mice typically use homozygotes). This could reflect 
differences in chromosomal context, transgene expression, the chimeric nature of 
knockin Htt inserts, or strain background. HdhQ140 rotarod latency appears at 4 months 
at 30 rpm on a fixed-speed rotarod (3,33), but another group reported no accelerating 
rotarod phenotype through 6 months (29,34), while rotarod deficits are not seen in 
HdhQ92, HdhQ111, and HdhQ150 mice until about 2 years of age (4,11,32,35). 
 Cognitive phenotypes can again be measured in many ways, but tasks based on 
spatial learning and memory such as the Morris water maze or T maze (swimming or 
elevated) have been used to reveal deficits in initial task learning and re-learning upon 
parameter changes. 4-5 week old R6/2 mice learn the Morris water maze as well as wild 
types when the platform is visible, but display spatial memory deficits when the platform 
is hidden, and cannot re-learn upon platform movement as well as wild type mice. Two-
choice swim testing revealed an earlier deficit in task reversal (6.5 weeks) than for initial 
visual learning of the task (10-11 weeks) (1,36). Initial visual learning deficiency of the 
two-choice swim test was also found in YAC128 mice (1-5,31), but HdhQ150 knockins 
displayed no learning deficits on the Morris water maze (6,7,11).  
Cognitive tests are challenging to standardize, as environmental conditions and 
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spatial cues are difficult to replicate from lab-to-lab and can influence animals’ 
performance in behavioral tests. Despite these challenges, these consistent 
observations from many different labs demonstrating a clear effect on cognitive 
performance in HD model mice suggests that the cognitive decline commonly observed 
in HD patients is well represented by HD model mice. 
 
Neuropathology of Murine Models 
 Human neuropathology is characterized by a severe loss of striatal volume (in 
particular the caudate nucleus). Medium spiny neurons but not interneurons are lost, 
and reactive gliosis is apparent (8-10,37). Cortical degeneration is also prominent in late 
stages. HTT inclusions in patients are only found in a small fraction of cells (11-17,38), 
though they are visible in almost all HD patient brains with a clinical grade of at least 2 
(18-28,39). Within HD model mice, the progressive neuropathology is unique for each 
strain, but they share some commonalities.  
N-terminal transgene strains display neuropathology at or prior to symptom 
onset. In contrast to patients, neuron loss is somewhat minimal, but R6/2 brains 
decrease in weight as much as 20% with enlargement of the lateral ventricles (1,2). 
They demonstrate neuronal intranuclear inclusions (NIIs) as early as at birth (3,40), 
though NII’s are typically reported in this strain around 3-4.5 weeks (29,41-43), 
significantly prior to onset of easily observed symptoms. Inclusions were found in the 
cortex, striatum, cerebellum, spinal cord, and hippocampus, and progressively increase 
in prevalence and size (4,42). Despite this, chimera studies suggest that medium spiny 
neurons (MSNs) bearing large inclusions can survive for almost a year (30,44) when 
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surrounded by wild type cells. R6/2 MSN dendritic diameters and spine density also 
decrease with age (10,31,45). 
 R6/1 mice share most of the R6/2 pathology, but at a later age. NII’s appear by 9 
weeks (32,46) and also show minimal gliosis (33,47) and similar dendritic spine atrophy 
by 8 months (34,48). Apoptotic and necrotic cells are rarely seen in the striatum of R6/2 
and R6/1 mice, despite significant atrophy and ventricular enlargement; instead, 
electron micrographs contain so called dark neurons, displaying condensation of the 
cytoplasm and nucleus without the chromatin fragmentation and nuclear blebbing 
characteristic of apoptosis (11,32,35,47). In contrast, 3 month old N171-82Q mice do 
demonstrate cortical and striatal apoptotic neurons, with reactive gliosis by 4 months. 
Note that in old (22-30 week) R6/2 chimeras, gliosis is apparent in regions densely 
populated in transgenic neurons (44), and particularly old R6/2 animals (17 weeks) 
show astrocytes with processes enveloping degenerating neurons (49). Therefore, the 
signals necessary to develop gliosis in R6/2 mice may be present, but the mice may die 
before glial recruitment and activation. N171-82Q mice also presented with striatal 
degeneration and ventricular enlargement by 17 weeks (50) and NII’s in many brain 
regions (cortex, hippocampus, cerebellum, and striatum among others) by late endstage 
of 6.5 months. 
 NII’s are not seen until far after symptom onset in full-length transgenic HD lines. 
YAC128 mice display behavioral symptoms at 12 months, and striatal neuron loss of 
~15% is seen by this time (10) along with increased intranuclear HTT staining of certain 
brain structures (51). However, NII’s did not show up until 18 months of age, and only 
populated ~30% of striatal neurons and ~5% of cortical neurons. NII’s were absent in 
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the YAC128 hippocampus, a site of NII staining in endstage R6/2’s (43). In the other 
distinct full-length transgenic strain, BACHD mice also display atrophy of the cortex and 
striatum by as much as 30% at 12 months (8), with 14% of striatal neurons with the 
aforementioned “dark” morphology. Interestingly and as opposed to R6 mice, inclusions 
(over 90%) were extranuclear and were more common in the cortex than striatum, a 
feature reminiscent of adult onset HD.  
 R6/2 chimaeras suggest that inclusions themselves may be neither toxic nor 
markers of cells about to die, and a strain arising with a spontaneous mutation in the 
YAC128 transgene (termed Shortstop or Ss for its early termination) provides further 
evidence to this end (52). The mutation truncated the transgene after exon 2, providing 
a product with 128 glutamines and an expected and observed protein size similar to that 
encoded by the R6/2 transgene. NII’s are particularly common (90% of striatal, cortical, 
and hippocampal cells) and appear earlier in Ss mice versus YAC128s; however, Ss 
mice had no obvious phenotype at all ages examined. Why this strain is free from the 
early onset behavioral symptoms one would expect in what is essentially an N-terminal 
transgene HD model is still under investigation, but as explained in Chapter 1, it may 
represent a unique kinetic balance favoring aggregation over toxic oligomer formation.  
 Knockin mouse neuropathology, as with their symptoms, usually occurs very late 
in life and is minor in comparison to transgenic strains. HdhQ72-80 mice demonstrate 
loss of brain weight by 16 months (15), while NII’s are primarily seen in striatal MSNs. 
Knockins with 94 repeats demonstrate striatal NII’s by 18 months (53) while HdhQ111 
mice show NII appearance at an earlier age (10 months), and mHtt nuclear 
accumulation is evident at a very early (6 weeks) age (54). HdhQ150 knockins lose as 
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much as 40% of striatal volume and neurons by 23 months, but significant gliosis and 
NII’s appear by 10-14 months (11,13,47,55). Degenerating neurons are not apoptotic in 
this strain, though occasional dark neurons are encountered. Knockin mice with 140 
CAG repeats display relatively early onset striatal NII’s and neuropil aggregates (4 
months) becoming progressively stronger in other brain regions as well by 6 months 
(14). These data do not imply that knockin brains only present with abnormality in old 
age, as HdhQ111 embryos demonstrate impaired neurogenesis as early as embryonic 
day 13.5 (56).  
As discussed in Chapter 1, inclusions are a historic histological hallmark of HD, 
though evidence continues to mount that their presence does not correlate with toxicity, 
as seen in chimaeric R6/2 or in Ss mice. Nevertheless, compounds that reduce levels of 
mHTT consistently reduce visible aggregates, so quantifying their presence in treated 
versus untreated samples continues to be a common assay for such approaches. While 
useful and relevant in certain settings, this approach (documenting a reduction in 
aggregate appearance) cannot be directly correlated to a reversal of toxicity. 
 
Cell Autonomous vs. Non-autonomous Pathology 
 Neurodegeneration in HD affects multiple brain regions, but striatal degeneration 
has been the focus of much of the research field, for two reasons: the massive loss of 
neurons suggests a particular vulnerability of striatal MSN’s, and more specifically, the 
characteristic motor phenotype is classically attributed to the early loss of one of two 
nearly identical arms of the corticostriatal loop, the indirect (striatopalladial) pathway. 
Nevertheless, recent research suggests that multiple cell types in the brain contribute to 
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pathology. Driving an expanded poly(CAG) HTT fragment in glial (GFAP+) cells also 
induces many features in common with other mouse models of HD (clasping, failure to 
keep on weight, rotarod phenotype, and premature death), albiet at a later time than is 
common for models expressing N-terminal transgenes in neurons (57). This is 
interesting when one considers the stark phenotype of the N171-82Q mice, whose N-
terminal transgene is driven primarily in neurons by the prion promoter (4). However, a 
conditional model of HD suggests that expression of mutant HTT in multiple cell types is 
required for motor symptoms. A lox-STOP-lox poly(CAG) HTT exon 1 strain mated to 
Nestin-Cre mice (pan-neuronal expression) induced a behavioral phenotype at 6 
months of age, but mating it to Emx1-Cre (cortical pyramidal cell expression) (58) or 
Dlx5/6-Cre mice (striatal MSN expression) produced EM48+ aggregates in the expected 
brain regions but no observed motor phenotype; the animal’s short lifespan may limit 
phenotypic progression in these models. Taken as a whole, we can see that mHTT can 
cause neuropathology (aggregate formation at the least) in nearly every neuronal or 
glial cell in which it is expressed, and while MSN expression plays a large role, cells 
other than MSNs can contribute to manifest disease in mice. This has particular 
importance from a therapeutic perspective, as it suggests that drugs which by default 
cannot affect neurons (e.g. the target enzyme is not expressed in neurons) should not a 
priori be set aside.  
 
Specific Excitotoxicity Responses in Various Models 
 The cellular and molecular causes of excitotoxicity (glutamate receptor 
hyperactivation with resulting Ca2+-mediated mitochondrial toxicity, normally induced by 
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NMDA-receptor ligand analogs quinolinic acid or kainic acid) were discussed at length 
in Chapter 1, but many of the HD model mice react quite differently to the insult. R6/1 
and R6/2 mice injected presymptomatically (18 weeks and 6 weeks, respectively) 
displayed marked resistance to excitotoxic lesions compared to wild type littermates 
(59); this resistance was progressive with age. N171-82Q mice displayed resistance to 
intrastriatal quinolinic acid (QA) administered at 15 weeks (60), and asymptomatic 
shortstop mice are also QA resistant (52), but this phenotype is not ubiquitous among 
the N-terminal transgene strains. Older R6 mice have five-fold higher basal levels of 
Ca2+, suggesting that resistance might be the result of compensatory mechanisms (61). 
Modest protection from mHTT is observed upon decortication or administration of 
glutamate release inhibitors, glutamate transporter upregulators, mGluR5 antagonists, 
and mGluR2/3 agonists (62-65). YAC mice display early QA sensitivity but a 
progressive loss of sensitivity, becoming resistance to QA in 10 month YAC128 mice 
(66).  
While the above studies document changes in excitotoxicity resistance as 
molecular pathology sets in, it should be noted that different strains of mice demonstrate 
different basal susceptibilities to kainic acid (KA) or QA (61,67). Furthermore, F1 hybrids 
demonstrate different inheritance of susceptibility depending on the tissue. This tells us 
that vulnerability to these toxins is mHTT expression, age, and also strain dependent. 
Most interestingly, though, it also suggests that excitotoxicity vulnerability may be 
altered based on natural genetic variants, which could plausibly contribute to some of 
the residual age of onset variance in HD patients after accounting for CAG repeat size. 
In at least four HD mouse models, there is consistent resistance to excitotoxic 
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stress, either pre-symptomatic (R6/1, R6/2, and N171-82Q) or after symptom onset 
(YAC128). The nature of the resistance phenotype is still under investigation, but as laid 
out in Chapter 1, may be mediated by compensatory adjustments to higher basal Ca2+ 
levels (61) and could be aided by observed decreases in dendritic spine density and 
length (45,48). Despite compensatory pathways, even the loss of normal glutamatergic 
afferents increases neuronal survival, suggesting that despite tolerance to acute 
excitotoxic insult, corticostriatal glutamate signaling still contributes to neuropathology in 
HD. 
 
Murine Mitochondria and Energy Imbalance 
As discussed in Chapter 1, neurons are sensitive to perturbations of 
mitochondrial activity (such as the succinate dehydrogenase inhibitor 3-NP) (68), 
particularly striatal MSNs. Reducing oxidative damage helps, as the toxicity of 3-NP in 
rats is significantly ameliorated by dietary creatine supplements (69), a compound that 
also improved survival, rotarod latency, weight, and neuronal atrophy in R6/2 (70) and 
N171-82Q mice (71) in the absence of an exogenous mitochondrial poison. In addition, 
studies of HD mouse model mitochondria demonstrate resistance to Ca2+. R6/2, 
HdhQ92 and HdhQ111 striatal mitochondria become progressively desensitized to Ca2+ 
depolarization over time by 3, 12, and 3 months of age, respectively (72). Total 
forebrain mitochondria also show increase in Ca2+ buffering capacity in 12 week R6/2 
and 12 month YAC128 mice prior to permeabilization, though no difference was seen in 
16 week HdhQ150 mice (73), at an age when subtle gait abnormalities are visible (13). 
These observations may be indicative of progressive compensation to heightened basal 
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Ca2+ levels in aged HD mouse striatal neurons, perhaps explaining QA resistance. In 
all, mitochondria from mouse models of HD consistently demonstrate attempts to 




 Many motor and behavioral symptoms in HD arise from the massive loss of 
MSNs, and the motor symptoms that acute 3-NP and QA toxicity produce are 
reminiscent of advanced Huntington’s Disease. However, many mouse models of HD 
demonstrate almost no neuronal death. That neurons can be intact but still clearly 
malfunctioning, combined with the cognitive and memory deficits seen in most patients, 
suggest that synaptic abnormalities may be significant in HD pathology. 
 Disturbances in long term potentiation (LTP) and long term depression (LTD) are 
presented as evidence of a synaptic plasticity dysfunction, and such abnormal 
responses to LTP and LTD are seen in almost all mouse HD models. Such defects are 
seen in R6/1, R6/2, and HdhQ140 mice, which are known to display obvious motor 
symptoms (74-77), but are also seen in several full length transgenic and knockin mice 
with shorter alleles that display only subtle behavioral phenotypes (9,75,78). LTP or 
LTD deficits have not been reported in BACHD mice, but reduction in high amplitude 
miniature excitatory postsynaptic currents (a measure of steady state synaptic activity) 
of MSNs at 6 months (8), as well as cortical synaptic alterations at the same age (79) 
demonstrate some corticostriatal circuitry impairment in this strain as well. As impaired 
performance at cognitive tasks such as the Morris water maze or T maze is seen in 
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R6/2s (36) and YAC128 (31) animals, as well as somatosensory associative memory 
problems in R6/1s (80), the LTP and LTD impairments likely represent behaviorally 
relevant plasticity deficits. Because these phenotypes exist in mice that recapitulate 
many HD pathologic features but without massive neuronal loss, these studies suggest 
that defects within existing neuronal circuits contribute to early behavioral symptoms.  
  
CAG Expansion  
 The CAG repeats within human HD and mouse HD models are prone to 
mutation, both in the germline and in somatic tissue. Germline expansions are more 
common in males (81), correlating with baseline mutant repeat length, and are thought 
to occur during mitosis, based on the very high percentage of sperm found with mutated 
alleles (averaging over 80%) in HD patient samples (82). 
R6/2 mice are notoriously prone to intergenerational CAG repeat expansion (83). 
This has prompted many labs studying this strain to adopt a selective breeding strategy 
using only breeders with the desired number of repeats. R6/1 mice are almost as prone 
to expansions as R6/2s (84), but contractions are also seen, notably an R6/1 substrain 
with 89 CAG repeats that demonstrates a later onset of neuropathology and motor 
symptoms than standard R6/1s (85). Interestingly, in spite of the fact that CAG repeat 
length is the strongest correlate for age of onset in HD, R6/2 substrains carrying 
anywhere from 150 to over 400 repeats have demonstrated that in this transgene and 
background, higher CAG lengths strongly correlate with a later age of onset (83), 
perhaps due to changes in mHTT subcellular localization. Knockin mice also 
demonstrate intergenerational CAG repeat length instability, with more mutations seen 
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in mice with higher repeat lengths (HdhQ92, HdhQ111) and higher rates in males 
(15,16,86). I am not aware of germline instability in YAC HD model mice, but BACHD 
mice do not expand due to the alternating CAA-CAG repeats of the transgene (8). 
Somatic poly(CAG) instability is also observed in most HD model mice; that 
BACHD mice display symptoms despite the absence of CAG instability demonstrates 
that somatic expansions are not required for neuropathology. However, knockins 
(HdhQ111) lacking DNA mismatch repair enzyme Msh2 have delayed intranuclear mHtt 
accumulation with absence of somatic CAG repeat expansion (87). Msh2 knockout R6/1 
mice also lacked somatic expansion (88). HdhQ72-80 knockins also display prominent 
striatal, cortical and cerebellar expansions, and HdhQ150 animals show somatic 
expansions as early as at 4 months of age (89,90).  
The phenotype of BACHD mice clearly demonstrates that somatic CAG 
expansion is unlikely to be a major driving force in early disease onset. A possible 
propensity to cancer that could arise from reducing the activity of mismatch repair 
proteins also demands caution in exploring this specific pathway for HD therapy. 
Nevertheless, the mouse Msh2 ablation studies and correlation of expansions to patient 
samples demonstrate that somatic expansion may contribute to HD. 
 
Transcriptional Dysregulation: Striking Similarities Among Models 
 Abnormal interactions between mHTT and transcription factors may play a 
prominent role in neuropathology, and as they are expected to be quite pleiotropic, it 
suggests both an intriguing explanation for the wide-ranging systems disrupted in HD 
neurons as well as a promising target for therapy. The reduction of neurotransmitter 
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receptors in the HD striatum (91-93) is one of the earliest observed symptoms, and 
mHTT is known to interact with or sequester numerous transcription factors (94-98). 
The advent of more advanced transcriptional profiling in the last 10 years along with a 
bevy of mouse models of HD have provided ample opportunity for assaying this 
dysregulation and attempting therapies. 
 Microarray transcriptional profiles were compiled for R6/2 mice both before (6 
weeks) and after (12 weeks) onset of overt motor symptoms. ~1.5% of transcripts 
displayed altered levels at each age, with a majority (75%) displaying decreased 
expression (99). Many of these transcriptional changes were verified in N171-82Q mice, 
though they were not shared by YAC72 mice (100). Further analysis from this group 
demonstrated that 12 week old R6/2, 16 week old N171-82Q, and 12 month old animals 
modeling DRPLA (a disorder resulting from polyglutamine expansion in the Atrophin-1 
gene) all show significant overlap of cerebellar profiles (23). That cerebellar tissue and 
also laser-capture microdissected interneurons (101) of R6/2 mice demonstrate 
transcriptional dysregulation suggest that this phenomenon is not unique to the cells 
most vulnerable to degeneration, nor are inclusion-bearing cells more prone to 
transcriptionally-altered neurotransmitter receptor levels (102). What has been 
particularly striking is the significant similarities in transcriptional profiles of most genetic 
HD mouse models tested, both among each other and with human HD. Simultaneous 
profiling of R6/1, R6/2, HdhQ150, HdhQ92, and YAC128 mice demonstrated that every 
model correlated significantly with every other model and with human HD, with the 
caveat that the strains had to be aged appropriately (22). Other studies have reached 
similar conclusions (3,26). 
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 Given that the global transcriptional changes are more commonly 
downregulations than upregulations in HD model mice (99), and that there are altered 
chromatin dynamics associated with repressed transcription (increased histone 
methylation, decreased acetylation) (103), it has been investigated whether general 
modifications to histone dynamics in the form of histone deacetylase (HDAC) 
modulation could be therapeutic. Suberoylanilide hydroxamic acid (SAHA) and sodium 
butyrate, two HDAC inhibitors, both caused a delay in motor symptom onset in R6/2 
animals, though SAHA was toxic. (104,105). HDAC inhibitors 4b and valproate 
alleviated locomotor deficits in R6/2 and N171-82Q mice, respectively (106,107). N171-
82Q mice demonstrated marked improvement in lifespan, striatal atrophy, and histone 
methylation:acetylation ratio upon administration of HDAC inhibitor phenylbutyrate after 
symptom onset, an important result for a disease in which not every carrier chooses to 
know their gene status and may only initiate treatment after overt symptoms are 
detected (50). In order to limit the off target effects of a general HDAC inhibitor, drugs 
with tighter specificity are needed as well as more focused targets. Recently, R6/2 mice 
have been bred to strains carrying either homozygous (if not lethal) or heterozygous 
deletions in HDACs to parse out which HDACs are the best modifiers of pathology. So 
far Hdac7 has been discounted as a potential modifier (108), but Hdac4 does show 
some promise (Gillian Bates, personal communication). 
 The similarity in transcriptional profiles between many aged HD model mice and 
patient samples suggests a fundamental consequence of mHTT on basal levels of 
transcription, either by direct interaction with transcription factors, attempts at 
compensatory changes, or both. That this phenotype is directly quantifiable in mice and 
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correlates so strongly with patient samples supports its utility as a biological measure 
for pathology. 
 
From Preclinical to Clinical Treatment of HD  
Candidate based approaches and success in mouse models have resulted in 
many drug trials progressing from preclinical mouse work to patients. Two excellent 
reviews (109,110) enumerate the trials conducted in the R6 lines, and Mestre et al. 
(111) provide a detailed summary and discussion of published HD clinical trials. Of 
those treatments tested in rodents, many have made it to clinical trials; nine trials 
passing the Mestre et al. criteria (randomized, placebo-controlled, symptomatic therapy 
with at least 10 participants), plus the combination remacemide / Coenzyme Q10 trials, 
are listed in Table 3. The majority of these selected clinical trials were aimed at safety 
and tolerability, rather than efficacy, so it comes as little surprise that no improvement in 
clinical outcome was seen for most. However, to date, only tetrabenazine (TBZ) has 
demonstrated a reduction of motor symptoms in both mice and patients (112-114), and 
though the mouse studies showed a reduction in striatal atrophy and motor symptoms, 
reduced neurodegeneration has not been documented in human patients on TBZ. Mice 
have also served as a proving ground for more cutting-edge therapeutic strategies like 
gene and oligonucleotide therapies (discussed earlier in the chapter). None have made 
it to clinical trial in HD patients, so evaluation of the HD mouse models’ predictive value 




 The commonplace clinical failure of drugs that appear to benefit murine models 
makes clear the need for refinements in the measurements of pathology in these mice. 
In the last few years, imaging modalities such as MRI have been minaturized for use in 
HD model mice (115,116), and show promise. Nevertheless, it may be that behavioral 
alterations and volumetric imaging in mice have only limited correspondence, and better 
predictive value could require measuring phenotypes at a cellular level, representing the 
earliest stages in pathology. One such well-studied phenotype, present early in 
pathology in mouse models and patients and with unparalleled similarity between 
patients and mice, is transcriptional dysregulation of neurotransmitter receptors. Hence, 
for my graduate studies, I chose to address the need for efficient evaluation of 
candidate therapeutic efficacy in mouse models of HD by first exploring this well 
established phenotype (transcriptional dysregulation of the gene Drd2) in many mouse 
models, then developing a technique for rapid and highly accurate analysis of the 
progression of this phenotype, and finally demonstrating the ability to both induce and 








Figure 1. Timeline of behavioral and neuropathological symptoms in selected HD 
model mice. Strains are categorized by color: red indicates N-terminal transgenic, blue 
indicates full-length transgenic, and green indicates knockin. Approximate age of onset 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1: Commonly used mouse models of HD. Tg NTF = Transgenic N-terminal 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2. Selection of Drugs Tested in Both HD Model Mice and in Clinical Trials 
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CHAPTER 4 – D2GFP FLOW CYTOMETRY ASSAY DEVELOPMENT 
 
Introduction 
As discussed in Chapter 2, effective therapeutic interventions for 
neurodegenerative diseases such as ALS, Parkinson's Disease, Alzheimer’s Disease, 
and Huntington’s Disease (HD) require cell and animal models, many of which have 
been developed. While cell models allow higher throughput and lower cost, any 
therapeutic intervention initially evaluated in a cell culture model must subsequently be 
assessed in an appropriate animal model system before clinical trials in humans can be 
considered. However, the inherent variance in quantitation of the behavioral or 
pathological readouts in animals has practical consequences, requiring large cohorts to 
detect all but the most overt benefits, which limits experimental throughput. I sought to 
develop and implement an approach to this problem that combines the quantitative 
accuracy and direct relationship to molecular processes of a cell based assay with the 
medical relevance of evaluating endogenous neurons in the animal brain. 
To develop the quantitative, cell-based preclinical assay system for HD, I focused 
on a well-characterized early feature of disease pathology in both these animal models 
and HD patients, transcriptional dysregulation in the medium spiny neurons (MSNs) of 
the basal ganglion, a phenotype with substantial consistency amongst mouse models 
and between the models and patients (1-4). One such dysregulated gene, dopamine 
receptor D2 (DRD2 or D2), shows high expression levels in MSNs of the indirect 
pathway (striatopalladial) of the basal ganglion, which are among the earliest to die in 
HD (Reviewed in (5)). Measuring the binding of the D2 ligand raclopride using PET 
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scanning demonstrates reduced levels of DRD2 protein in the basal ganglia at, or even 
prior to, the onset of overt disease (6,7). Many mouse models for HD show a 
corresponding loss of Drd2 expression early in the progression of neuronal pathology 
(1,8,9). Because mouse models of HD do not lose neurons in great numbers until very 
late in disease progression (10,11), this reduction is likely on a cell-by-cell level. 
Dopamine signaling, and hence dopamine receptor alterations, likely plays a 
significant role in HD pathology. Selected evidence include studies demonstrating that 
knocking out the dopamine transporter in an HD mouse model accelerates aggregate 
formation (12), that dopaminergic input depletion by 6-OHDA treatment reduces striatal 
glutamate levels (13), and the fact that the only current FDA-approved drug for 
symptom management in HD is an inhibitor of VMAT2 (the main vesiclular dopamine 
reuptake transporter), tetrabenazine. Downregulation of such receptors may be an 
indirect byproduct of pathological transcriptional dysregulation, or a specific 
compensatory response by MSNs undergoing polyglutamine-induced stress. 
The NIH-supported GENSAT project proved to be an excellent resource to 
identify a mouse Drd2 reporter strain (14). Using BAC transgenic methodologies, this 
project has created many GFP reporter mouse lines, amongst which is a Drd2-GFP 
(D2GFP) reporter strain that appeared extremely well suited to my goals. Extensive 
characterization of this mouse strain by the GENSAT project and others (15) 
demonstrates a clear correspondence to the expression pattern of the endogenous 
mouse Drd2 gene.  
HD mouse models carrying the D2GFP reporter transgene were constructed by 
crossing, with demonstrable pathology typical for HD mouse models. A rapid and 
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reliable flow cytometry-based protocol for quantitatively assessing the GFP levels of 
MSNs in these animals was developed. I found that HD mouse models show highly 
reproducible reductions in GFP levels in the indirect MSNs during the early stages of 
disease progression, and that per-cell levels of GFP eventually stabilize at reduced 
levels, even while other pathologic measures are known to continue progressing. Time 
courses for decline in transcription levels of the reporter for a series of mouse models 
expressing either full length or N-terminal fragments of mutant huntingtin were 
evaluated. It is my hope that the availability of an effective, quantitative reporter system 
in the mouse brain for therapeutic intervention efficacy in HD will improve the rapidity 
with which therapeutic interventions for HD can be discovered, validated and made 
ready for human clinical use.  
 
Methods 
Mice: All procedures were done in accordance with Massachusetts Institute of 
Technology Committee on Animal Care guidelines. R6/2 mice (~110 CAG repeats) were 
maintained on a mixed background, either by crossing a transgenic male each 
generation to B6CBAF1 females, or using an ovary-transplanted female bred to 
B6CBAF1 males. N171-82Q mice were maintained on a mixed background, crossing a 
transgenic male each generation to B6C3F1 females. R6/1 (~140 repeats) and CAG140 
male mice were bred congenic to C57BL/6, and HdhQ111/111 homozygotes were 
originally maintained on an outbred CD1 background before homozygosing and 
interbreeding within a small colony. BACHD mice were bred congenic to FVB. D2GFP 
mice were maintained homozygous, congenic to FVB. No differences were observed in 
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progression of the GFP decline phenotype between males and females, and the data 
were pooled. Animals were weaned at 3 weeks of age, housed with 1-5 mice per cage 
on a 12-hour light/dark cycle, and were fed at libitum from a wire cage-top hopper. 
 
Rotarod and weight change: Weight was recorded at the start of every week of 
rotarod trials. Motor dysfunction on the rotarod was measured on a 4-40 RPM 
accelerating protocol, taking 10 mins to reach top speed, at which point mice were 
removed and 600 seconds was recorded (a rare occurrence). Otherwise, a fall was 
recorded and the time marked when the mouse failed to remain on top of the rod, either 
by falling off or hanging on while rotating around the bottom. An exception (“re-do”) was 
made for falls within the first minute or falls while the mouse was in the process of 
turning around; in this circumstance, the time was recorded but the mouse was returned 
to the rod, and if it did not have a second fall within the next minute, the first fall time 
was erased. A second re-do was not given. Trials took place 3 days per week, 3 trials 
per day, with at least 10 mins separating the trials. For a given mouse on a given week, 
the trials were averaged, eliminating any trials more than 2 standard deviations away 
from the mean of the remaining trials. That average was assigned as that mouse’s 
rotarod time that week for statistical purposes. 
 
Histology:  Mice to be processed for histology were terminally anesthetized with 
pentobarbital overdose. Mice were transcardially perfused with ~25 mL of 4% 
paraformaldehyde in PBS. Brains were sectioned (40 µm) on a vibratome and sections 
were stored in PBS with 0.4% NaAzide before staining. For immunofluorescence 
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analysis, free floating sections (1 to 4) in Netwell inserts were rinsed 4 times (5 min 
each) with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 5 mins. Sections 
were blocked in Blocking Buffer 1 (2% BSA in PBS-T [PBS with 0.1% Triton X-100] and 
4 drops of MOM Ig Blocking Reagent [Vector Laboratories] per 5 mL buffer) for 1 hr. 
Two more PBS rinses (5 min each) preceded additional blocking for 5 mins with 
Blocking Buffer 2 (2% BSA in PBS-T containing MOM Dilutent [400 µL per 5 mL buffer]), 
before primary EM48 (1:500, Millipore) antibody was added. Sections were incubated 
overnight at 4°C and then rinsed 4 x 5 min in PBS. Secondary antibody (Donkey anti-
mouse Alexafluor 647, 1:1000, Invitrogen) was used in Blocking Buffer 2 and sections 
were incubated for 1 hr at RT. Four final 5 min PBS rinses (the second containing 1 
µg/mL DAPI) preceded mounting. After mounting, sections were dried overnight and 
then sealed under coverslips with Vectashield Fluorescent Mounting Media (Vector 
Laboratories). Images were collected on a Nikon A1R confocal microscope, taking the 
maximum projection of the section’s Z-stack images, then processed and 
pseudocolored in ImageJ software. 
 
Buffers and reagents for dissociation: HABG: Hibernate-A (Brainbits) with 2% B27 
supplement (Invitrogen), 0.25% Glutamax (Invitrogen), and 1% Pen/Strep. Papain 
buffer: Hibernate-A minus Ca2+ (Brainbits) with 0.25% Glutamax. Papain and DNase 
(Worthington product codes PAP2 and D2, respectively) were distributed as lyophilized 
aliquots. 
 
Papain dissociation of MSNs for flow cytometry: The following protocol for 
 141 
dissociation of MSNs for flow cytometry represents the current, highest-yield version. 
Previous versions produced some of the data presented, but other than a reduced yield 
of intact neurons, they did not demonstrably affect GFP profiles. Mice were euthanized 
by CO2 asphyxiation. Brains were removed and dissected immediately. One or both 
striata were removed and stored in room temperature HABG for no more than 20 
minutes while remaining samples were dissected. Striata were minced in 0.5-1 mL 
HABG in a petri dish using a razor, producing pieces no thicker than 0.5 mm. During 
dissection, the papain solution was prepared. Contents of 1 vial of papain were 
resuspended in each 5 mL papain buffer required, and incubated at 37˚C for 20 mins. 
Contents were then filtered (0.45 µm), and DNase added (1 vial DNase per 5-10 mL 
papain solution). Papain solution was aliquotted (1 mL per sample), and minced tissue 
bits were added using razor-trimmed pipet tips on a P1000, minimizing transfer of 
HABG (see note 1). Tissue was incubated with gentle rotation at 31-32˚C for 30 mins. 
After papain incubation, tissue pieces were transferred as above into 1-2 mL room 
temperature HABG and incubated for at least 5 mins. Fire-polished, silonized Pasteur 
pipettes (end width narrowed to ~0.8 mm) were used for trituration: material was pipeted 
up and down 10-20 rounds, ~4 seconds per round, until most tissue was in suspension 
(see note 2). Afterwards, using razor-blunted pipet tips, dissociated tissue was filtered 
(70 µm) (see note 3) and either used immediately for flow cytometry (after addition of 
propidium iodide or DAPI) or subjected to an additional BSA cushion purification step 
(see note 4). For further purification, dissociated tissue (~2 mL in HABG) was gently 
placed on top of a 3 mL cushion of HABG plus 2% BSA in a 15 mL conical tube (note 
5). The material was centrifuged at 20xg (slow acceleration/deceleration) for 20 mins to 
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pellet neurons. After centrifugation, the top layer (debris, devoid of neurons) and most of 
the BSA cushion layer were aspirated, leaving 0.5-1 mL of HABG+BSA and the cell 
pellet. Pelleted neurons were resuspended in the remaining HABG+BSA, refiltered (70 
µm), and used for flow cytometry (propidium iodide or DAPI added). 
I found the total time, when performed by someone experienced in the protocol, 
is approximately 3 hours for 10 samples. It may take as much as twice as long as this 
for a novice. Because many facilities require advanced scheduling of the flow 
cytometers, to minimize the time neurons are kept on ice prior to use in the cytometer, 
this time should be factored in. 
 
Note 1: I found it worked well to bring tissue into the tip, holding the pipette vertically. 
The tissue pieces settle towards the bottom after a few seconds. When the tip/tissue 
contacts the papain solution, it will break the surface tension, and the tissue chunks will 
flow into the papain, minimizing HABG transfer that would happen by simply expelling 
the tissue into the papain solution. Gently wiggling the pipette sometimes helps. If 
chunks need to be knocked off the wall, a small air bubble (created by gently releasing 
the plunger while holding vertically out of solution) will knock the tissue off the inside of 
the tip, allowing it to settle for transfer as above. 
 
Note 2: The details of the trituration are as follows. Using a pipet-aid, tissue is drawn up; 
in 2 mL media, it should take ~2 seconds. Tissue is expelled immediately afterwards, 
taking ~2 seconds. This cycle is repeated 10-20 times. Great care should be taken to 
prevent bubbles from forming (which limit yield), but the rate of drawing up and 
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expulsion can be increased if pieces are getting small and still not breaking up. By the 
end, some pieces will likely remain, but this is often white matter, which is hard to break 
up and poor in neurons. 
 
Note 3: The filtration was best accomplished using cut P1000 tips (opening ~5 mm), 
holding the tip in the mesh and slowly forcing ~800 µL through each time. A cut tip is 
preferable because a substantial amount of material will be caught in the filter, but a 
wider area of filtration prevents clogging. Care must be taken not to tear the filter 
membrane when holding pipette tip in it, but it must be held in place firmly enough that 
material actually passes through the filter membrane rather than collecting above it. 
 
Note 4: Additional purification was usually only done when sorting was performed or 
time on the required analysis machines was limited, as it removes the majority of debris 
and concentrates the sample, but it sacrifices some yield, and is unnecessary for simple 
analysis and GFP quantitation. 
 
Note 5: Layering the filtrate above the BSA cushion is made much more simple using 
cut P1000 tips. I recommend the following technique. The filtrate is retrieved in a cut tip, 
and the tip is then gently placed in contact with, but not below, the surface of the BSA 
cushion. Slow expulsion of the filtrate will allow it to remain above the cushion, while 
rapid expulsion forces it below the surface, preventing the formation of a clean interface. 
The above can be repeated until all of the filtrate is in a clean layer above the cushion. It 
should be noted that, should the samples be disturbed (e.g. dropped accidentally) 
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before centrifugation, the samples can still be centrifuged as above to prevent loss of 
the sample. The neurons will still be visible by flow cytometry, but debris events will not 
be removed. 
 
Flow cytometry data processing: Flow cytometry for D2GFP quantitation took place on 
FACSCalibur or LSRII cytometers (BD). Data collected on flow cytometers was 
exported in an appropriate format (.fcs). If compensation was used, care was taken to 
ensure that all samples in a given dataset are compensated equally to not introduce 
biases. Exported files were opened in FlowJo analysis software (Treestar). GFP+, 
DAPI- MSNs can be seen without any gating, but there is a substantial amount of debris 
in every data set, so clean data was obtained by removing from analysis any events 
whose forward scatter (FSC) and side scatter (SSC) profiles were inconsistent with that 
of MSNs. To do so, first, GFP+, low side scatter events were selected to provide the 
initial gating parameters, as these are chiefly MSNs. These gated events were re-
plotted by FSC x SSC and the central population of events was re-gated. The data 
could be further purified by gating using the Height and Width parameters of FSC and 
SSC if desired, but this was typically unnecessary. Once the hierarchical gating 
parameters for MSN-like events were established, the gates were re-assigned to the 
whole population of events (back-gated), removing events with scatter profiles not 
resembling MSNs. After this back-gating, GFP+, DAPI- MSNs were now selected for 
export of GFP (and RFP as appropriate) raw values for further analysis. MATLAB 
(Mathworks) expectation maximization and Gaussian means regression scripts were 
used to fit the exported GFP+, DAPI- events to a pair of probability distributions. The 
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mean of the higher GFP distribution was used as the raw GFP value of that sample’s 
MSNs. For mutant mice, this value was normalized to that of one or more 
simultaneously processed control samples. The script will be provided upon request. 
 
QPCR: For RNA isolation, tissue or cells were added to 1 mL Trizol reagent, 
homogenized (18G needle or glass bead homogenizer), and extracted with 200 µL 
chloroform (vortexed for 8 seconds, rested for 2 mins, and then centrifuged at 4°C for 8 
mins). The upper aqueous phase was used for standard alcohol precipitation. RNA was 
further purified using RNeasy columns, including on column DNase digestion (Qiagen). 
cDNA was synthesized using iScript RT-PCR kits (Bio-Rad), and reaction products 
either diluted 5x (purified flow sorted cells) or 25x (tissue samples). QPCR was 
performed using iQ SYBR Green mastermix (Bio-Rad) on a LightCycler 480 System 
(Roche). 
 
mRNA purification and fragmentation for RNAseq: Total RNA was prepared as for 
QPCR (tissue) or using Qiashredder columns followed immediately by RNeasy column 
purification (Qiagen) (flow sorted cells); when sorted cells were destined for RNA 
purification, they were sorted directly into Qiagen buffer RLT. mRNA was further purified 
as follows. 2-10 µg purified total RNA (from tissue) or all of the purified RNA (sorted 
cells) was dissolved in 50 µL H2O (all H2O used was RNase-free), and heated to 65°C 
for 5 mins before placing on ice. 100 µL oligo(dT) magnetic beads (New England 
Biolabs) were added to an eppendorf and placed on a magnetic rack (Dynal MPC-S or 
similar), and washed twice with 100 µL Binding Buffer (20 mM Tris-Cl pH 7.5, with 1 M 
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LiCl and 2 mM EDTA). Beads were resuspended in 50 µL Binding Buffer, combined with 
the 50 µL RNA, and shaken gently by hand for 5 mins at RT. Tubes were then placed 
on the magnetic rack, supernatant was removed (bringing with it ribosomal and other 
non-polyA RNA), and the beads were washed twice with 100 µL Wash Buffer (10 mM 
Tris-Cl pH 7.5, with 150 mM LiCl and 1 mM EDTA). Beads were then resuspended in 30 
µL 10 mM Tris-Cl pH 8.0, and heated for 2 mins at 80°C to remove mRNA from beads. 
Supernatant was quickly removed using the magnetic rack, temporarily moved to a new 
tube, and mixed with 70 µL Binding Buffer. The beads were washed twice with 100 µL 
Wash Buffer while the mRNA was melted for 5 mins at 65°C. After the beads were 
washed and the mRNA melted, mRNA was added back to the washed beads, shaken 
again gently for 5 mins at RT, and washed twice more with 100 µL Wash Buffer. Finally, 
beads were resuspended in 20 µL 10 mM Tris-Cl pH 8.0 and heated for 2 mins at 80°C 
to elute mRNA from the beads. The tubes were rapidly placed back on the magnetic 
rack, and the purified polyA+ mRNA was moved to a new tube. mRNA was fragmented 
(RNA Fragmentation Reagents, from Ambion) at 70°C for exactly 5 mins, before stop 
solution was added and tubes were placed on ice. mRNA was then purified with sodium 
acetate, glycogen, and ethanol per standard protocols. After precipitating, centrifuging, 
and washing the pellet (70% ethanol), the clean, purified, fragmented mRNA was 
resuspended in 10.5 µL H2O for cDNA synthesis. 
 
Library prep for Illumina sequencing: Purified, fragmented mRNA was converted into 
double stranded cDNA using first and second strand synthesis reagents (Invitrogen). In 
short, for first strand synthesis, random hexamer primers (3 µg/µL, 1 µL) were added to 
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RNA and heated for 5 mins at 65°C. 5x First Strand Buffer (4 µL), 100 mM DTT (2 µL), 
dNTPs (10 mM each, 1 µL) and RNase inhibitor (0.5 µL) were added to each reaction, 
which were then incubated at RT for 5 mins. Afterwards, 1 µL Superscript III reverse 
transcriptase (Invitrogen) was added, and the reactions were incubated sequentially at 
25°C for 10 mins, 42°C for 50 mins, and 70°C for 15 mins. For second strand synthesis, 
H2O (51 µL), 5x Second Strand Buffer (20 µL), and dNTPs (10 mM each, 3 µL) were 
added to each reaction and incubated on ice for 5 mins. Afterwards, RNaseH (2 U/µL, 1 
µL) and DNA polymerase 1 (10 U/µL, 5 µL) were added and reactions were incubated 
at 16°C for 2.5 hrs. Double-stranded cDNA was purified with Qiaquick PCR purification 
kit columns and reagents (Qiagen), and eluted in 50 µL Tris-Cl pH 8.0. End repair, 
adaptor ligation, and size selection (200-400 bp) were performed by staff at the MIT 
BioMicroCenter. Samples were then PCR amplified 12-16 cycles using barcoded 
primers. Paired end reads were processed on the Illumina HiSeq 2000 platform and 
reads mapped and analyzed using a combination of in-house pipelines for differential 
gene expression calling. Data was further processed using Excel (Microsoft) and 
MATLAB (Mathworks). Heat maps were made using GENE-E Software (The Broad 
Institute, available at http://www.broadinstitute.org/cancer/software/GENE-E/index.html 
). Amongst the associated topics (Figure 3) for dysregulated genes, Canonical 
Pathways and Upstream Regulators were called using Ingenuity Pathway Analysis 
(Ingenuity Systems), while enriched Components, Functions, and Processes were 




Histological and Behavioral Assessment of D2;HD Model Mice of the Strain R6/1. 
I wished to assess the potential for the D2GFP transgene to serve as a 
quantitative marker in the HD model mouse context. After establishing a colony of 
D2GFP mice (known to demonstrate some behavioral and gene expression alterations 
that only exist in the homozygous state) (16,17), I began breeding them to various HD 
model mouse strains. The R6/1 strain demonstrates robust and reproducible behavioral 
alterations (18) and neuropathology (19). Offspring of D2GFP and R6/1 animals 
demonstrate minor neuropathology (an enlarged lateral ventricle) at age 12 weeks 
(Figure 1B), relatively early in pathology and prior to previously published motor 
symptoms (3,20). The GFP transgene shows the expected striatal enriched expression 
(15), with axons out of the ventral striatum projecting towards the globus pallidus. 
Compared to a wild type littermate (Figure 1A), there is a significant reduction in GFP 
within the striatum. Closer inspection (Figure 1C) demonstrates that, as expected, only 
~1/2 of nuclei in the striatum are found within GFP+ cells, the other half presumably 
within neurons of the direct pathway, known to express dopamine receptor D1 but not 
D2 (21). Compared to the wild type littermate, the R6/1 animal (Figure 1D) shows a 
similar pattern of GFP expression but with lower absolute levels of GFP. Additionally, 
staining with EM48 (recognizing mutant huntingtin exon 1) reveals pervasive neuronal 
intranuclear inclusions, present in almost every neuron but largely absent from the 
nuclei in the axon fiber bundles. This suggests that the cells of the axon fibers, largely 
oligodendrocytes, are less prone to mutant huntingtin (mHTT) aggregation. 
A small cohort of animals (N=5 per genotype) were tested for weight loss and 
performance on the rotarod through 16 weeks of age, approximately half of the upper 
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limit of the lifespan of these mice in my colony. No statistically significant decline in 
weight was observed (Figure 2A) in this cohort, but others tested by my lab have 
demonstrated an eventual reduction in weight in R6/1 mice in the D2GFP background 
(not shown). However, even in this small cohort, a significant decline in performance on 
the rotarod was apparent from 12 weeks of age until euthanasia at 16 weeks (Figure 
2B). 
 
Transcriptional Profiles of D2;R6/1 Versus D2;WTL Mice Confirm Previous 
Observations in Non-D2GFP Background 
 The D2GFP transgene has no effect on the behavioral or neuropathological 
sequelae common to HD mice, but to confirm that transcriptional dysregulation is 
uniformly altered beyond the observed loss of GFP signal, RNAseq analaysis was 
performed on striata from 12 week old D2;R6/1 mice and non-HD littermates (Figure 3). 
At this age, the mice have either no or mild symptoms. Over 1200 genes, or 8% of 
genes with mapped reads, had significant dysregulation (fold change >log2(0.5), q < 
0.05), 2/3 of which were downregulations versus upregulations in the HD state. Despite 
only 8% of the transcriptome being reported as significantly altered, these values were 
more than adequate to demonstrate hierarchical clustering of samples (Figure 3A) 
which separated wild type from R6/1 littermates, a clustering that did not change when 
only those genes with reported dysregulation were subjected to the same algorithm 
(Figure 3B). Pathway and other functional analysis (Figure 3C) confirmed the alteration 
of many pathways with previously identified dysregulation in R6/1 mice (3). This 
includes many pathways and functions associated with G-protein coupled receptor and 
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cAMP signaling, cation transport, and protein binding. Such in depth transcriptional 
analyses present a wealth of information and can be used to identify candidate 
modifiers whose reduction or increases may contribute to pathology (for example, both 
Bdnf and Hdac4 are significant predicted upstream regulators of downregulated genes). 
However, for my purposes in this study, it is enough to note that the D2GFP transgene 
(including the resulting introduction of the FVB strain background) does not appear to 
influence the transcriptional profile alterations common to this HD mouse model. 
 
Improved Yield for Isolation of MSNs from Adult Mouse Striata. 
 The decline in GFP seen histologically prompted further study. To best leverage 
any decline in GFP fluorescence, I wished to develop a way of following this loss on a 
single-cell level. This would facilitate rapid assessment of alteration of this phenotype, 
as well as allow for pooled screening in a mixed population expressing a variety of 
potentially therapeutic constructs. 
In order to robustly quantify this Drd2 dysregulation in mHTT-expressing 
neurons, I optimized a previously reported protocol (22) for dissociation of D2GFP 
MSNs that originally gave limited yields (~1200 GFP+ cells per striatum), inadequate to 
carry out the detailed analyses here. My modified protocol increased yield to 15,000-
25,000 GFP+ cells per adult striatum, a sufficient number for subsequent experiments. 
The throughput of this protocol is sufficiently high that one individual can prepare a 
dozen samples for flow cytometry in roughly three hours. This compares extremely 
favorably with the other methods commonly used for transcriptional assessment. With 
the obvious caveat that this analysis is limited to that of one or two transcripts, 
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strategies like QPCR require at least one day (RNA isolation and purification, cDNA 
conversion, and QPCR analysis) while in situ techniques require multiple days (fixation, 
sectioning, slide preparation, hybridization, washes and detection). I will elaborate on 
the specific merits of this analysis, but by adding my novel technique to a conventional 
repertoire, a rapid and limited interrogation of Drd2 levels could be used to determine 
whether further analysis of the remaining tissue is worthwhile. Also of significance is the 
fact that this technique measures Drd2 expression accurately on a cell-by-cell basis. 
This is particularly important when analyzing a sample with a mix of construct-
expressing or non-expressing cells (to be discussed in Chapter 5), but it also removes 
the risk of contamination from nearby non-striatal tissue. Classical transcriptional 
analysis can be thrown off by the appearance of transcripts from neighboring brain 
structures, but here, precise dissection is less crucial. 
Suspensions of MSNs were subjected to flow cytometry. Event-by-event raw 
GFP quantities were acquired and further processed to assign a GFP level to the 
population (and therefore the mouse), using a method to be discussed in the next 
section. Subjectively, MSN suspensions only demonstrate a GFP+, DAPI- population 
(presumably that of intact, Drd2-expressing MSNs) from animals expressing the D2GFP 
transgene (Figure 4). To further test this, we bred a small cohort of animals expressing 
tdTomato under control of the Drd1a promoter (D1tdTomato) (15) to D2GFP animals 
and subjected them to similar flow cytometry analysis (Figure 5). As expected, only 
animals carrying the D2GFP transgene showed GFP+ events, while mice carrying 
D1tdTomato had RFP+ events. Also, as expected, double transgenic animals (Figure 
5C) have each single-fluorescent population in roughly equal numbers, but very few 
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double-fluorescent cells. This is consistent with the knowledge that most MSNs express 
either Drd1 or Drd2, each making up approximately half of the MSN population (15). 
This technique is not limited to striatal MSNs, either. A BAC transgenic GFP 
strain CDG2GFP, driving GFP under the transcriptional control of Rasgrp1 (also known 
as CalDAG-GEFII), has proven useful for analysis of both cortical and striatal neurons. 
The gene is primarily expressed in the striosomes of the striatum, but also is expressed 
in the motor cortex (23). Hence, when subjecting D2GFP cortex and striata to flow 
cytometry, GFP+ events are only visible in the striatum (Figure 5D) and are absent in 
the cortex (Figure 5E). However, from CDG2GFP animals, GFP+ events are visible in 
suspensions from both the striatum (Figure 5F) and cortex (Figure 5G). This agrees with 
immunostaining versus GFP available on the GENSAT website (Figure 5H-I) for these 
two strains, where antigen staining is visible only in the striatum in D2GFP animals, but 
is visible in both the striatum and in several layers of the overlaying cortex in CDG2GFP 
brains. 
 
QPCR Validation that GFP+ Events are Indirect MSNs 
 By analyzing the pre-sorting and post-sorting events (Figure 6), I was able to 
confirm that debris is pervasive prior to sorting (Figure 6A-C), and within this 
suspension, there are a few visible GFP+ cells that remain intact (staining negative for 
DAPI) while un-intact cells (DAPI+) never contain GFP. After sorting (Figure 6D-F) the 
GFP+, DAPI- population, imaging confirms the absence of both DAPI+ un-intact cells as 
well as debris. For confirmation that GFP+, DAPI- events were indeed MSNs of the 
indirect pathway, these events from D2GFP mice were collected and transcript levels 
 153 
compared to whole striata (Figure 7A, black versus striped bars). The sorted events 
demonstrated significant enrichment of transcripts known to be characteristic of MSNs 
of the indirect pathway (Drd2, Adora2a, and Penk) as well as significant reduction of 
transcripts known to be enriched in direct pathway MSNs (Drd1a and Tac1) (24,25). 
The previously reported downregulation (1,9) of Drd2, Adora2a, and Penk in HD models 
was reproduced in the aged HD model R6/1 striatum (Figure 7A, black versus grey 
bars), which agrees with my RNAseq data in confirming that the D2GFP background 
does not significantly alter this phenotype. 
 
Small Numbers of MSNs Can Be Sorted and Analyzed by RNAseq  
 It has been previously demonstrated that flow sorted D2GFP neurons can be 
transcriptionally studied (22), and it was worth verifying that those genes demonstrably 
upregulated in indirect MSNs by previous studies are also altered in my hands. 
Additionally, it is worthwhile knowing the minimum number of cells required for high 
quality transcriptomic analysis. Hence, populations of D2GFP+ MSNs (1000, 4000, 
16,000, or 64,000) were processed by RNAseq to determine mapped transcripts and, if 
possible, differential expression versus whole striatum (Figure 8). Overall transcriptional 
profiles of sorted cells had significant similarity to that of whole striatum (Figure 8A-D), 
though the most striking similarity was between replicates of whole striatum (Figure 8E) 
and between libraries from 64,000 and 16,000 sorted D2GFP cells (Figure 8F). Further 
dilutions, comparing libraries from 16,000 with 4000 cells or 4000 with 1000 cells 
(Figure 8G-H), demonstrate both less linearity in the correlations, and also a reduction 
in the presence of transcripts with low FPKM values. Globally (Figure 8I), fewer overall 
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genes with mapped reads were detected in libraries made from fewer cells, and such 
libraries also showed an apparent inflation of many FPKM values, particularly on the 
low-expression end. This was brought on by a specific loss of detection of transcripts 
whose expression in the whole striatum was weakest (Figure 8J), whereas highly 
expressed transcripts were present in all sorted cell libraries. As a further confirmation, 
transcript levels of genes reportedly enriched in direct or indirect MSNs (22) were 
assessed, and as expected, were either depleted (direct MSN genes: Lingo2, Slc35d3, 
Tac1, Zpf521, Stmn2, Drd1a, Nrxn1, and Gnb4) or enriched (indirect MSN genes: Penk, 
Drd2, Adora2a, Plxdc1, Arpp19, Adk, Ubp1) in D2GFP MSNs versus whole striatum. In 
all, this is confirmation of previous studies that sorted D2GFP cells are a pure 
population from which RNA can be collected for informative transcriptomic studies. 
Furthermore, given my improvements to the yields from flow sorted populations, pooling 
mice may no longer necessary for the collection of sufficient material for such analysis. 
Certain low abundance transcripts may not be detected, but the quality of such libraries 
is sufficient for the study of significant transcriptional differences in specific neuronal 
subpopulations. 
 
Quantitation of GFP Levels in D2GFP MSNs by Flow Cytometry  
For use as a preclinical marker of HD pathology, robust and consistent 
quantitation of D2GFP levels in MSNs required removal of contaminating 
subpopulations from analysis. Figure 9 represents an example of the quantitation 
pipeline for a mouse of strain R6/1 at 16 weeks of age and a wild type littermate, 
processed simultaneously. Initial backgating computationally filtered out events with 
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forward and side scatter profiles inconsistent with that of GFP+, DAPI- events (which 
contain intact Drd2+ MSNs). In this example, the GFP values of GFP+, DAPI- events 
from a control littermate (Figure 9A, blue gate) and an R6/1 mouse (Figure 9B, red gate) 
were exported. Overlaying them (Figure 9C) allows one to qualitatively distinguish wild 
type from HD model samples, but also demonstrates that each contains two sub-
populations. This phenomenon was particularly apparent in older R6/1 and R6/2 mice, 
for which specifically gating the entire GFP+ population was not possible without 
including a portion of the neighboring debris field. These sub-populations can be 
separated using Gaussian means regression into two population distributions (Figure 
9D). It was determined that the high GFP population demonstrated the lowest variance 
within cohorts, so for robust quantitation, the mean of the high-GFP distribution is used 
as the GFP value of each mouse (Figure 9E). Normalizing this R6/1 mouse to the 
control littermate revealed a reduction to 34.4% of control GFP. The minimal variance of 
this analysis is demonstrated in Figure 9F for the entire 16-week-old R6/1 cohort (6 
R6/1 and 3 control mice were overlayed, producing values of 34.5 ± 1.8% for R6/1 
normalized to 100 ± 2.3% in controls). 
I normalized each mutant mouse’s GFP value to that seen in age-matched 
control animals processed simultaneously (when more than one control animal was 
processed on a given day, the average was used). Normalized data of many mutant 
mice of the same or similar age, processed on the same or different days, were 
aggregated for study in time courses. 
 
D2GFP Loss is Progressive in Both Fragment and Full-length HD Mouse Models 
 156 
R6/2 mice:  I systematically crossed D2GFP mice to a number of HD model strains 
and analyzed the time course of decline in GFP expression (Figure 10A). Strain R6/2 is 
the product of strong expression of a transgene containing human mHTT exon 1 and its 
promoter (26). It has been widely used in the assessment of potential therapeutic 
interventions for HD (27,28). I found that D2GFP expression in the MSNs of R6/2 
showed significant differences from the values for wild type littermates at the earliest 
age I evaluated, 4.5-5 weeks of age. At this point, R6/2 GFP values were 80% of 
controls. As R6/2 animals aged, the differences in GFP values between R6/2 and 
control animals increased. Between 8 and 12 weeks, when R6/2 animals decline 
precipitously in performance on behavioral tests (29), there was minimal further decline 
in normalized GFP levels between R6/2 and control, which remained in the range of 30-
40%. The low variance of the measurements were demonstrated by power analysis 
(Table 1, power = 80%, alpha = 0.05), demonstrating that end-stage R6/2 mice (age 
10.5-12 weeks) would require only 5 animals to detect a modest 10% rescue of GFP 
levels. 
 
R6/1 mice:  A sister strain to R6/2 that has a similar transgene but delayed pathology, 
R6/1 mice (26) were also bred and tested at numerous time points. A similar 
progression to that seen in R6/2 was observed for R6/1 (Figure 10B), with the expected 
delay of progression. A subtle but statistically significant decline (to 94% of wild type 
levels) was observed at 4 weeks of age. GFP levels had declined precipitously by 7 
weeks of age in R6/1, plateauing at 35% of wild type levels by 16 weeks of age; no 
further decline was seen in 20-week-old animals, when morbidity precludes further 
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aging. Variance was even smaller in R6/1 mice than that seen in R6/2, possibly due to 
the uniform C57BL/6 background of R6/1. Power analysis in this strain (Table 1) 
suggests a 10% rescue in 7-week-old mice requires only 7 animals. Furthermore, by 16 
weeks of age, when D2GFP loss is no longer progressive, only 3 mice could reliably 
detect a 5% rescue. As estimated by power model curve fitting (Figure 11), R6/1 mice 
lose D2GFP at half the rate of R6/2 mice upon onset (23% per week in R6/1 versus 
54% per week in R6/2), though the age of onset is ~4 weeks for both strains. 
 
CAG140 mice:  Knockin models of HD either introduce an expanded CAG repeat 
into exon 1 of mouse Htt, or have the Htt gene modified to contain a hybrid 
human/mouse exon 1 with an expanded CAG repeat. In contrast to the R6 lines, most 
knockin lines (including CAG140 and HdhQ111) show no reduction in lifespan (30,31), 
even when bred to homozygosity. However, heterozygous CAG140 (also known as 
HdhQ140) mice (Figure 10C) demonstrated significant GFP loss as early as 12 weeks 
of age, to 81% of controls. D2GFP decline progresses through 31 weeks of age before 
plateauing at ~62% of wild type levels. This D2GFP loss is prior to the reported rotarod 
latency deficit, and is also prior to the age at which reliable detection of Drd2 loss by in 
situ hybridization is reported (32). Before plateauing, this strain demonstrates greater 
variance at the younger ages tested. Normalized GFP values ranged between 92% and 
68% of wild type values at 12 weeks of age and between 74% and 59% of wild type 
levels at 24 weeks of age. However, by 31 weeks of age, when progression had halted, 
variance was small enough that power analysis (Table 1) suggests only 6 mice would 
be sufficient for detection of a 10% rescue in GFP loss. Curve fitting (Figure 11) 
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estimates an age of onset of 7.5 weeks, and an initial rate of 5% per week lost. 
 
HdhQ111 mice: HdhQ111 mice are another knockin HD model, and were also 
tested in this assay, though I chose to compare HdhQ111 homozygotes to 
heterozygotes. According to a previous report by the strain’s generator, heterozygotes 
and homozygotes have few reported differences (33), but if this assay is sensitive it 
should readily distinguish the two genotypes. Comparing homozygotes to heterozygotes 
(Figure 10D) also demonstrated progressive GFP loss, beginning at 6 months of age. 
As in the CAG140 mice, the decline was significant early on, to 82% of heterozygote 
levels, but was more variable, ranging between 94% and 67%. By 12 months of age, 
homozygote D2GFP had reached 59% of heterozygote levels and variance was minimal 
in the three mice tested. Power analysis (Table 1) demonstrates a quite robust assay at 
12 months of age, requiring only 5 mice for detection of a 10% rescue. Compared to 
heterozygotes, homozygotes begin their D2GFP decline at ~18 weeks of age with a 
3.1% per week initial loss rate (Figure 11). 
 
N171-82Q mice: Like R6/2 and R6/1 mice, the N-terminal transgenic strain N171-
82Q has strong neuropathology (34,35) and a diminished lifespan. However, after 
crossing to D2GFP mice and aging, I was not able to detect a consistent decline in GFP 
levels (Figure 10E). While some animals showed no detectible decline, others had lost 
as much as 40% of D2GFP levels (Figure 10F). This is reminiscent of what was seen 
for young (<20 weeks of age) CAG140 mice, although even in spite of high variance in 
young mice from that strain, there is a progressive decline in mean levels, where no 
 159 
progression is present for N171-82Q animals. Unlike R6/2 and R6/1 mice, there is 
pervasive cell death in N171-82Q MSNs (35), so it is possible that there is selection 
against cells with strong toxic responses that would otherwise facilitate significant Drd2 
loss in surviving neurons. This seems unlikely, though, simply based on the wildly 
variant phenotype, which seems to manifest as incomplete penetrance.  
 
BACHD mice:  BACHD mice have become a popular strain in the last few years 
(36) for many reasons, including an interrupted repeat preventing intergenerational or 
somatic CAG repeat expansion, as well as some neuropathological features that are 
more reminiscent of human HD than is typical for mouse models. However, it has been 
previously published in a study comparing the two most commonly used full-length 
transgenic models, YAC128 and BACHD, that in spite of their numerous similarities, 
BACHD mice fail to display transcriptional dysregulation as assessed by QPCR (37). 
Their data were convincing, but I wanted to see whether my particularly sensitive 
method would be able to detect a difference where previous less-sensitive methods had 
not. However, after aging BACHD mice for 9 months, the GFP profiles of the transgenic 
littermates were indistinguishable from that of the wild type animals (Figure 10G). 
Animals aged further may produce dysregulation, but this strain exhibits significant 
mortality in my colony when animals reach ~12 months of age, precluding detailed 
studies in older mice. 
 
D2GFP Levels Decline in Wild Type Animals 
The assay I have developed demonstrates remarkable day-to-day and 
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instrument-to-instrument robustness. This is mainly because each experiment is done 
with a cohort containing one or more wild type animals, to which all mutant animals are 
normalized. The absolute GFP values from many cytometers will vary widely, but 
because flow cytometry accurately quantitates fluorescence over several orders of 
magnitude, the absolute values are irrelevant after normalization. That being said, this 
precludes analysis of data between days. Ideally, a given cytometer would produce the 
same value from an identical sample on any given day (assuming instrument 
parameters like filter sets and voltages are kept constant). In practice, however, this is 
often not the case; something as simple as replacing a filter, let alone a laser, will 
change the absolute values produced, and with an assay as sensitive as this one, even 
subtle changes would prevent such cross-cohort analysis. 
With this in mind, I wanted to assess whether there is any change in D2GFP 
levels as wild type animals age. For this, I used wild type littermates from R6/1 x 
D2GFP matings of a variety of ages, and processed them all on one day (Figure 12). 
There was a significant decline in D2GFP levels as the wild type animals aged from 4 to 
21 weeks of age, still very young in the life of these mice (~100 week lifespan). I have 
not done further analysis to determine whether this change is specific to the GFP 
transgene or represents decline of Drd2, but the minor loss (15% after 21 weeks) pales 
in comparison to that seen in their R6/1 littermates, whose GFP decline was re-plotted, 
adjusted for the declined GFP levels present in wild type mice. Hence, while wild type 
animals lose ~15% of their original (4 week old) GFP levels by 20 weeks of age, R6/1 




Quantitative markers for neuropathologic progression in HD mice are few and far 
between. Standard measures for evaluating phenotypic progression are survival, 
rotarod, or mHTT aggregation, occasionally including volumetric assessments (36,38-
41). In these and many other studies, the power of the assay (i.e. the phenotype’s effect 
size and variance) and the difficulty of assessing it determine the required resource 
investment. Typically, a rescue on the order of 30% requires 10-20 animals for reliable 
detection. Because most of these strains have somewhat complicated breeding 
requirements and, by their nature, need to be aged before sacrifice and tissue 
investigation, testing even a single compound necessitates a substantial investment. 
Any method by which ineffective candidates can be efficiently eliminated or 
recommended for further study is valuable. For therapeutic modalities that have been 
identified through cell based systems or chemically based screens, the systems 
described here provide the opportunity to rapidly and systematically measure efficacy in 
vivo, at powers facilitating the evaluation of multiple dosages and time points without 
becoming a practical burden. 
Several promising therapies based on modulation of known disease-related 
pathways have failed at either the preclinical or clinical stages, and this might be the 
result of correcting one downstream pathway while leaving the many other disease 
processes uncorrected. A truly promising therapeutic will likely need to target the core 
pathogenic mechanisms in HD, of which it is reasonable to believe transcriptional 
dysregulation to be one. It appears early and influences the levels of many genes 
involved in the highly pleiotropic response to polyglutamine toxicity, suggesting that 
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demonstration of transcriptional normalization could signify a fundamental molecular 
intervention. 
The ability to relatively rapidly and quantitatively measure the impact of 
therapeutic intervention on a full-length model of disease for HD is of particular 
importance. From a candidate evaluation perspective, N-terminal fragment models have 
a more rapid and severe pathology in nearly all known tests when compared to full-
length models (including CAG140 and HdhQ111), a pattern recapitulated in our assay. 
The predictability of the D2GFP decline allows one to rapidly pilot potential therapeutics 
in fragment models and assess efficacy before deciding whether to extend the study to 
larger cohorts or slower full-length models. These strains are based on the configuration 
of the HD expanded repeat in its native environment and are critical for most effectively 
reflecting the situation encountered in the HD patient. The ability to make a go/no-go 
decision in a small cohort, within a matter of weeks and with great statistical confidence, 
may significantly improve the rate of progress in assessing potential HD therapies.  
The techniques developed are not limited to the study of Drd2, or even of HD. 
Drd2 was chosen to develop for many reasons, though others were an option. The 
GENSAT project, for example, contains hundreds of validated strains of mice, making it 
a good place to search for already-existing strains. However, I wanted a marker whose 
change occurred early in disease progression. Murine models commonly demonstrate 
transcriptional profile changes prior to overt symptom onset. This is important from a 
therapeutic evaluation perspective, because as has been demonstrated in patients, by 
the time symptoms have set in, there may be little that can be done to improve patient 
lives other than providing pharmacological symptom management; neurorestorative 
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tissue transplants are still too ineffective for use. Drd2 dysregulation is an early and 
common effect in HD patients and models, consistently occurring before symptom 
onset, so I reasoned that protection of its dysregulation could indicate a neuroprotective 
effect, rather than just symptom management.  
Another advantage provided by Drd2 is its cell type specificity. Admittedly, a 
marker common to all neurons in the striatum whose levels decline would have allowed 
me to effectively double the number of cells useable in a given piece of tissue. 
However, the striatum, as with all other brain structures, is not a uniform tissue. In this 
case, the cells project to either the globus pallidus or the substantia nigra, in roughly 
equal ratios. While both cell types certainly undergo dysfunction, those of the indirect 
(striatopalladial) pathway seem to be affected earliest in adult onset patients. This 
explains the impairment of motor control and dyskinesia, whereas blockade of the direct 
(striatonigral) pathway leads to bradykinesia (21). Drd2 is one of the primary markers of 
indirect pathway MSNs, so its specific study not only ensures that my population is as 
uniform as possible, but represents the cells hit earliest and hardest by mHTT toxicity. 
I have, however, demonstrated that my technique can be used to evaluate at 
least two other fluorescent models (D1tdTomato and CDG2GFP), in at least two 
different tissues (striatum and cortex). It stands to reason that any neuronal population 
of interest could be monitored accurately for the dysregulation of a marker of choice, 
provided a fluorescent protein-expressing strain exists. Also, at least two markers can 
be monitored simultaneously, provided they occupy different fluorescent spectra. 
Finally, other neurological diseases also demonstrate transcriptional dysregulation. In 
Alzheimer’s Disease patients and mouse models, Sp1 is elevated, potentially producing 
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wide ranging effects on relevant genes including APP and Tau (42). Furthermore, EGR1 
transcription factor binding sites are common among dysregulated genes (43), 
suggesting a pathogenic mechanism whose progress could be followed by monitoring 
one or more downstream dysregulated transcripts, similar to the approach taken in HD 
for REST/NRSF or Sp1 dysregulation. Meanwhile, FoxO1-regulated genes are 
upregulated in Parkinson’s Disease (PD), and there may be an impact on PD age of 
onset for certain SNPs in FoxO1 itself (44). It remains to be seen whether other disease 
models can leverage transcriptional dysregulation for a quantitative fluorescent marker, 
but there is nothing about this assay or the underlying biology to suggest that the 
techniques are only relevant for HD models. 
The robustness of HD transcriptional profile alterations is remarkable, but it can’t 
be ignored that it does not appear to be ubiquitous. As others have shown (37) and I 
verified, BACHD animals have no dysregulation of Drd2. There is no simple explanation 
for why every single mouse model of HD that has been tested has demonstrated 
transcriptional profile changes other than BACHD. The closest strain to it, YAC128, was 
also generated by transgenic implantation of full-length mHTT with a large span of 
surrounding genome, and these mice have reproducible transcriptional alterations. It is 
formally possible that the transgene insertion site may have impacted a modifier, or that 
differences in the genomic regions surrounding mHTT can be modulating the 
transgene’s effects. These are difficult to investigate, and the latter would likely only 
affect the transgene’s levels, which would primarily alter the age of onset. On the other 
hand, because they were generated using two different individuals’ HTT genes, there 
are different SNP markers between the two strains (45). Notably, there is little evidence 
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that SNPs within the HTT region can affect age of onset (46). Instead, it seems most 
likely that a SNP the BACHD transgene subtly alters either the proteolysis of mHTT or 
its posttranslational modifications, impacting its subcellular localization. Indeed, in spite 
of their identical strain background (FVB) and similar mHTT expression levels, BACHD 
mHTT produces very few striatal intranuclear inclusion bodies, while YAC128 mice have 
pervasive striatal aggregation (36,37,39). This at least demonstrates a difference in 
subcellular localization of the N-terminal fragment. Furthermore, because Sp1 
aberrantly interacts with N-terminal mHTT (47), it seems most likely that mHTT spends 
too little time in the nucleus of BACHD mice to significantly impact Sp1-regulated 
transcripts, including Drd2. That these animals demonstrate other pathological sequelae 
common to HD tells us that the dysregulation of Sp1 targets is not necessary for many 
HD symptoms. That being said, the fact that virtually every other model of HD shows 
both intranuclear inclusions and a similarly altered transcriptional profile strongly 
suggests that the failure to produce such a phenotype from BACHD mice may simply be 
an artifact of a unique transgene in that strain, rather than evidence of the irrelevance of 
transcriptional dysregulation to HD pathology. 
The inconsistency of the N171-82Q D2GFP phenotype is another matter. N171-
82Q mice have demonstrable transcriptional profile alterations, with striking similarity to 
that of R6/2 animals (48), though interestingly, Drd2 showed variability in this study as 
well, as one replicate produced significant downregulation, while the other showed no 
change. The variability could be due to the breeding scheme, which involves crossing a 
male in each generation to an F1 animal from a C57BL/6 x C3H mating. A similar 
scheme is used for R6/2 animals (C57BL/6 x CBA F1 offspring), but this strain has a 
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consistent phenotype, so a mixed genetic background alone cannot explain it. However, 
a polymorphism within the C3H background could be impacting dysregulation. I have 
not initiated any of the kinds of crossing studies, such as those using recombinant 
inbred lines, to investigate this in detail, but one example is of particular interest. It is 
known that C3H mice lack the Tlr4 receptor (49), impacting their response to 
inflammatory stimuli. Because there is substantial evidence for a role of inflammation in 
neurodegenerative diseases, including HD, this is a reasonable candidate, and is being 
actively investigated in our group. 
All told, I have developed an assay method for following HD progression in model 
mice, whose consistency in many of the most commonly used strains is unparalleled by 
conventional methodology, and that can be assayed in a fraction of the time. That killing 
the animal is required for the assay precludes its use for longitudinal studies (unless 
substantial improvements are made in in vivo fluorescent imaging methods), and only 
one gene of many relevant choices is assayed, which are its chief limitations. 
Nevertheless, only one piece of striatal tissue is required to rapidly analyze for GFP 
alteration, leaving the other parts of the animal available for more detailed, lengthy, and 
costly analyses should the D2GFP assay suggest value to such studies. Every common 
measure of pathogenic process (inclusion body formation, volumetric alterations [as 
measured by ventricle enlargement], motor impairment, weight loss, diminished 
lifespan, and consistent transcriptional alterations) has been demonstrated in HD mice 
carrying the D2GFP transgene, so its presence clearly fails to alter pathology and hence 
allows other analyses to take place without fear of being modified by GFP transgene 
expression. These experiments provide sensitive, quantitative data on the dysregulation 
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of a relevant gene representative of the early stages of polyglutamine toxicity, but 
further testing must take place before the assay can be recommended as a 
commonplace inclusion in preclinical drug development. Chapter 5 will cover my efforts 
to both induce and ameliorate this phenotype with viral vector delivered transgenes, as 
well as an attempt to use D2GFP dysregulation for the evaluation of a small molecule’s 







Figure 1: D2GFP mice bred to HD model mice demonstrate visible reduction in 
GFP, and apparent mHTT aggregates. (A) Coronal sections of brains from mice (12 
weeks of age) carrying the D2GFP transgene demonstrate robust GFP expression in 
the striatum, including visible axons travelling through the ventral striatum towards the 
globus pallidus. (B) A littermate of the animal in (A) but expressing N-terminal mHTT 
(strain R6/1) has reduced absolute GFP expression with a similar anatomic pattern. 
Note the enlarged lateral ventricle (outlined in cyan in (A) and (B)). (C) DAPI (blue, 
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nuclear DNA), GFP, and EM48 (red, anti-mHTT antibody) co-staining of the animal from 
(A) indicates that GFP+ cells only represent ~1/2 of the cells in the striatum, the other 
half presumably made of direct MSNs expressing D1 but not D2 dopamine receptors. 
No EM48 staining is apparent. (D) In the animal from (B), a similar pattern (~1/2 of 
neurons are GFP+) is observed with reduced absolute GFP expression. EM48+ 
intranuclear inclusions are pervasive in neurons, but are largely absent from nuclei that 
make up the neuron-poor axon fiber bundles, suggesting that mHTT is less aggregation 
prone in oligodendrocytes. Scale bars represent 1 mm in (A) and (B), 32 µm in (C) and 






Figure 2: HD model mice carrying the D2GFP transgene demonstrate progressive 
motor performance decline. (A) Male mice carrying the D2GFP transgene either with 
or without N-terminal mHTT (D2;R6/1 or D2;WTL) demonstrate only minor weight 
differences as they age. (B) D2;R6/1 mice do, however, show progressive decline in 
performance on the accelerating rotarod beginning at approx. 12 weeks of age. N = 5 
per genotype. WTL = wild type littermate. 
  





























































Figure 3: Transcriptional profiling of D2GFP;R6/1 mice reveals canonical HD-
associated pathways. (A) Hierarchical clustering of all protein-coding genes (N = 
15,416) in the samples produces a separation of wild type and HD mice. (B) When 
focusing on genes that are significantly differentially expressed (N = 1235), this 
clustering does not change, indicating a significant change in global transcriptional 
profile in HD mice. (C) The top 8 listings for selected topics are shown when 
downregulated (left column) or upregulated (right column) genes were analyzed by 
Ingenuity Pathway Analysis or GOrilla gene set enrichment tools. Many are commonly 







Figure 4: GFP+ events are visible by flow cytometry only in mice carrying the 
D2GFP transgene. Striata were dissected and neurons processed into single cell 
suspension as described in the Methods. When analyzed by flow cytometry, a 
population of GFP+ (X axis), DAPI- (Y axis) events is only visible in mice carrying the 








Figure 5: In mice carrying D2GFP, D1tdTomato, and/or CDG2GFP, the appropriate 
populations are visible by flow cytometry. Mice carrying D2GFP only (A), 
D1tdTomato only (B), or both transgenes (C) were analyzed by flow cytometry. Events 
fitting the forward scatter and side scatter profile of MSNs were analyzed for GFP (X 
axis) and RFP (Y axis). Mice carrying only the D2GFP transgene (A) showed GFP+ 
events but no RFP+ events, while those carrying only the D1tdTomato transgene (B) 
showed no GFP+ events but a population of RFP+ events. Double transgenic mice (C) 
showed both populations, but very few events positive for both events, consistent with 


























































































the fact that MSNs typically express either D1 or D2 receptors but rarely both. 
Separately, either cortical or striatal tissue from mice expressing either D2GFP or 
CDG2GFP were subjected to flow cytometry for detection of GFP+, DAPI- events 
(gated). In D2GFP mice (D and E), such events were only seen in the striatum, while 
CDG2GFP animals (F and G) had GFP+ events in both cortex and striatum. This 
agrees with the immunostaining patterns of GFP from these strains (H and I), as 







Figure 6: GFP+ events can be sorted, eliminating debris and dead (DAPI+) events. 
(A) Striata from D2GFP mice, when processed into single cell suspension, contain 
largely debris. (B) Rare GFP+ events, with a size and shape reasonable of a cell, are 
visible, while (C) some other events are DAPI+. Consistent with flow cytometry analysis, 
no cells contain both GFP and DAPI. (D) After sorting, no debris is visble, and all of the 












Figure 7: GFP+, DAPI- events sorted from D2GFP striatal suspensions have 
mRNA profiles consistent with indirect MSNs. After sorting, GFP+, DAPI- events 
from D2GFP mice (striped bars) show enrichment of Drd2, Penk, and Adora2a 
transcripts compared to whole striatum (black bars). These transcripts are known to be 
present in MSNs of the indirect pathway, while those of Drd1a and Tac1 are enriched in 
direct MSNs and are depleted in D2GFP events compared to whole striatum. 
Additionally, Drd2, Penk, and Adora2a were reduced in R6/1 striatum compared to wild 







Figure 8: Flow-sorted D2GFP events can produce viable RNAseq libraries. (A-D) 
Plotted versus the transcripts in whole striatum (X axis), sorted D2GFP RNAseq 
libraries (Y axis) have significant similarities to non-sorted tissue. (E-H) Striatal 
replicates have striking similarities, as do libraries prepared from either 64,000 or 
16,000 D2GFP cells. Further dilutions reveal weaker correlations (16,000 vs. 4000, or 
4000 vs. 1000 cell libraries). (I) Not only are fewer total genes mapped in sorted cell 
libraries (top), but genes with >0 reads have higher absolute FPKM values on the lower 
and upper ends of libraries from fewer cells. (J) Low abundance transcripts in whole 
striatum are completely absent from RNAseq libraries made from fewer sorted cells. (K) 
Transcripts reportedly enriched in direct (top eight) or indirect (bottom seven) MSNs 
also demonstrate either depletion or enrichment in D2GFP MSNs compared to whole 







Figure 9: GFP content from D2GFP neurons can be accurately quantitated using 
Gaussian means regression (GMR). (A) The GFP (X axis) and DAPI (Y axis) profiles 
of wild type mice show a clear population of GFP+ MSNs. (B) Similar profiles from 16 
week old R6/1 animals are nearly identical, except for the reduced GFP content of the 
cells. (C) When viewed as a histogram, the GFP+ events appear to each contain two 
distributions. (D) These distributions can be computationally separated using Gaussian 
means regression (in red and magenta, the two distributions from an R6/1 mouse; in 
blue and cyan, the distributions from a wild type mouse). (E) For the purposes of 
quantification, the mean of the higher (right-most) distribution is used as an animal’s 
GFP level. (F) When such analysis is performed, animals within a cohort can 
demonstrate striking similarity within a genotype. For (C) through (F), R6/1 is plotted in 









Figure 10: When quantified by Gaussian means regression, most strains of HD 
model mice show remarkable intra-cohort consistency in their GFP declines. 
MSNs from D2GFP mice crossed to the R6/2 (A) and R6/1 (B) strains show a rapid and 
consistent decline in GFP levels, reaching a floor of approximately 35% of control levels 
in both strains by end stage. Two knockin strains, CAG140 (C) and HdhQ111 (D), also 
demonstrate a decline in MSN GFP levels, though it is less consistent in young animals. 
Both strains have a similar floor of ~60% of control levels. However, this phenotype is 
not universal in HD model mice. D2;N171-82Q animals (E) have a highly inconsistent 
phenotype in spite of statistically significant differences. Looking at each individual 
N171-82Q’s normalized GFP levels (F), it is clear that penetrance is incomplete and the 
degree of impairment is highly variable; also, there appears to be no worsening as mice 
age. Additionally, mice of the strain BACHD (G) show no significant decline in GFP at 9 
months of age. (ns) = not significant; (*) = P < 0.05; (**) = P < 0.01; (#) = P < 0.001. For 
strains R6/2, R6/1, CAG140, N171-82Q, and BACHD, comparisons were between 
hemi- or heterozygous mice and wild type littermates. For strain HdhQ111, comparisons 






Figure 11: GFP analysis can be used to predict age of onset and rate of GFP loss 
for strains at a given age. The data from Figure 10, when scatter plotted and curve 
fitted, can be used to predict the age of onset for a given strain (the age at which the 
curve crosses the 100 value, representing the latest age at which the genotypes are 
expected to have equal GFP levels to controls). In addition, this fit curve can give the 
rate of decline at a given age, shown calculated for the initial rate of decline (the slope 
at the age of onset). The different floors of the strains as well as the differences 








Figure 12: D2GFP levels decline over time in wild type mice. Because each sample 
collection is internally calibrated to control littermates, there is no reliable way to 
compare the absolute GFP values between cohorts gathered on different days, as the 
cytometer settings can be altered, producing significant differences. For this reason, to 
analyze GFP changes in wild type animals, several cohorts of different ages (blue) were 
analyzed on the same day, demonstrating a weak decline in GFP values over 21 weeks 
(two animals per age, analyzed in duplicate). For comparison, the decline of R6/1 mice 
is plotted (red), having been readjusted to the wild type values expected from the 








Table 1: Power analyses for D2GFP levels versus control in HD models. Based on 
the mean and standard deviations of the normalized GFP levels (Mean±SD GFP) for 
selected cohorts, power analysis was carried out (power = 80%, P = 0.05) to determine 
how many animals would be required to reliably (80% chance) detect a given degree of 
therapeutic D2GFP rescue at a significance of P ≤ 0.05. PI = Post-infection. Note: the 
final experiment listed (Q94 AAV) is described in Chapter 5, but was included in this 
table for context. 
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CHAPTER 5 – ASSESSING AAV AND CYSTAMINE MODULATION OF D2GFP LOSS 
 
Introduction 
My D2GFP flow cytometry assay has potential as a preclinical assay. For further 
validation, I wished to see whether the phenotype could be altered genetically or 
pharmacologically. For genetic modulation, there is a substantial literature on the ability 
to introduce, upregulate, or downregulate potential modifiers of HD in mice in order to 
investigate the therapeutic potential in altering a given gene or pathway. A sampling of 
such studies accomplished purely through crossbreeding is given in Table 1. Studies 
are often done genetically because relatively few proteins of interest have an activity 
that can be drugged with enough specificity and proper pharmacokinetics to obtain a 
relevant result. Such drugs can often be developed through a concerted effort including 
small molecule library screening and medicinal chemistry, but the research community 
must be sure that modulating a given target will actually have a beneficial impact in HD 
models before devoting the time and resources to identifying such a molecule.  
The studies in Table 1 were each designed based on the belief that knockout or 
overexpression of a given gene is expected to modulate a pathway relevant to mHTT 
toxicity. While most were able to come to conclusive results, they require a tremendous 
amount of resources in the form of time and material investment. With my D2GFP flow 
cytometry assay, there is now a rapid way of measuring the progression of a single 
disease-relevant phenotype in small cohorts of animals. At minimum, there is potential 
here for using this assay as a pre-screen of sorts. Clearly, proper preclinical trials 
require careful behavioral and neuropathological analyses to detect improvement, but 
 201 
many of the trials in Table 1 demonstrated transcriptional improvements in addition to 
the motor, behavioral, and/or survival benefits. Importantly, none tested for and failed to 
detect transcriptional rescue while succeeding in demonstrating behavioral 
normalization. Because of the pleiotropic nature of transcriptional dysregulation and its 
appearance prior to most behavioral symptoms, it is plausible that rescue of the HD 
transcription profile (as measured by rescue of D2GFP loss) would be an ideal early 
signal that a given modifier or drug warrants further study. 
While this could be achieved by crossing knockout or transgenic strains into the 
D2GFP;HD background, there are several advantages to using viral vectors for the 
introduction of transgenes. Rather than working to acquire and breed knockout or 
transgenic strains into D2GFP;HD model mice, transgenes or knockdown constructs 
can be cloned and validated rapidly in tissue culture prior to delivery to D2GFP;HD 
animals. There would be less of an opportunity to test for behavioral improvements, 
which would require significant infectivity in the tissue, but as I will demonstrate, the flow 
cytometry protocol allows for conclusive results to be generated despite minimal tissue 
infectivity. This only requires that the vector co-delivers a fluorescent protein in a 
different fluorescence spectrum to that of GFP (in this case, RFP).  
Therefore, to further test and validate the potential of my D2GFP flow cytometry 
assay in preclinical therapeutic testing, I constructed viral vectors to both induce and 
ameliorate this phenotype, and assayed for protection as either single vectors or in a 
pool. Additionally, I tested a small molecule (currently in clinical trials), cystamine, for an 
ability to alter transcriptional dysregulation as reported by D2GFP levels. It is my hope 
that the availability of a rapid, quantitative reporter system in the mouse brain for HD 
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pathology will improve the rapidity with which therapeutic interventions for HD can be 
discovered, validated and made ready for human clinical use. 
 
Methods 
Mice breeding, rotarod, flow cytometry of MSNs, QPCR, and RNAseq:  Please see 
the Methods section of Chapter 4 for detailed protocols on our mouse breeding 
schemes, rotarod analysis, papain dissociation of MSNs, and transcriptional analysis by 
QPCR and RNAseq. 
 
Cystamine treatment:  Cystamine dihydrochloride (Sigma) was prepared to 15 
mg/mL in PBS and filter sterilized (0.2 µm), and was either used fresh or stored at -
20°C. PBS vehicle was prepared identically. Mice were dosed IP to 150 mg/kg by giving 
0.01 mL per 1 g weight. On days when mice were tested on the rotarod, dosage came 
after all three rotarod trials. 
 
Small-scale AAV production and purification: Viral capsids were assembled by 
cotransfection (TransIT LT1, Mirus, or calcium phosphate) of 32 µg AAV vector with 96 
µg AAV rep2/cap1 helper plasmid (pDP1rs, PlasmidFactory) into a pair of 15 cm dishes 
of AAV-293 cells (Stratagene). Media was changed 24 hours post-transfection, and 
virus harvested 72 hours post-transfection. Cells were scraped, spun down (1100xg for 
5 mins), and pellets resuspended in 5 mL PBS while media was kept and set aside. 
Next, cells were lysed by three successive freeze-thaw cycles (freeze in dry ice / 
ethanol, thaw in 37˚C water bath). Finally, the lysate was clarified by spinning at 3700xg 
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for 20 mins at 4˚C. Clarified lysate was mixed with media, and precipitated with a PEG – 
NaCl solution (5x solution contained 40% PEG-8000, 2.5 M NaCl, sterilized by 
autoclaving, and stored at RT). Precipitation took place at 4°C for >2 hrs, then pellets 
were spun at 2500xg for 30 mins at 4°C. Pellets were resuspended thoroughly in 4 mL 
PBS. AAV was next purified from the resuspended PEG precipitate using a stepwise 
iodixanol density gradient. Iodixianol (OptiPrep, 60% iodixanol solution, Sigma) buffers 
of various concentrations were prepared and underlayed into Beckman Ultra-Clear 
tubes (Catalog # 344085) as follows. First (top) layer, 3 mL: 15% iodixanol in PBS / 1 
mM MgCl2 (PBSM) with 0.86 M NaCl. Second layer, 2 mL: 25% iodixanol in PBSM. 
Third layer, 2 mL: 40% iodixanol in PBSM. Fourth (bottom) layer, 2 mL: 54% iodixanol in 
1x PBSM. Viral lysate was then added up to the top of the tubes. The tubes were sealed 
with appropriate caps, and centrifuged at 40,000 rpm (150,000xg average) for 3.5 hrs at 
18˚C. Layer 3 (second-to-bottom, 40% iodixanol) was collected with a syringe (18G) 
and concentration / LRS buffer exchange was carried out with 2-3 successive spins in 
Amicon Ultra-4 100K columns (Millipore), first 1500xg for ~25 mins, then 4000xg for ~15 
mins, at 18˚C. Concentrated virus was titered by QPCR (PCR primers directed against 
the CAG promoter) and used for delivery in vivo. Viral titers were 1-2 x 1012 vector 
genomes/mL. 
 
Stereotaxic delivery of AAV to mouse striatum: Animals (4 or 5 weeks of age) were 
given preemptive analgesia (0.1 mg/kg buprenorphine, 1.5 mg/kg meloxicam) and 
anesthetized (10 mg/kg xylazine, 120 mg/kg ketamine). The head was shaved, the 
animal was mounted into a stereotaxic frame, and the scalp sterilized prior to a 1 cm 
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midline incision to the scalp. Stereotaxic coordinates (left striatum) were 0.7 mm 
anterior, 1.8 mm left, and 3.5 mm ventral to bregma. A syringe (5 µL, Hamilton) carrying 
3 µL virus was lowered and left in place for 5 mins. Virus was injected at 0.2 µL/min, 
and the needle was left in place for 3 mins post-injection, raised by 0.5 mm, then left for 
a further 4 mins before removal and wound closure. Animals were fed wet food for the 
first day post-op, and were singly housed after surgery until euthanasia. 
 
Direct PCR of shRNA transgenes from flow sorted neurons: PCR amplification of the 
shRNA transgenes from sorted cells was specifically designed to perform only the 
minimal number of cycles required to gel isolate the amplified band. Cells were 
collected and spun down (2000xg), and the supernatant removed. 50 µL reactions of 
PCR Reaction 1 were prepared (Phire Direct PCR kit: 25 µL 2x Mix, 22 µL H2O, 2 µL of 
a 5 µM barcoded primer stock, 1 µL Phire DNA polymerase). These 50 µL reaction 
mixes were added to the pelleted cells and mixed thoroughly, then incubated at RT for 5 
mins. PCR Reaction 1 was performed for 22 cycles using the following cycling 
parameters: 
Step 1: 50°C, 2 min 
Step 2: 95°C, 10 min 
Step 3: 98°C, 10 seconds 
Step 4: 71°C, 1 min 
Repeat of Steps 3-4 for a total of 22 cycles 
PCR Reaction 2 was prepared (Phire Direct PCR kit: 30 µL 2x Mix, 23.3 µL H2O, 2.4 µL 
of a 5 µM barcoded primer stock, 1.2 µL Phire DNA polymerase), enough for 60 µL 
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reactions per sample, and 3.1 µL of Reaction 1 was added to the appropriate PCR 
Reaction 2 (taking care to match the barcoded primers used), while the remainder of 
Reaction 1 was kept on ice. All Reaction 2 samples were mixed thoroughly and split into 
four 15 µL sub-reactions, which were cycled as follows: 
Step 1: 50°C, 2 min 
Step 2: 95°C, 10 min 
Step 3: 98°C, 10 seconds 
Step 4: 71°C, 1 min 
Repeat of steps 3-4, total of either 4, 8, 12, or 16 cycles. 
The sub-reactions were run on a 2% agarose gel to determine how many additional 
cycles of PCR Reaction 1 are required for proper amplification of the shRNA transgene 
(180 bp including primers), which is represented by first identifying the reaction at which 
this band is just clear enough for proper gel cutting, and then subtracting 4 from this (as 
PCR Reaction 2 includes 1/16 of PCR Reaction 1). PCR Reaction 1 was then cycled 
additionally (Steps 3-4) as appropriate, and was loaded in its entirety and run on a 2% 
gel for isolation of the 180 bp band. This band was submitted for Illumina sequencing, 
and reads were mapped to the predicted PCR products for each hairpin vector and 
counted.  
 
Barcoded PCR primers used were as follows: 





Reverse primer (NNNNN designates barcode for multiplex analysis, and terminates 





Adeno-associated Viral Vector Production and Purification  
To deliver exogenous transgenes by AAV vector, I chose to produce the vectors 
myself rather than have them made for me by an outside group. This was because I 
anticipated needing many different vector preps, and both industrial and academic viral 
core facilities are expensive (~$2000-$5000 per prep by a survey of various sources) 
and slow (no less than 2 months). Thus, I adapted previous protocols (1) and began 
subcloning and producing my own AAV vectors capable of use in vivo. For most small-
scale preps, the producer cell line is the standard HEK293, for many reasons. They are 
commonly available in most labs, are easy to culture, and are readily transfected. 
Importantly, they also naturally express an essential protein for AAV production, 
adenoviral E1 (the cell line was originally immortalized by introduction of sheared 
adenoviral DNA, as E1 inhibits p53 and Rb in a similar mechanism to SV40 large T 
antigen). Because AAV production requires E1 and several other adenoviral proteins, 
plus the two essential AAV cistrons (Rep and Cap), those not already in the cell line can 
be transiently transfected along with the vector plasmid for efficient AAV production and 
encapsidation.  
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A schematic for the production and purification is presented in Figure 1A, and is 
discussed in detail in the Materials and Methods. In short, virus is found both in the 
cytosol and in the media due to cell rupturing. To collect both, the clarified lysate is 
combined with the cell media, and viral particles in both are precipitated with 
polyethylene glycol. After centrifugation, this pellet contains many cellular proteins and 
vector particles, which are further purified by stepwise iodixanol density gradient 
ultracentrifugation. Vectors equilibrate in the third layer, and can be concentrated and 
buffer exchanged by dialysis or spin column concentrated (100 kDa MW cutoff) prior to 
delivery. A sample of the proteins present at each stage is shown in Figure 1B. As AAV 
infectivity is highly variable in culture (2), it is poorly predictive of in vivo infectivity; 
hence, rather than infectious units, titers are usually simply reported as genome copies 
per mL (GC/mL), determined by dot blot or QPCR. 
 
AAV-delivered Transgenes Require 2 weeks for Activation in MSNs 
 To establish both the ability to identify AAV-infected cells by flow cytometry and 
the minimal incubation time, mice were injected with AAV vectors and incubated for 1, 
2, 3, or 4 weeks, then harvested and their striata processed for flow cytometry (Figure 
2A-D). All four demonstrated RFP fluorescence only in the injected hemisphere 
(uninjected not shown), but substantial transgene expression was not reached until two 
weeks post-injection. Cells identifiable as infected (Figure 2E) were specifically checked 
for the amount of visible RFP, which also required at least 2 weeks for maximum cell-
by-cell transgene expression. This means the delay is not one of variable infectivity 
(some cells becoming infected sooner than others and reaching maximal transgene 
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expression quickly thereafter), but instead is a delay of transgene expression within the 
infected cells. 
 
Exon 1 of HTT is Cytosolic, and Forms Perinuclear Inclusions Only with an 
Expanded polyQ 
 To demonstrate whether AAV-delivered transgenes can alter D2GFP levels, first 
I tested whether it can be induced acutely by exogenously-delivered mHTT. To do so, I 
cloned exon 1 of HTT into an AAV vector that I had prepared for shRNA delivery (Figure 
3A). Because I wanted to be able to identify infected cells on the flow cytometer, I 
cloned the HTT fragment in frame with an RFP (specifically, AsRed) separated by a 
self-cleaving T2a peptide. There is evidence that this peptide cleaves, but incompletely 
(3), and I also observed this pattern. Transiently transfected HEK293 cells expressing 
the Q20-2a-RFP construct demonstrated significant cytosolic and nuclear fluorescence 
(Figure 3B), but nuclear RFP is the result of post-cleavage diffusion, as demonstrated 
by the absence of nuclear fluorescence in cells transfected by a similar construct 
missing the 2a peptide (Figure 3B inset). Meanwhile, HTT exon 1 with a pathogenic 
polyQ repeat (Q94-2a-RFP) shows similar cytosolic and nuclear fluorescence, but also 
the presence of inclusion bodies. This means the RFP present there is either 
fluorescing after becoming caught in the inclusions, or is the result of non-cleaved 
fusion proteins associating with inclusions through mHTT. The latter seems more likely, 
because fluorescent proteins are highly β-sheet rich, but if they associated with 
inclusions without the aid of fused mHTT, they would likely become denatured to the 
point of non-fluorescence. Histological sections from D2GFP mice carrying mHTT 
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transgenes support this, as there is no evidence of GFP flurescence in EM48+ inclusion 
bodies (Chapter 4, Figure 1D). Cells transfected with Q94-RFP constructs lacking the 
2a peptide (Figure 3C inset) show similar inclusions, mostly found in cells without any 
other cytosolic or nuclear fluorescence, suggesting that most of the mHTT in these cells 
finds its way into inclusions. 
 
mHTT Exon 1 Induces an Acute Drop in D2GFP Levels 
The Q20-2a-RFP and Q94-2a-RFP constructs were packaged into AAV2/1 
(genomic cis-elements from AAV2, capsid from AAV1) as described above, and 
delivered to the striatum of adult D2GFP animals (5 weeks of age). After a brief 4-week 
incubation period, where the transgene would only be expected to be fully active for 2 
weeks, the mice were sacrificed and their striata processed for flow cytometry. In spite 
of low infectivity, RFP+ MSNs were visible in both groups (Figure 4A-B). However, 
because of the single-cell nature of the analysis, I do not rely on whole-tissue 
assessment of pathologic changes, so I can rapidly assess the specific impact of the 
transgene on infected cells, with the uninfected cells serving as an internal control. By 
separating the populations and analyzing their respective D2GFP levels (Figure 4C-D), I 
observed a significant reduction of GFP only in cells infected with the Q94 construct. 
When quantified (Figure 4E), this resulted in a 54% loss (P = 0.0013). 
 Closer inspection of the profiles of the Q94 infected mice suggested a possible 
correlation between higher RFP levels and lower GFP levels within the population. 
Because RFP and mHTT are monocistronic in the vector, they are produced in a 1:1 
ratio, so cells with twice as much RFP fluorescence can be expected to have twice as 
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much mHTT, perhaps leading to more severe pathology and D2GFP loss. Analyzing 
these Q94 RFP+ populations (Figure 4F-I) revealed a significant correlation in 2 of 3 
mice, and for the three populations analyzed as one. Significance was interrogated by 
permuting the RFP values 100,000 times and counting how often the resulting 
randomized population demonstrated stronger correlation than the original. These 
results demonstrate that transcriptional dysregulation can be acutely induced by 
expression of mHTT in adulthood, that AAV represents a rapid means of assessing the 
impact of mHTT on transcript levels, and that the amount of mHTT present in a given 
cell impacts the severity of the D2GFP loss. 
 
Demonstration of Therapeutic Impact of an AAV-delivered shRNA Using the 
D2GFP FACS Assay 
 To further determine whether the observed progressive loss of GFP in D2GFP-
expressing HD model mice is dependent on mHTT expression and could be alleviated 
by therapeutic intervention, I produced AAV vectors delivering two genes: RFP, and one 
of two short hairpin RNAs (shRNAs) (Figure 5A). shRNAs are short transcripts 
consisting of sense and antisense sequences of ~21 nucleotides separated by a small 
loop sequence, and they engage the RNAi machinery in the cell (4), degrading target 
mRNAs for which perfect complementarity is present. I generated two shRNA 
sequences, one negative control targeting a transcript absent in MSNs (LacZ, called 
shLacZ) and one targeting the polyCAG tract of HTT (called DhEx1_5). DhEx1_5 can 
effectively reduce HTT exon 1 protein product (Figure 5B) by 74% versus shLacZ, as 
assessed using an mHTT exon 1 fusion with luciferase. These AAV genomes were 
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separately packaged into viral particles (AAV2/1 as above) and delivered to the striatum 
of 4-week-old R6/2 mice in the D2GFP background, 3 mice per vector, and samples 
were harvested at 8 weeks of age (4 weeks post-infection). 
Note that the expected rescue depends not just on the efficacy of the hairpin, but 
also on the duration of exposure, constrained in this case by the AAV life cycle. As 
demonstrated in Figure 2, AAV-delivered transgenes take at least 2 weeks for peak 
expression. I have not yet systematically assessed how long it takes an shRNA 
transgene to reach peak knockdown ability after AAV infection, but if we generously 
assume that the time course is similar to that of RFP expression, it may take 2 weeks 
for mHTT expression to be significantly reduced, and for D2GFP levels to stabilize post-
infection. In this case, I can use the R6/2 progression curve (Chapter 4, Figure 10) to 
predict the maximum rescue. For this experiment, D2;R6/2 mice were injected at 4 
weeks of age and harvested at 8 weeks of age. Halting of D2GFP decline by 2 weeks 
post-infection might cause infected cells’ D2GFP levels to resemble those of 6-week-old 
mice, estimated to be ~51.9% of control, as opposed to ~39.2% of control in uninfected 
cells at 8 weeks of age. This would represent a 21% rescue (reduction in the amount of 
D2GFP lost) under ideal conditions, a small dynamic range for most behavioral assays 
but well above the detection threshold for my D2GFP assay. 
After the brief 4-week incubation, the 8-week-old mice were sacrificed, striata 
were harvested and MSNs analyzed for GFP content. Comparisons were made within 
each striatum between the GFP content of RFP+ (infected) and RFP- (uninfected) cells. 
DhEx1_5 partially protected cells from GFP loss upon aging (Figure 5C). DhEx1_5 
expressing cells’ GFP levels were reduced to 47% of WT levels, while uninfected cells 
 212 
had 39% of WT GFP (Figure 5E), perfectly agreeing with predictions from the time 
course and representing a rescue of 14 ± 4% in infected cells (P = 0.0014, Paired 2-
tailed Student’s T-test). This result is consistent with our power analysis (Chapter 4, 
Table 1), which suggests 8-week-old R6/2 mice require only 2 mice to detect a 10% 
rescue in D2GFP loss. Also, this is ~2/3 of the maximum rescue (21%) under the 
aforementioned assumptions of a 2-week post-infection delay in shRNA expression and 
arrest of D2GFP loss. The control AAV (shLacZ) had no effect on GFP loss (Figure 5D).  
The shRNA data suggest that this AAV system can be used as a rapid, efficient 
system to assess cell autonomous effects of the modulation of a target gene on HD 
transcriptional dysregulation. However, it is worth emphasizing the importance of the 
disease model’s rapidity for the therapeutic window and dynamic range. R6/2 mice have 
an extremely rapid progression, particularly in the D2GFP dysregulation assay, in which 
their levels bottom out by only 8 weeks of age. If an AAV is going to reach peak 
expression prior to the onset of D2GFP loss (4 weeks of age), the vector must be 
introduced to either embryos or pups, which complicates the protocol. On the other 
hand, if the same experimental paradigm were attempted in CAG140 mice (a strain 
whose D2GFP decline begins at ~7.5 weeks of age, as seen in Chapter 4, Figure 10), 
complete rescue of D2GFP dysregulation is plausible, with the tradeoff that this model 
requires ~7 months before reaching sufficient power to allow for small cohorts (Chapter 
4, Table 1).  
 
Knockdown Constructs Delivered as a Pool Reveal Hairpins Against mHTT as 
Enriched in Rescued Cell Populations 
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 The power of this assay in using small cohorts to reliably detect subtle changes 
in D2GFP levels was an unexpected bonus and was worth exploring in detail, as there 
is definitely a paucity of rapid, highly quantitative assays for therapeutic efficacy in HD 
model mice. However, a goal of this project from the beginning was to use GFP rescue 
and flow cytometry as a way of detecting therapeutic rescue within a mixed pool of 
constructs. This has had tremendous power in cancer models (5,6), through which 
genes and pathways specifically relevant to medically relevant to topics like 
chemoresistance can be interrogated in an unbiased way, without the need for 
candidate genes. An obvious advantage that cancer models have for this technique is 
that infections can take place in millions of cells in tissue culture, and enrichment or 
depletion of relevant genes are related to the cell population’s survival, under selective 
pressure in the mouse. Unfortunately for my goals, HD mice do not have significant cell 
death to use survival as a simple genetic selection criterion, which is why D2GFP loss is 
used as a surrogate disease progression measure, allowing rescued cells to be studied 
in isolation. 
 With this in mind, I investigated the potential for this assay to detect disease 
modifying genes by delivering shRNA pools to D2GFP;HD model mice. The 
experimental model is given in Figure 6. Pools of shRNA would be cloned into AAV 
vectors and delivered to the striata of HD model mice in the D2GFP background (Figure 
6A). Upon initial infection (Figure 6B), all cells robustly express GFP, while those 
infected with the virus also express RFP. After the animal ages and pathology begins to 
impact D2GFP levels (Figure 6C), in theory, only those cells infected with therapeutic 
constructs are protected from GFP loss. To practically and powerfully interrogate 
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constructs present in this rescued population, I delivered such pools to R6/2 mice and 
littermate controls, in a small cohort (as the assay robustness suggests few mice are 
required). As illustrated in Figure 6D, I collected the cells with the highest GFP levels as 
a population, and amplified the pool of viral shRNA constructs within by PCR. The 
primers contained bardcodes and adaptors to facilitate multiplex Illumina sequencing. In 
this way, I asked whether given hairpins are found more often in this “high GFP” 
population in HD mice, where selective pressure for loss of GFP is present, versus wild 
type cells under no such pressure. 
 Knockdown constructs against genes of a variety of pathways (Table 2) were 
cloned into the AAV vector. Most of the shRNAs cloned had been pre-validated for 
knockdown efficacy in lentivectors delivered to 3T3 fibroblasts by The RNAi Consortium 
of the Broad Institute, and I re-validated a subset of them to confirm that shRNA 
expression is not impacted in the AAV vector plasmid setting. This was challenging 
because, unlike lentivectors, generating a separate AAV prep for each construct was 
not practical, so infection in vitro was not attempted. However, the cell type used, 
Neuro2a murine neuroblastoma cells, did not transfect efficiently enough to use the 
whole population for knockdown efficacy analysis. Hence, after subcloning into the AAV 
vector plasmid, I transfected cells in culture, and flow sorted the RFP+ cells before RNA 
purification and QPCR (Figure 7). For a large majority of the hairpins, subcloning into 
the AAV vector did not impair their activity. 
 After knockdown validation, a pool was constructed containing 2 shRNAs versus 
each of these 16 genes, plus five against exon 1 of mHTT and one control against 
LacZ. Mice (5 R6/2, 3 wild type, in the D2GFP background) were injected at 4 weeks of 
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age and harvested at 8 weeks of age. Preparation of vector shRNA sequence libraries 
from high-GFP neurons took place as described in Figure 6. Reads of each shRNA 
were analyzed as a population of the total pool, were compared between R6/2 and wild 
type populations, and were reported as enrichment over wild type (Figure 8). In other 
words, if a construct makes up 2% of the library in WTL MSNs but 3% of the library in 
R6/2 MSNs, the enrichment would be reported as 1.5-fold. 
 Only one shRNA was enriched significantly (P = 0.011), as calculated with an 
FDR of 0.2, while two others trended towards enrichment (P < 0.1). Admittedly, this is a 
very generous FDR, but because I reported the data as enrichment based on population 
composition, it necessitates that there appears to be as much enrichment as there is 
depletion (an increase in one hairpin’s percentage of the pool means one or all of the 
remaining hairpins must make up less of the total population). Therefore, it is likely that 
enrichment is underreported by this method, and that, unless there are hairpins in the 
population that exacerbate toxicity, depletion may be largely an artifact. 
 It is, however, notable that all three of the enriched or trending hairpins target 
exon 1 of mHTT (Table 2), and the top hairpin (and only one significantly enriched) is 
DhEx1_5, validated alone in vivo (Figure 5). The presence of 3 of 5 hairpins against 
mHTT from a pool of 38, all within the top 3, seems highly unlikely by chance. Indeed, 
by arithmetic permutation predictions, one might see this this (the top 3 items of a 
ranked list of 38 all coming from a specific group of 5 items) by random chance at a rate 
of 1.185x10-3. I further tested this possibility computationally by simulating this 
randomization 5,000,000 times, and produced this result (the top 3 contained only 
hairpins against mHTT) 5,873 times for a rate of 1.175x10-3, closely agreeing with the 
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mathematical predictions. 
 In all, this was a small cohort experiment with limited scope, but there is clear 
demonstration of an ability to apply pooled screening protocols amenable to populations 
under extreme selection to a neurodegeneration model, provided that a population of 
rescued cells can be collected and specifically studied. In D2GFP rescue, we have a 
disease-relevant phenotype to be rescued, and flow cytometry allows it to be measured 
rapidly, quantitatively, and on a single cell level, allowing collection and both simple and 
complex analysis of interesting subpopulations. 
 
A Small Molecule Therapeutic Candidate, Cystamine, Failed to Produce 
Demonstrable Rescue by D2GFP and QPCR in a Small Cohort 
 While the use of D2GFP dysregulation to identify and validate genetic modifiers 
of toxicity is a powerful tool, the method also has the accuracy and speed to potentially 
allow for rapid small molecule candidate assessment in small cohorts. Indeed, there is 
no shortage of candidate therapeutics, but most studies analyzing their efficacy utilize 
cohorts of roughly 20 per group. The requirement for large cohort size makes it a 
significant drain on resources and scientist time to evaluate more than a small number 
of such compounds. Hence, as a proof of principle, I evaluated D2GFP flow cytometry 
as a means of evaluating the rescue effects of cystamine in small cohorts. Cystamine is 
a small molecule with transglutaminase inhibitory and antioxidant capabilities which is 
currently in clinical trials. Cystamine is easily administered to HD model mice in drinking 
water or by intraperitoneal injection, and has established preclinical efficacy, including 
some transcriptional rescue effects (7-10). 
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 A pair of small cohorts (15 mice total) was dosed with cystamine (6 R6/1 mice; 
150 mg/kg/day, 5 days/week) or PBS vehicle (4 R6/1 mice and 5 wild type mice). A note 
on the dosing regimen: one of the previous studies (10) reported efficacy at a dose of 
112.5 mg/kg/day, but also demonstrated some toxicity at higher doses that was 
ameliorated by giving a “drug holiday” (a week off of drugs). Hence, I tried incorporating 
this into my dosing regimen, giving drug in a “5 days on, 2 days off” pattern at a dose 
(150 mg/kg/day for 5 days/week) that should be roughly equivalent to the previously 
effective weekly dose of 112.5 mg/kd/day for 7 days/week. 
 During dosing, I monitored weight loss and performance on the rotarod. While 
there appears to be a trend towards worsening rotarod performance by week 12 (when 
mice were sacrificed), which would agree with data from a previous D2GFP;R6/1 cohort 
(Chapter 4, Figure 2), the difference was not significant at any age, nor was there a 
difference in weight gain in this cohort before euthanasia. I sacrificed the animals at 12 
weeks of age, prior to obvious motor problems, because their D2GFP loss is expected 
to be nearing its maximum by this point. This is important because if a treatment delays 
onset without altering its rate of progression, assessing D2GFP fluorescence in older 
mice may miss this effect, as the drug simply shifted the progression curve to the right. 
However, this necessitated tissue collection early enough that significant behavioral 
dysfunction or weight loss were not seen, so rescue there could not be evaluated. 
 There were reports that cystamine could alter the transcriptional profile of HD 
model mice (7), so it was plausible that D2GFP levels would be altered. One of the 
cohorts of mice was sacrificed 72 hours after the final dose (Figure 10A), and D2GFP 
levels were analyzed by flow cytometry. Initially, the 72 hour after final dose time was 
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chosen because I did not want any acute effects of injection or handling to impact the 
data. Although I observed the expected change of D2GFP in R6/1 mice versus wild 
type, there was no demonstrable difference between cystamine treated and PBS 
treated mice.  
However, some of the transcriptional effects of cystamine previously published 
(8,9) were acute and rapidly changed, so by giving the animals 72 hours drug-free, 
interesting transcriptional changes could be normalizing. Hence, I decided to sacrifice 
and analyze the second cohort 1 hour after the final dose (Figure 10B). This also failed 
to demonstrate any significant difference between cystamine treated and PBS treated 
R6/1 mice in D2GFP fluorescence, although there were only two animals per group, so 
only a substantial and consistent difference in GFP levels would be seen as significant. 
There is a significant preclinical literature on the benefits of cystamine treatment 
in HD model mice, particularly in R6/2 mice, a sister strain to R6/1. There was no 
behavioral alteration to begin with, so the failure to alter a nonexistent phenotype was 
not notable. However, the lack of demonstrable transcriptional alteration on Drd2 
prompted more detailed analysis. First, QPCR was used to assay a few genes of 
specific interest. Bdnf, Capn2, Dnajb2, and Ntrk2 are all reported to increase in 
cystamine-treated R6/2 mice (8,9). Meanwhile, Drd1a and Drd2 are of particular interest 
to me as demonstration of transcriptional dysregulation in the direct and indirect MSNs, 
respectively, and the Drd2 reduction is clearly expected from the D2GFP loss. There 
was a significant decrease in R6/1 mice for the transcripts Bdnf, Drd1a, and Drd2 in the 
mice euthanized 72 hours after the final dose (Figure 11A). These transcripts, plus 
Ntrk2, were also reduced in mice euthanized 1 hour after the final dose. (Figure 11B). 
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However, in no case was there a significant difference between the transcripts in PBS-
treated R6/1 mice and cystamine-treated R6/1 mice. 
 
RNAseq Revealed Subtle Transcriptomic Rescue by Cystamine Treatment 
 While there was no significant differences from cystamine treatment in D2GFP or 
in the six transcripts tested by QPCR (including Drd2), it is possible that this dosage of 
cystamine either was too low or is less effective with 2 days off per week, so to look for 
particularly subtle changes on a global transcriptional level, I performed RNAseq 
analysis. I focused on the 72 hour after final injection cohort to be confident that any 
changes seen are the result of altered physiology from the near-continuous cystamine 
treatment. 
 Overall analysis demonstrated very few significant (q < 0.05, fold change 
>log2(0.5)) differences between R6/1 mice treated with cystamine versus those treated 
with PBS, as only 138 genes were differentially expressed out of >16,000 total genes 
with mapped reads (Figure 12A). Compared to the >1000 genes differentially expressed 
between the wild type littermates and R6/1 mice, this is a very subtle transcriptomic 
change. The transcriptional changes were subtle enough that hierarchical clustering 
failed to differentiate cystamine-treated with PBS-treated R6/1 animals, within those 
genes differentially expressed between R6/1 and wild type littermates (Figure 12B). 
However, there is an indication that this cohort showed some minor 
transcriptional benefit from cystamine treatment (Figure 12C). Of the 138 genes 
significantly altered by cystamine treatment, 38 of them are found within those genes 
dysregulated in R6/1 mice versus wild type, a highly significant overlap (P = 7.9x10-18). 
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Furthermore, of those 38 genes differentially expressed in both comparisons (WTL-PBS 
vs. R6/1-PBS, and R6/1-PBS vs. R6/1-cystamine), 34 of them are altered in opposite 
directions in both datasets (reduced in R6/1 vs WTL but increased in Cys vs PBS, or 
vice versa), suggesting rescue. This improvement was similar enough within the 
overlapping gene set that cystamine-treated R6/1 mice clustered more closely to wild 
type mice than to PBS-treated R6/1 mice. Therefore, it may be concluded that with this 
dosing regimen, sacrifice delay, strain, and age, cystamine may have only very subtle 
effects. Nevertheless, what few effects cystamine does seem to have (that are 
detectable by deep sequencing of mRNA) in this setting strongly suggest rescue. This 
agrees with previous reports that cystamine not only rescues overt neuropathology and 
behavior, but the dysregulation of selected transcripts as well. That the D2GFP assay 
failed to detect this effect (Figure 10) is likely not a failure of detection but rather a 
successfully determined negative result, in that cystamine treatment by this regimen 
had no effect on most transcripts, including Drd2. 
 
Discussion 
Chapter 4 presented a method for rapidly measuring transcriptional dysregulation 
in HD model mice, and I have expanded on this by demonstrating the ability for virally 
delivered genes to modify this phenotype. This provides a small but significant 
demonstration of my assay as a potential tool for screening genetic modifiers of HD 
rapidly and in small cohorts of mice. The standard set of tools for measuring disease 
progression in HD model mice remains the most medically relevant way of predicting a 
modifier’s effect, but such studies require significant resource investments. Many simply 
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reveal a candidate to be ineffective at affecting HD pathology. Clearly a negative result 
is as significant a contribution to the existing literature as a positive result is, but I hope 
that my assay and others like it can help groups pre-screen their candidates in small 
cohorts with minimal time and resource investment before devoting additional resources 
to more detailed and time-intensive analysis. For example, the group of Gillian Bates at 
King’s College in London has had a long-standing interest in the repair of altered 
transcription profiles for therapeutic testing, and hence her group and others have made 
great strides in testing HDAC inhibitors such as SAHA and sodium butyrate (11,12). 
Because these drugs are relatively non-specific in their inhibition, a more targeted 
approach may produce fewer off-target effects, but this requires careful dissection of the 
many HDACs potentially involved in HD, which is in progress (13-16) but has thus far 
only succeeded in eliminating candidates. To be fair, using my D2GFP flow cytometry 
assay as a rapid replacement for this systematic crossing of knockout strains into R6/2 
mice and careful phenotypic assessment would deny the field much of what we now 
know about the intersection of transcriptional control and disease pathology. However, 
from a clinical perspective, it may be a better use of time and resources to prioritize 
those modifiers with the most therapeutic potential. Continuing this example, if a 
researcher can use this technique to sift through the various HDACs to find those that 
most efficiently modify HD-relevant transcriptional dysregulation through D2GFP 
rescue, it may at least focus initial study on certain HDACs, rather than use a 
systematic approach to their elimination from consideration. Alternatively, if none of the 
HDACs individually has a significant effect on D2GFP loss, this could inform 
researchers that multiple HDACs may require simultaneous inhibition, and the speed of 
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experimentation allowed by viral delivery could facilitate the pairwise (or more) 
assessment in short order. 
 Meanwhile, from a small molecule testing approach, a truly efficacious therapy 
often requires the use of a combination of therapeutic interventions. Such may be the 
case for HD, as single therapeutic tests rarely produce more than a 20% improvement 
in R6/2 lifespan, while one of the most successful preclinical trials to date, effecting a 
32% increase of R6/2 lifespan, was a combination of remacemide and coenzyme Q10 
(17). To systematically evaluate the interaction and synergy between two or more 
therapies, particularly in the rapid R6/2 strain for which the therapeutic window is quite 
narrow, requires a readout that is highly quantitative and reproducible, and D2GFP 
dysregulation assays would facilitate this. Therefore, the strategies described here 
could be of particular use in optimizing a therapeutic approach for HD even if several 
targets or modes of action are necessary to achieve an optimal effect. 
Another use for my novel assay was demonstrated by the ability to induce an 
HD-like phenotype by exogenous delivery of an mHTT transgene. Viral models of HD 
are relatively commonplace (18,19), and are often used for animals for which genetic 
models are uncommon or impractical. All demonstrate a common symptomology, at 
least on a cellular level, validating the gain-of-toxic-function aspect of HD. An additional 
advantage that could potentially be exploited involves the co-delivery of genes, 
demonstrated in a simple form by mHTT and RFP. Modifier testing, commonly involving 
the crossing of knockout or overexpression strains to genetic models of HD (Table 1), 
could potentially be expedited or even carried out in other animal models rapidly using 
monocistronic vectors. mHTT, plus a candidate cDNA or shRNA, can be delivered in the 
 223 
same vector particle, guaranteeing that every infected cell expresses both transgenes, 
allowing for well-controlled assessment of therapeutic impact. This can be analyzed by 
flow cytometry (requiring a fluorescent gene included in the vector) or by classical 
neuropathological methods, but flow cytometry would facilitate the collection of infected 
cells, which I and others (20) have demonstrated can be reliably studied by 
transcriptionally profiling.  
The flow cytometry approach presented here allows for not just the rapid 
identification and study of cells carrying a viral transgene, but for the study of 
subpopulations within a group of infected cells. The observation that there is correlation 
between high RFP expression and low GFP expression in the monocistronic mHTT-2a-
RFP vector could facilitate the detailed study of the specific effects on cells of low levels 
or high levels of mHTT. Similar studies have been carried out in some detail using 
YAC128 mouse models, because in its initial characterization multiple lines were 
created. Some happen to express more mHTT than others (21), and this can also be 
induced by breeding mice to homozygosity, but the ability to do this rapidly without 
constructing new strains of mice is inviting, making viral models attractive. Additionally, 
there is much known about the effects of posttranslational modifications on HD because 
additional strains have been created with point mutations at interesting residues (22). 
Competition studies are commonplace in the cancer field, and could be rapidly adapted 
to my flow cytometry system. One could imagine the preparation of pairs of mHTT 
transgenes with subtle mutation differences, which are then co-delivered to a single 
piece of tissue, allowing for perfectly controlled analysis of the populations of cells best 
protected from pathology. 
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The pairwise delivery of genes (mHTT variants or potential modifier genes) is 
elegant, but the pooled delivery demonstrated here could not only expedite modifier 
searches by a significant margin, but with enough improvements to the protocol, could 
potentially even facilitate unbiased screening. The chief limitations to the assay in its 
current form are both mathematical and practical. There is limited tissue for infection; 
even with high infectivity (~50%), only ~10,000 infected cells from a single striatum 
would be recovered under ideal conditions, unless tremendous strides are made in the 
improvement of MSN yield from my already improved protocol. Furthermore, selective 
collection of only a subset of these cells (those with highest GFP levels, as was used 
here) further reduces cell yield. This places limits on the potential pool size; for 
example, delivery of 1000 genes of interest may only allow infection of an average of 5-
15 collectible neurons, leaving it at risk for substantial randomness in determining 
enrichment. Additionally, the collection of only a few thousand cells places crucial 
importance on the post-flow-sort workup, namely the PCR of the shRNA pool. One 
mistake in the complex protocol results in a wasted experiment (an eventuality with 
which I have much experience), and these experiments can be time consuming to 
replicate given the breeding schemes involved.  
A potential solution to these issues could come from the delivery of mHTT. There 
is nothing saying this analysis must take place in previously established genetic mouse 
models of HD. By using viral mHTT, D2GFP animals could be bred in substantial 
quantities for smaller pools of vectors carrying both mHTT and various shRNAs to be 
delivered to reasonably sized cohorts, without the need for age synchronization. 
Additionally, this D2GFP dysregulation assay is demonstrated in an animal carrying a 
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large BAC transgene containing GFP and the genomic region surrounding murine Drd2. 
It may be possible to identify a smaller region of transcriptional control responsive to 
mHTT expression, place it in front of GFP, then co-deliver this with mHTT and an 
shRNA. In this way, this kind of experiment to take place in rats or larger animal models, 
from which more cells would be available for flow cytometry collection. 
One of the most immediate uses for an assay like this is facilitating preclinical 
drug trials to take place more rapidly and with greater power. The speed and 
consistency of this assay (Chapter 4, Table 1) could allow for rapid candidate 
assessment in small cohorts. I wished to demonstrate this using a small molecule 
currently in late stage clinical trials and with published transcriptional profile alterations, 
so I chose cystamine. However, it demonstrated only subtle rescue effects. 
Given previous preclinical success with this drug, the most likely reason for my 
inability to demonstrate benefit would be the drug-dosing regimen. Cystamine is 
tolerated at a wide range of doses, but no other successful preclinical study used a “5 
days on, 2 days off” regimen. It was a reasonable idea to include a weekly drug holiday 
given reports of toxicity at high doses, as other cytotoxic drugs like chemotherapeutics 
are administered at reduced frequencies to limit side effects. Nevertheless, it is possible 
that the effects of cystamine are only maintained in the R6 mouse lines by daily dosing. 
There is only weak evidence that cystamine has an effect on the clearance or 
production of mHTT (in that there is some minor reduction in aggregation) (10), many of 
the transcriptional changes are transient (8,9), and it is rapidly cleared from serum 
(23,24), so its effects may indeed be short-lived and subtle enough that dosage only 5 
of 7 days a week abrogates its therapeutic effects. Furthermore, the most advanced 
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clinical trial of cystamine is using a formulation specifically designed for delayed, 
consistent release, placing further emphasis on constant dosage.  
Re-testing this to establish the proper dosing regimen using previous studies 
would be possible, and the small cohort sizes necessary for confident efficacy 
determination using D2GFP would be perfect for such a study, but it is still necessary to 
breed up the D2GFP;HD model cohorts. Perhaps taking advantage of viral or toxin 
models of HD would be more useful here, as virally delivered mHTT rapidly induces 
D2GFP loss, and 3-NP, a well-tested chemical model of HD, has already been 
demonstrated to be less toxic in animals pre-treated with cystamine (25). I have not 
tested whether 3-NP or quinolinic acid (the two most common chemical models of HD) 
induce a D2GFP loss, and this would be a valuable continuation of my genetic model 
work. Regardless of the potential problems with the chosen dosing regimen, it should 
not be ignored that the D2GFP assay demonstrated no significant rescue by a small 
molecule, and more detailed inspection only succeeded in revealing a very subtle effect. 
Therefore, whether or not the drug itself has potential, it can be stated that the D2GFP 
assay successfully determined that this particular drug and dosage regimen had no 
effect on the HD phenotype. 
Being a novel assay with successful but limited validation, there is much more to 
do going forwards if this assay is to significantly aid in the testing of potential HD 
therapeutics. Nevertheless, mice carrying the D2GFP transgene faithfully present HD 
symptoms when mHTT is present, and measurement of GFP in their MSNs represents 
a rapid and valid way of assessing cellular health that could potentially be leveraged in 




Figure 1: Production and purification of adeno-associated viral vectors. (A) 
Schematic depicting the steps of adeno-associated viral (AAV) vector production and 
purification. AAVs are produced in HEK293 cells transiently transfected by standard 
methods (calcium phosphate or commercial reagents). (1) Plasmids encoding AAV Rep 
and Cap, and adenoviral helper proteins, are cotransfected with the vector plasmid, 
containing the gene(s) of interest flanked by AAV ITR sequences. (2) After a 3-day 
incubation period, media is collected and set aside, and cells are lysed by freeze-thaw 
cycles and clarified. The media and clarified lysate each contain serum proteins 
(primarily albumin), cellular proteins, and viral particles. (3) Precipitation with 
polyethylene glycol (PEG) followed by centrifugation concentrates the viral particles and 
serves to remove much of the serum proteins. (4) This PEG precipitate, containing 
cellular proteins and viral particles, is laid on top of a stepwise iodixanol density 
gradient. (5) After ultracentrifugation, viral particles are in a lower layer, which can be 
isolated. (6) This layer contains viral particles and is relatively free of cellular proteins, 
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and after concentration and buffer exchange, is ready for delivery in vivo. (B) Proteins 
from the various purification steps were silver stained. The clarified cell lysate (Cl Lys) 
contains many cell proteins, while the media (Sup 1) has several proteins with a 
prominent albumin band (~65 kDa); titration reveals a significant amount of vector. After 
PEG precipitation, the supernatant (Sup 2) shows a removal of ~95% of the vector 
genomes, and a strong albumin band. The PEG precipitation pellet (PPP) has some 
albumin but not much more than the original clarified lysate. Density gradient 
ultracentrifugation places the vectors into layer 3 (Lay 3), which has only dilute proteins 
and low vector titer, but after concentration (Conc), the most prominent protein visible 
corresponds to the expected molecular weight of AAV capsid protein VP3 (62 kDa). (C) 
Two different pairs of AAV preps, prepared with (+PEG) or without (Reg) PEG 
precipitation, reveal similar proteins and differ mainly in titer, where the titer also 






Figure 2: AAV-delivered transgenes require at least 2 weeks for significant 
transgene expression. (A-D) GFP vs RFP cytometer profiles of MSNs from mice 
receiving AAV delivering RFP demonstrate weakly-expressing RFP+ cells after 1 week 
(A), and significant numbers of RFP+ cells by 2 weeks (B), without a tangible increase 
in numbers or RFP levels at 3 weeks (C) or 4 weeks (D). (E) Plotted as a histogram for 
better visibility, the amount of transgene produced (level of RFP in the infected MSN 
population) requires at least 2 weeks to reach near-maximal levels. 
  













































Figure 3: Exon 1 mHTT cloned into an AAV vector forms visible inclusions. (A) A 
map of the AAV vector used for introduction of exon 1 constructs, which was based on 
an shRNA-delivery vector. The inverted terminal repeats (ITRs) flank the delivered 
elements, consisting of a CAG promoter driving expression of Exon 1 of HTT in frame 
with the red fluorescent protein AsRed. The two protein sequences are separated by a 
self-cleaving T2a peptide. Irrelevant to this experiment, an shRNA expression cassette 
(mU6 promoter driving an innocuous hairpin against LacZ) is also present. (B) In 
transfected HEK293 cells, the Q20 construct demonstrates free diffusion of RFP into the 
nucleus, not seen for a similar construct missing the T2a peptide (inset). (C) The Q94 
construct also demonstrates free diffusion of RFP, but the T2a peptide cleavage is 
incomplete, as some RFP is present in inclusion bodies. A construct missing the T2a 
peptide (inset) shows that most transfected cells have either inclusions or diffuse RFP. 
  
























Figure 4: AAV-delivered mHTT exon 1 causes significant D2GFP declines, while 
wtHTT exon 1 does not. (A and B) Flow cytometry profiles (X axis: GFP; Y axis: RFP) 
of striatal suspensions from D2GFP mice injected with AAV delivering either exon 1 
wtHTT (Q20) (A) or mHTT (Q94) (B) after a 4-week incubation. (C and D) The GFP+ 
MSNs were divided into RFP+ (infected) or RFP- (uninfected) populations, which were 
quantified for GFP levels. The Gaussian means regression profiles are plotted. Q20 had 
no significant effect on the profiles (C), but Q94 caused a significant decline (D). (E) 
Quantification of the GFP changes which demonstrate both minimal variance of the 
assay and a significant loss of GFP only in cells infected with the Q94 construct. (F-I) 
Cytometry profiles of the Q94-infected cells revealed a correlation between high RFP 
expression and low GFP expression, which was significant (P < 0.05) in 2 of 3 mice and 






Figure 5: Knockdown of mHTT partially prevents the D2GFP loss seen in mice 
carrying the R6/2 mHTT transgene. (A) Schematic of the strategy, where AAV will 
deliver an shRNA knockdown construct either targeting the polyCAG tract of mHTT or 
an innocuous LacZ sequence. (B) The shRNA used reduces levels of an exon 1 mHTT 
luciferase fusion protein by 75% compared to the LacZ hairpin. (C) Upon delivery to 4 
week old D2GFP;R6/2 mice and harvest 4 weeks later, GFP profiles from RFP+ 
(infected) or RFP- (uninfected) MSNs were plotted. Infected MSNs from mice receiving 
the polyCAG-targeting hairpin AAV demonstrated less GFP loss than uninfected MSNs. 
(D) No such rescue was seen in cells infected with AAV delivering the shLacZ hairpin. 
(E) A significant rescue of GFP loss (14 +/- 4% reduction, P = 0.0014)) was seen for the 








Figure 6: Strategy for pooled vector delivery to HD mice and interrogation of 
therapeutic construct enrichment using high throughput sequencing. (A) Pools of 
virus are delivered to the striatum of HD mice expressing D2GFP. (B) In young mHTT-
expressing animals, some cells are infected with non-therapeutic constructs “C” while 
constructs with therapeutic potential “T” infect others. (C) After aging, both uninfected 
 238 
cells and cells infected with “C” constructs lose GFP expression, but cells infected with 
“T” constructs are protected. (D) These protected cells were collected by sorting only 
the neurons with high GFP expression (green box). Three wild type and 5 mutant mice 
received the pools, and those high GFP cells were compared to each other and to the 
original AAV pool for library composition and enrichment. This is done by PCR 
amplifying the shRNA sequences using primers with animal-specific barcodes, and 






Figure 7: shRNAs from lentivectors possess similar knockdown potential in AAV 
vectors. A selection of the shRNAs used in the pool were re-validated after cloning into 
the AAV vector. Most demonstrated similar knockdown capability to that seen from 
lentivector experiments (not shown). Knockdown was evaluated in Neuro2a cells after 
transfection and sorting of RFP+ cells, followed by RNA isolation and QPCR. For each 
gene, transcript levels are shown compared between one or more targeting hairpins (T) 












































































Figure 8: Pooled shRNA delivery demonstrates an enrichment of hairpins 
targeting mHTT within MSNs with high GFP levels. shRNA-infected MSNs with high 
GFP levels were collected and hairpins were analyzed by Illumina sequencing as 
illustrated in Figure 6. Data is presented as enrichment in R6/2 MSNs versus WTL 
MSNs. For example, if a construct makes up 2% of the library in WTL MSNs but 3% of 
the library in R6/2 MSNs, the enrichment would be reported as 1.5-fold. Only one 
hairpin was significantly enriched (P = 0.01, significant by FDR) while two hairpins 








































Figure 9: In the small cohort of cystamine treated animals, there was no 
difference in rotarod performance or weight by 12 weeks of age. Mice treated with 
either cystamine (150 mg/kg/day, 5 days/wk) or vehicle (PBS alone) were tested on the 
rotarod and weighed weekly. The cohort was euthanized at a young age (12 weeks), 
and in this cohort, no difference in weight or rotarod performance was observed by the 
age of euthanasia. N = 5 WTL(PBS) mice, 4 R6/1(PBS) mice, 6 R6/1(Cys) mice. WTL = 
wild type littermate. 
  























































Figure 10: By D2GFP flow cytometry, cystamine did not alter GFP levels. (A) In the 
first set of mice, animals were euthanized 72 hours after the final dose, to allow for any 
transient response to cystamine to normalize. While there was a robust reduction in 
GFP in the R6/1 (N = 6) mice versus WTL (N = 2), cystamine did not alter this reduction 
(N = 4 Cys, N = 2 PBS). (B) To see if the response is actually transient, the second 
cohort was euthanized 1 hour after the final dose of the week. No obvious alteration in 
the GFP loss was observed, though the numbers were too low to have statistical 







































































Figure 11: QPCR validated both the GFP loss and the lack of demonstrable 
response to cystamine. Striatal and cortical samples from cystamine or PBS treated 
mice were tested by QPCR for several genes. Cortical RNA was used for Bdnf, Capn2, 







Figure 12: Cystamine treatment produced subtle effects detectible through deep 
sequencing of striatal mRNA. (A) Differential expression (DE) called 1078 genes as 
dysregulated between PBS-treated R6/1 and WTL mice (pink), but only called 138 
genes as altered by cystamine treatment in R6/1 mice (blue). The overlap (38 genes) 
was highly significant (P = 7.9x10-18). (B) Among the R6/1 vs WTL DE gene set, there 
was poor differentiation between cystamine-treated and PBS-treated R6/1 animals, as 
demonstrated by hierarchical clustering, meaning the effect of cystamine on the HD 
transcriptional phenotype was subtle overall. (C) However, focusing on the 38-gene 
overlap set not only differentiated the three groups readily as expected, but R6/1-Cys 
animals clustered closer to WTL-PBS mice than to R6/1-PBS mice. This is because, of 
the 38 genes dysregulated in both comparisons, 34 demonstrate improvement (rescue 
towards wild type levels) in R6/1-Cys mice and only 4 demonstrate worsening. All 
analysis was performed on the male 12-week-old cohort sacrificed 72 hours after final 
dose, so acute effects of dosage will not be seen. Genes reported as part of the HTT 
network by Ingenuity Pathway Analysis are highlighted in purple; this network includes 








Table 1: Selected examples of genetic modifiers, evaluated through genetic 
crosses of knockout or transgenic overexpression strains. 
  
      
          
       
         
           
           
          
          
          
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         








Table 2: Top 15 enriched hairpins in R6/2 versus WTL amplified from high GFP 
MSNs. Hairpins from in vivo shRNA enrichment were ranked, and the top 15 are listed. 
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CHAPTER 6 – FUTURE DIRECTIONS FOR THE (PRE)CLINIC IN HD 
 
Introduction 
 In dissecting the Drd2 dysregulation phenotype in HD mice, my work has 
provided three key findings to the HD community. First, that transcriptional 
dysregulation of Drd2 is a consistent, highly predictable phenotype in many mouse 
models of HD. Second, that flow cytometric analysis of virally transduced cells can 
facilitate rapid analysis of candidate genetic modifiers. Third, that flow cytometry of 
neurons allows their collection and characterization, whether as a whole population or 
as sub-populations. Whether these methods and data are used directly, or as evidence 
of their feasibility for others to adapt their own techniques, the HD preclinical and clinical 
fields can hopefully benefit in a meaningful way from what I have learned and produced. 
Here I will discuss my thoughts on the future of therapeutic development for HD in 
patients and mouse models, including whether (and how) my novel assay can play a 
role. 
 
Toward a UHDRS for Mouse Models 
 One of the main factors facilitating the determination of efficacy in HD clinical 
trials is the use of a standard method for monitoring phenotypic progression, the 
UHDRS (1). While it has its disadvantages (some subjectivity in the ratings, partly 
inherent to medication state and other variables), its focus on quality of life 
measurements while remaining relatively fast to administer makes it a clear favorite for 
clinicians. Postmortem neuropathology is similarly standardized by the Vonsattel 
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Grading System, through which disease state is assessed by careful classification of 
cell populations in different regions of the brain (2). These systems require training and 
expertise to administer reproducibly enough to maintain similarity across multiple 
centers and by different clinicians and pathologists. Nevertheless, they are essential to 
the study of a rare disease that almost always requires the combined efforts of patients 
and doctors in different parts of the world to assemble meaningful data sets. 
Preclinical trials, on the other hand, lack this standardized set of assays for 
monitoring progression and postmortem disease state. While mice can be bred to 
substantial quantities and can include comparisons to (often inbred) wild type 
littermates, the interpretation of data is not the same. In the clinic, studies can be cross-
compared by assessing changes in a patient cohort’s UHDRS Motor Subscore, for 
example. However, when analyzing mouse data, improvement is somewhat of a binary 
determination, either beneficial or not beneficial. An improvement of rotarod score 
requires an understanding of many lab- and study-specific variables such as animal 
weight, specific rotarod protocol, and even the material on the rod itself. 
Neuropathology, similarly, can have some standard analytical measures (volumetric 
increases of the lateral ventricle, for example), but even here, histological assessment 
can change based on coronal section location, while MRI techniques and calculations 
can change upon a software update, let alone between laboratory facilities. Clearly, an 
improvement in multiple measures in a given mouse study often bodes well for others 
who repeat the experiments in mice to demonstrate improvement in their own hands. 
That being said, I believe the field would benefit greatly from a standard set of 
behavioral, molecular, and neuropathological measures from which a generalized 
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assessment of efficacy could be assigned. This would not only allow the research 
community to determine a drug or modifier gene’s ability to improve (or worsen) the 
phenotype, but would allow the direct comparison of multiple such interventions done by 
different groups. In short, it would let clinicians prioritize the drugs that will enter clinical 
trials based on which ones perform best in animals, without having to consider the 
particulars of the techniques used. 
The individual measures of the UHDRS were chosen by selecting those with the 
greatest ease at standardization (minimizing subjectivity) and speed of assessment. 
Those that best represent patient quality of life were then chosen, with an additional 
emphasis on those that change most rapidly in the early stages of the disease. In 
simple terms, this assigns a set of numbers to how a patient’s manifest disease is 
affecting his or her life. With mouse models, we are less adept at determining how “bad” 
a mouse is feeling on a given day (for example, it is not uncommon for sick animals to 
feign health in an attempt to fool potential predators). Hence, it is not a simple task to 
assign a preclinical measure with a human quality of life. However, certain techniques 
are more robust than others, in that a reproducible change in performance is present in 
most mouse models as neuropathology progresses. 
For the UHDRS, all measurements are by their nature longitudinal, in that 
patients are measured over the course of the disease to quantify progression. In mice, 
standard measurements of survival, weight loss, and clasping phenotype, when 
applicable, are simple and generalizable, even though survival can differ based on 
various mouse research facilities’ definitions for the need to euthanize a given sick 
animal. Additionally, mouse models have several longitudinal quantitative behavioral 
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measurements, but the two most common methods, accelerating rotarod and balance 
beam, both measure balance and coordination. They each contain confounding 
variables, such as the specific rotarod duration. For example, we use a 4 to 40 RPM 
over 10 mins protocol, while others may use a 0 to 44 over 5 mins method (3). 
Additionally, the time to run will typically encounter a ceiling effect, in that wild type 
animals will often remain on the rod for longer than the acceleration protocol, 
complicating quantitation. Finally, the material of the beam (wood, plastic, or even 
bicycle innertubes over other materials can be used) can change how the mouse grips 
and drastically change how often it falls. Balance beam, on the other hand, can give 
different results for time to cross or foot slips based on the width and style of the beam. 
Some use tapered beams, others use a uniform width; the beam can be square or 
circular, and can be of a variety of lengths and angles. Overall, though, the main 
advantage that the rotarod provides is ubiquity, because it has been used in virtually 
every preclinical study for alteration of phenotypic progression. However, rotarod only 
provides one set of measurements (time to remain on rotarod), while the balance beam 
can measure time to turn when the mouse is placed backwards on it, the speed of the 
crossing, and number of foot slips. Overall, both are useful and demonstrate changes in 
performance across many models, but if forced to choose, I would propose to make 
balance beam (of a given length, width, style, and angle) a standard motor performance 
measure, if only for its multiple measurements and the speed with which it is analyzed, 
facilitating larger cohorts to be tested in a given time. There are many other tests for 
motor activity, but many of them either require substantial time, such as open field 
activity monitoring (which can require 30 minutes or more of observation), while others 
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require equipment that can be difficult to acquire and maintain, as is the case for 
swimming test apparatuses. 
Much like volumetric imaging and the Vonsattel Grading Scale, neuropathological 
measurements in mice are consistent in that advanced disease state correlates 
worsening performance at behavioral tasks with greater neurodegeneration. For mouse 
studies, it may be impractical to expect researchers to have access to advanced in vivo 
volumetric imaging equipment (i.e. MRI), but brain weight could be a standard, simple, 
and relevant measure, and histological assessment is commonplace and relevant 
enough to patient data to be included. If a given set of locations within the brain were 
standardized for ideal analysis of certain structures, it would allow rapid assessment of 
differences in brain structure volumes. For example, the cortex, striatum, lateral 
ventricle, and hippocampus have demonstrable volumetric changes by MRI in multiple 
models (4), and could be quantitated with only two sections of mouse brain. 
Additionally, if they could be measured without the need for tissue fixation, the 
remaining tissue to be either used for other analyses that require protein or nucleic acid 
purification. mHTT inclusions are also commonly assessed and could be considered. 
While I agree that they are a rapid and quantitative indicator of proteotoxic stress, I 
would be hesitant to include their analysis in a standard measurement for disease 
pathology. This is due to the weight of data suggesting their limited direct role in 
neurotoxicity and the poor correlation across models between their appearance and the 
appearance of motor symptoms. However, for studies that are specifically evaluating a 
reduction in mHTT levels or investigating aggregation kinetics, it clearly remains useful. 
On the molecular level, I believe my and others’ work have unequivocally 
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demonstrated the ubiquity and progressive nature of transcriptional dysregulation. It is 
not yet well established which genes’ alterations are the direct result of pathological 
processes (let alone which specific ones) and which are compensatory changes from a 
cell under stress. However, there are some whose alterations are well established as 
not only a byproduct of disruption, but as potential drivers. For example, transcripts for 
PGC1α were reported to be reduced in HD patients and models (5), with direct binding 
of mHTT to the Ppargc1a promoter thought to be the cause of this downregulation. This 
is likely not a passive alteration, given that PGC1α knockout within an HD mouse model 
exacerbates toxicity (5) in addition to the number of mitochondrial toxins modeling HD. 
mHTT also disrupts many transcription factors, such as REST/NRSF and Sp1, with 
direct physiological consequences. While whole transcriptome analysis by array 
profiling or RNAseq may be preferable in terms of data complexity, perhaps it would be 
more practical to limit analysis to a few select transcripts with the highest reproducibility 
among many samples, and representing many different factors’ disruption of activity. 
Drd2 is a candidate for which I have the most data, with relatively well-defined control 
by Sp1 (6), while genes such as Chrm4 are REST/NRSF targets in the striatum (7) with 
demonstrable reductions in my striatal RNAseq profiles. QPCR would be a cost-
effective, rapid, and simple way of analyzing a select few genes, and this could 
potentially be done with the leftover tissue from any volumetric analysis, conserving 
animal tissues. 
In all, what could help is a standard, disease-relevant, and relatively easy set of 
measurements that can be administered without having to devote significant amounts of 
tissue. Ideally, this would allow lab- and study-specific analysis through other methods. I 
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wish to emphasize that the point of this is not to unseat a given lab’s “favorite” 
techniques, in favor of a ubiquitous singular measurement system; even clinical trials 
often have primary endpoints other than UHDRS score improvements. It is only to add a 
set of data to each study that would facilitate cross-study analysis, without being a 
significant burden. This would certainly require thorough discussion in the HD research 
and clinical community, but a reasonable starting point for such a discussion might be 
as follows: 
1) Longitudinal measurements: survival, weight, suspended limb clasping 
(submeasures age of onset and duration of suspension until clasp), and 
balance beam (submeasures time to turn around, time to cross, and number of 
foot slips) and/or rotarod (with a standard acceleration protocol and rod 
material). 
2) Postmortem neuropathology: brain weight, cortical area (two sections), striatal 
area, ventricle area, and hippocampus area, taken from very specific coronal 
sections based on standard guides of mouse neuroanatomy. 
3) Molecular pathology: transcriptional alterations of at least one Sp1 target (e.g. 
Drd2), at least one REST/NRSF target (e.g. Chrm4 in striatum, BDNF in 
cortex), at least one direct target (e.g. Ppargc1a), and others deemed most 
relevant, normalized to one or more standard neuronal markers (e.g. Tubb3 
[βIII Tubulin]). For those treatments with whole-body exposure, it would also 
be wise to assess a similar set of genes in skeletal muscle. 
All of these measurements (with the exception of clasping) are relatable to the human 
disease condition, require little in the way of specific equipment (a balance beam can be 
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purchased or constructed for little money), are simple to assess and standardize, and 
are not resource-intensive in either time or tissue. Importantly, they all have 
demonstrated sufficient power that reasonable cohort sizes are allowed. 
 The above assumes a relatively standard rate of progression in the various 
mouse models, but we know that there is significant variance among the mouse models 
for the onset and severity of such phenotypes. Hence, it would also be necessary to 
standardize the mouse strains used for rigorous preclinical studies. In general, they can 
be roughly divided into the N-terminal transgenic strains (R6/2, R6/2, and N171-82Q) 
versus the full-length strains (either transgenic, such as YAC128 or knockin, such as 
CAG140). While the N-terminal transgenic strains properly model the severe motor 
impairment, loss of brain tissue, and lethality present in HD patients, they do not model 
the genetic condition of patients or the slow progression of disease, which are faithfully 
recapitulated in full-length models. For this reason, it seems reasonable to make testing 
one of each standard practice. Among the N-terminal transgenic models, R6/2 have 
been most thoroughly studied, primarily due to their rapid progression, allowing even 
survival studies to be performed in a 3-4 month period. However, given the difficulty of 
producing even a modest phenotypic improvement in R6/2 mice, plus the speed at 
which pathogenic markers appear (mHTT aggregates by birth (8) and severe Drd2 
dysregulation by 6 weeks of age), I believe the slower R6/1 model would be more 
forgiving and sensitive to alterations. Its phenotypic progression appears nearly identical 
to that of R6/2 (9), albeit slower, and it has three added advantages: reduced rates of 
triplet repeat expansion (10), increased fecundity, and an inbred background. These 
make it both more genetically tractable than R6/2 and easier to breed in large numbers. 
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For full-length strains, there is great variability in the genetic structures. Testing a 
human full-length model like the well-studied YAC128 seems preferable due to the 
ability for human-specific interventions (such as oligonucleotides) to have an effect, but 
it has the downside of an altered genetic dosage, in that both wild type alleles of mouse 
Htt are also present. It would perhaps be possible to humanize YAC128 mice on a 
knockout Htt background, as has been done with BACHD (a similar strain but one which 
produces no transcriptional dysregulation and has very little intranuclear mHTT) (11,12), 
but the strength of the currently existing models is the glut of literature defining their 
expected phenotypes. The “best” full-length strain might not exist, but it seems 
reasonable to use YAC128 mice when the intervention requires human mHTT. 
Meanwhile, a pure murine knockin strain like HdhQ150 (also known as CHL2) (13) can 
be used when human mHTT is not essential, but emphasis is placed on the proper 
genetic balance of mutant and wild type Htt. 
 
Pharmaceutical Interventions: When is the Target Specific Enough? 
 One of the primary reasons for the lack of an effective disease altering 
therapeutic in HD may be the diverse number of cellular pathways impacted by mHTT. 
For drug trials, both preclinical and clinical, it is often difficult to specify the target and its 
effects, but with HD, careful targeting may not always be desirable. Given the diverse 
suite of symptoms, a drug with multiple effects may be ideal. For example, the 
compounds that are furthest along in the clinic (cysteamine, coenzyme Q10, and 
creatine) are all antioxidants, but coenzyme Q10 and creatine aid mitochondrial function 
(14,15), while cysteamine has documented transcriptional rescue effects (16,17). 
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Meanwhile, a specific Hsp90 inhibitor, geldanamycin and its analogs, can be dosed to 
primarily affect HSF1 binding (18,19). However, this specific interaction is only powerful 
from an HD perspective because it alters the expression of several chaperone genes 
and alters the proteasomal degradation rate of several Hsp90 client proteins, important 
in the context of the limited ability of single chaperones to significantly impact mouse 
model pathology (20). With this in mind, a viable strategy would be to identify those 
drugs with the greatest pleiotropic impact on the various phenotypes, which would be 
facilitated by the standardized assessments presented above. An additional example of 
this would be the green tea extract compound EGCG, which not only can alter mHTT 
aggregation and toxicity in cell and fly models of HD, but also has antioxidant properties 
(21). 
However, there are also situations where target specificity is required. A prime 
example for this is in the histone deacetylase (HDAC) field. General HDAC inhibitors 
may target many such proteins due to similarities in the binding sites, but often with 
toxic effects in HD mice despite some relief of the transcriptional phenotype (22,23). 
Parsing out the specific HDAC whose activity is most responsible for the relevant 
transcriptional alterations has been a goal for several labs, which has required a 
sizeable effort. The strengths of the assay I have developed are its sensitivity, low 
required cohort sizes, and the ability to pool candidates and assess their efficacy en 
masse. In the face of classical genetic techniques, this could be a rapid method of 
sorting out candidates as effective or ineffective at altering Drd2 levels, which could lead 
to closer studies of the genes’ impact on other phenotypic measures. HDACs are not 
the only large, druggable family of proteins for which specificity of inhibition could be 
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useful. Some kinases, like IKK (24), already have well-defined roles, but important 
phosphosites both within and outside of mHTT may be discovered by screening shRNA 
libraries directed against families of kinases or phosphatases. Given the necessity of 
specificity with kinase inhibitors in the clinic, this could be of great use from a medicinal 
chemistry perspective. 
 The specific targeting of a given protein to modify neurodegeneration is enticing, 
but the difficulty in this approach is that, to date, the only well-validated single target is 
mHTT itself. Others have been tested (Chapter 5, Table 1), and many have beneficial 
effects. Worth considering, though, is whether any single non-mHTT target truly 
provides enough therapeutic potential to justify the development of specific drugs or 
gene therapies to alter its activity. This is perhaps more of a philosophical question 
beyond the scope of a thesis, but it is clear that certain modifiers are better candidates 
than others. For example, one of the prevailing theories for the specificity of striatal 
degeneration in HD relies on the withdrawal of trophic support, specifically that of 
BDNF. As BDNF is not only poorly transported from the cortex, but is also 
downregulated (25,26) in HD, this is an attractive explanation, and transcriptional 
analysis of striatal tissue suggests a striking similarity between Bdnf knockout mice and 
HD models (27). Even amongst growth factors, though, there are many whose 
augmentation could be beneficial as single therapeutics. A rapid, small-cohort technique 
for assessing therapeutic impact would facilitate not only single-candidate testing, but 
combination therapeutics as well in order to investigate synthetic effects of multiple 
growth factor administration. Once promising single or combination growth factor 
regimens are selected, standardized phenotypic techniques could help carry successful 
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regimens to the clinic. 
 This is not to imply that mHTT itself is not the ideal target, and as in vivo 
oligonucleotide delivery or gene therapy improves, this will become a very attractive 
choice. However, allele specificity has become a point of (polite) contention in this 
subfield. Most of the tools for reducing mHTT RNA in vivo have demonstrated efficacy 
in an allele non-specific manner (28-30), but this has come with it the need to 
demonstrate the safety and tolerability of reduction of wild type HTT levels (31,32). 
Allele specific knockdown approaches would clearly be desirable, but there are only two 
ways of accomplishing this, each with drawbacks. One method is to identify highly 
polymorphic single nucleotide polymorphisms (SNPs) and utilize a small number of 
allele specific oligonucleotide (ASO) molecules with the greatest population coverage. 
The two downsides from this approach would be the fact that not every patient would be 
a candidate for this (e.g. homozygotes for the appropriate markers), and also that this 
would necessitate stratification of patient populations for clinical trials, which not only 
adds a degree of difficulty to recruitment, but puts the study at risk of artificial results 
due to a shared ancestry within this stratified population. Alternatively, targeting the 
poly(CAG) repeat would be applicable to every patient, and possibly more efficacious in 
those patients with highly expanded repeats. The risk with this approach would be the 
presence of poly(CAG) microsatellites in other genes, so off target effects would need to 
both be accounted for, and tested for disease influence. For any of these approaches, 
my novel assay could facilitate the specific collection of cells infected with a viral shRNA 
targeting the desired region. D2GFP rescue could be used as a first-pass therapeutic 




Beating Back mHTT on Multiple Fronts 
 Toxicity in HD affects multiple pathways, and I have discussed drugs known to 
affect multiple disrupted functions. However, there is nothing to say that multiple drugs 
cannot be co-administered. In truth, I believe it makes more sense to approach HD the 
same way one would approach cancer. Historically, only modest improvements in 
survival were achieved in patients when single drugs are given, with only rare drugs like 
Gleevec improving survival drastically, even when added to existing regiments. It is 
often only when multiple drugs, combined with radiotherapy and/or surgical resection, 
are administered that significant gains in survival have been made. This is because to 
even become a cancer cell, several checkpoints to growth, division, and migration have 
to be overcome. Targeting only one of these pathways with single agents, however 
effective they are, can often be brushed off by a tumor cell on its way to regrowth. 
 Neurons in HD do not divide, nor do they encounter selective pressure to 
maintain mHTT toxicity in the face of therapeutics. However, the progressive 
degeneration is still the result of the disruption of multiple pathways, so it is only logical 
that multi-drug regimens should be more thoroughly explored. This has already been 
attempted with coenzyme Q10 (an antioxidant with added benefits to mitochondrial 
energetics) administered with remacemide (an NMDA receptor antagonist) (33,34). 
While this combination had no significant protective effect after 30 months of treatment 
in patients, it is remarkable in that it provided the best increase to survival for a non-
surgical intervention in mice yet tested, greater than 30% in R6/2 mice. I would 
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comment here that, because the best improvement of survival for this strain has been 
only 30%, this leads me to the view that R6/2 is not the ideal model for a disorder with 
comparatively subtle effects over decades of life in patients.  
The paucity in clinical success for HD to date may well be due to the 
consequences of toxic effects on multiple cellular pathways. There are two reasons to 
consider these multiple pathways in the context of HD therapeutics. First, it may prove 
extremely difficult to directly eliminate the mutant protein while also preventing its 
expression from the point of therapeutic intervention onwards. Second, the impact of 
mutant protein may have had profound effects on the neurons, to the point that their 
eventual death will not be reversed by simply eliminating mHTT protein. For these 
reasons, I believe it is important to continue to focus on determining in detail the 
pathological impact of mHTT on cellular function at all stages of development and 
disease progression. 
 The different pathways to toxicity can be categorized any number of ways, but for 
simplicity’s sake, I will divide them into four: trophic support, mitochondrial health 
(including Ca2+ homeostasis defects), transcriptional dysregulation, and proteostasis 
(both protein folding and degradation). All four of these categories contain both genetic 
modifier studies and pharmaceutical trials that significantly alter the motor phenotype 
and/or survival. For trophic support, Bdnf overexpression is protective, as is the 
administration of agonists for its receptor (35,36). Mitochondrial health was impaired by 
Ppargc1a (the gene for PGC1α) knockout and is boosted by creatine and coenzyme 
Q10 (5,14,15). Transcriptional dysregulation is improved (albeit confusingly) by Sp1 
knockout and by a number of HDAC inhibitors, such as SAHA (37,38). Finally, 
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proteostasis is aided by Hsf1 overexpression and modestly improved in a different 
polyglutamine disease model (polyQ androgen receptor) by the Hsp90-inhibitor and 
geldanamycin analog 17-AAG (19,39). 
 Considering that all of these individually aid HD mice, some of which with 
crossover effects in other pathways (cysteamine, a mitochondrial energetic booster and 
andioxidant, also improves BDNF protein levels in the brain) (16), it should be fairly 
straightforward to test combinations of them. The best candidates, with the fewest 
predicted contraindications, can be selected and initially tested pairwise and singly. If, 
for example, a group were to focus on the four pathways I described above, this would 
mean four single-drug groups, six pair-wise drug groups, and at least one no-drug 
cohort. Through conventional drug studies, it is complicated to test even one 
therapeutic, so 11 trials would require a monumental effort. However, let us assume it 
could be established that the four drugs would individually have even subtle effects on 
Drd2 levels. In this case, it would be reasonable to use only 5 or fewer D2GFP;R6/1 
mice (which could detect an improvement of less than 10% with great confidence) in 
each test, so a synthetic effect could be confidently ascertained. Alternatively, if 
behavioral and neuropathological effects also should be taken into account, the beam 
crossing and histological volumetric assays proposed above could maximize clinical 
relevance and information with a minimum of hands on time by the researchers, and 
would likely necessitate only modestly larger cohort sizes. This is only an example (and 
an optimistic one at that), but it illustrates the fact that experimental throughput, not just 
information content, is one of the chief impediments to preclinical science. The 
bottleneck may not be on this end, given the difficulties in establishing a clinical trial 
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protocol and gathering a suitable patient population. Nevertheless, clinical trials might 
produce more success if they are not dependent on a significant health improvement to 
neurons arising from only a single pathway’s repair.  
 
Gene Therapeutics: Risks, Progress Remaining, and Potential 
 Pharmaceutical approaches have a long history of success for many diseases, 
and are often simple to test in mice, but for a disease like HD with a potentially long life 
of treatment in front of patients, it is worth exploring in greater detail those strategies 
that require one or a few interventions; namely, gene therapy. It also provides the only 
way for the administration of a complex protein whose isolation or synthesis in 
quantities adequate for consistent dosage would be prohibitively difficult or costly. 
Growth factors, for example, only have practical therapeutic potential in the context of 
either gene therapy or the surgical implantation of transduced cells secreting the growth 
factor, due to poor serum half-lives and the blood brain barrier. There is a growing 
literature on cell implantation in HD and other neurodegenerative diseases (in particular, 
Parkinson’s Disease) (40), and the poor outcomes have come primarily from either 
failure of cells to survive, or overgrowth. This perhaps should not be surprising, but 
implanting neuronal progenitors or fibroblasts, and expecting them to remain living cells 
in a foreign environment but not to grow, is a difficult task even in ideal conditions. This 
might be improved in the near future with the advent of induced pluripotent stem cell 
technologies (41,42), from which patients’ own cells provide the source material and 
hence preventing the necessity of immunosuppression. For the moment, however, AAV 
vector delivery, with good immune tolerance in the CNS and long-lived expression, is a 
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more viable option. The major downsides are the requirement of neurosurgery, and the 
inability to “turn off” the transgene should intolerable side effects arise. These effects 
can be minimized with proper GMP viral prep, skilled and accurate surgical 
implantation, and importantly, longitudinal preclinical studies in mice and longer-lived 
animals. 
 Of the options available for gene therapy, reduction of mHTT through small 
noncoding antisense RNA transgenes (e.g. shRNAs) is perhaps the most attractive 
choice. This was discussed in detail above, but given the difficulty in silencing viral 
transgenes, it is worth emphasizing the necessity of validating the safety and tolerability 
of HTT reduction if the construct is not allele-specific. Such efforts are underway with 
promising results (31,32). 
 Modulation of indirect modifiers, through either shRNA or cDNA transgene 
delivery, is more of an open question as to its utility. As outlined above, the ability of 
single factors to meaningfully alter disease progression is up for debate. However, a 
rapid, simple technique with which such factors could be evaluated in groups could aid 
in selecting those with the most potential. Particularly with shRNA screens and cDNA 
families whose members are likely to have cell-intrinsic effects (transcription factors, but 
not growth factors), pooled screens could rapidly assess these putative modifiers, and 
the single factors arising from these screens can be tested more rigorously individually. 
 Importantly, these pooled approaches need not be limited to known cDNAs or 
shRNAs against known genes. It is particularly enticing to screen small libraries 
generated from enriched therapeutic peptides tested in cell culture or lower organisms, 
for example. The polyglutamine binding protein QBP1 was screened in such a way and 
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has demonstrated therapeutic effects (43), but with a pooled in vivo approach, it would 
not be necessary to narrow down such libraries to only one or two top-performing 
candidates. Given the differences between disease progression in vitro and in vivo, 
some peptides with great clinical potential may be lost when researchers are forced for 
practical reasons to cull the promising hits down to only one or two top candidates. 
 A final note, which is relevant for any clinical trial, but particularly for gene 
therapy interventions that require neurosurgery, is the subject of when to administer the 
vector. It is well established that by the time symptoms set in, significant atrophy has 
occurred in the striatal cells that would presumably serve as the target for gene delivery. 
Fortunately, primary outcome measures of volumetric changes are substantial 
predictors of motor dysfunction in patients and mice (44-48) and can be measured prior 
to symptom onset. However, it would be no small task to convince regulatory agencies 
to allow a clinical trial to take place in a premanifest patient population, and for good 
reason. Neurosurgery, even when carefully and properly performed, carries with it 
significant risks. Asking patients to subject themselves to such a surgery prior even to 
any deficit in their quality of life is, at best, ethically challenging. Nevertheless, this may 
be the only setting in which meaningful phenotypic rescue would be expected, in that 
this is the setting where there are actually cells in substantial quantities (and quality) to 
be rescued at all by the transgene. For this reason, data from animal trials will need to 
be of extremely high quality, repeated several times, with demonstrable effects in 
premanifest and manifest animals, for any serious attempt to be made in the clinical 
setting. Even in this setting, it would be difficult to convince Institutional Review Boards 
to condone a gene therapy trial in premanifest patients, but this might be the only way 
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such a neuroprotective gene therapy trial even has a chance of success. 
 
Conclusions 
 The article documenting the definitive cloning of huntingtin, the causative 
mutated gene in HD, was published just over 20 years ago. Initially, there was hope that 
the mutant protein can simply be drugged directly and either “fixed” or destroyed. In the 
years since, the field has learned of mHTT’s altered protein-protein interactions and the 
difficulty in altering them pharmaceutically. We have looked for more easily drugged 
modifier proteins whose function facilitates mHTT toxicity, to learn that many such 
proteins exist but that no one protein seems to be the a key “spoke” other than mHTT 
itself. Animal models have been developed in great numbers, with different genetic 
bases and backgrounds allowing the core phenotypic effects to be more carefully 
studied. Finally, clinicians have made tremendous strides in the study of pathology in 
patients, if not yet in their ultimate outlook. This last step is all that remains, but for the 
next great drug to find success in the clinic, it must first have demonstrated effects in 
animal models, namely mice. My novel assay has provided further detail for a well-
documented and consistent phenotype, dysregulation of Drd2, as well as demonstrated 
the means to leverage this assessment for preclinical candidate evaluation using 
minimal cohort sizes with great sensitivity. My hope is that my method can make the 
task of sifting through several candidate drugs or modifiers less daunting, and will 
ultimately provide the basis for HD or other disease researchers to leverage flow 
cytometry in the adult neuronal setting for sensitive phenotyping and specific cell 
population collection alike. 
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APPENDIX: TARGETING HTT RNA SECONDARY STRUCTURE 
 
Introduction 
 Many hereditary diseases, including Huntington’s Disease (HD) and Myotonic 
Dystrophy (DM), involve a toxic gain of function. While DM type 1 (DM1) is brought on 
by an RNA gain of function mechanism, including muscleblind proteins aberrantly 
binding expanded CUG repeats in the 3’ untranslated region of DMPK (1), HD toxicity is 
encoded by an expanded poly(CAG) tract causing a polyglutamine expansion in the N-
terminus of huntingtin (HTT) (2). Both diseases are progressive in nature with 
pleiotropic symptoms (3,4), and as gain of toxic function disorders, could be treated by 
reducing the toxic species. In the case of DM1, this can only reasonably be 
accomplished by trying to either reduce the levels of the toxic RNA, potentially by 
treatment with oligonucleotides that engage RNase H (5), or by prevention of the 
poly(CUG) repeat in DMPK from interacting with the splicing factor MBNL, which also 
has tremendous potential (6-8). However, in HD, because the toxic species is a protein 
with aberrant protein-protein interaction tendencies, much of the attention has been at 
the level of removing the toxic protein. This might be done indirectly through modulation 
of protein folding pathways (9,10) or directly by administering transgenes that interact 
with mutant HTT (11-13), causing degradation machinery like the proteasome and 
autophagosome to destroy it more efficiently. 
 However, because the toxic species is a protein, a similar strategy to that of DM1 
can be attempted, targeting the mRNA directly. The conventional method for targeting 
mutant HTT RNA (mHTT) involves knockdown or oligonucleotide-based approaches. 
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Engaging the RNAi machinery of the cell using virally delivered short hairpin RNAs has 
had preclinical efficacy in several studies (14-17). Alternatively, using oligonucleotides 
to engage target RNA sequences through RNase H has promise because it would not 
risk altering miRNA homeostasis (through engaging the RNAi machinery), and there is 
also evidence of preclinical rescue through such methods (18). 
 There may be an intersection of these two strategies, and it relies on two facts. 
One is that poly(CAG) repeats can be highly structured with high melting temperatures 
(19). The other is that there are interesting sequences within the 5’ untranslated region 
(UTR) of HTT that modulate its transcription rate, such as an upstream open reading 
frame (uORF) whose ablation increases downstream HTT translation (20). Because of 
our lab’s longstanding interest in both DM and HD, we looked more closely at the 5’ 
region of HTT, both coding and noncoding, from an RNA structure perspective. In doing 
so, we noticed that the 5’ region of HTT appears highly structured, particularly a hairpin 
encompassing its start codon. While much of the efforts for DM1 have gone into 
interacting with repeat structures with the intent of freeing binding factors like MBNL, 
here, the strategy could be to stabilize the secondary structure of HTT, reducing 
translation. I therefore tested whether two separate predicted hairpins can be modulated 
in a fashion that would reduce translation rates, first genetically, then pharmaceutically 
using both oligonucleotides and small molecule libraries. This work is preliminary in 
nature and will be continued by the lab in the coming years, but demonstrates in 





Cloning and T7 transcription of constructs: The firefly luciferase vector pGL4.13 
(Promega) was the base vector for HTT construct cloning, while pGL4.73 (Promega) 
was used for generating renilla luciferase transcripts. Wild type sequences of HTT were 
PCR amplified from cDNA generated from patient lymphoblastoid cell lines. These were 
cloned into pGL4.13 using In-Fusion (Clontech) to generate the exon 1 constructs (Q20, 
Q47, and Q96), as well as the wild type UTR construct. The Strong hairpin, Weak 
hairpin, and start codon mutants were generated from the wild type UTR construct by 
site-directed mutagenesis using overlapping PCR primers amplifying in the opposite 
directions. Transcripts were produced by PCR amplifying the appropriate luciferase or 
HTT-luciferase gene from these plasmids using primers that caused the product to 
include a T7 consensus binding site upstream  
(5’-TACGTACGTTAATACGACTCACTATAGGGAGAGCCACC-3’) and 20 (dA) bases 
downstream. RNA (uncapped) is produced by T7 in vitro transcription (Epicentre) 
according to manufacturer directions, incubating 250 ng of PCR product for 1 hr. RNA is 
purified from the reactions with RNeasy columns (Qiagen) according to manufacturer 
instructions. Aliquots were dissolved in H2O to desired concentrations and stored at -
80°C until use. 
 
Oligonucleotides for translation inhibition: The following oligonucleotides 
(unmodified DNA oligos, IDT) were tested; those in bold were used for dose escalation 
and as screening controls. 
UTR Oligo 1: GTTTTTGGCATCTTCTGGCCTCGGGCCG 
 287 
UTR Oligo 2: GTTTTTGGCATCTTCTGCCTCGGGCCG 
UTR Oligo 3: GTTTTTGGCATCTTCGGCCTCGGGCCG 
UTR Oligo 4: GTTTTTGGCATCTTCGCCTCGGGCCG 
UTR Oligo 5: GTTTTTGGCATCTTCTAGGCCTCGGGCCG 
UTR Oligo 6: GTTTTTGGCATCTTCTTGGCCTCGGGCCG 
UTR Oligo 7: GTTTTTGGCATCTTCTTAGGCCTCGGGCCG 
UTR Oligo Scrambled: TGTGAGTTTGCTCTGCCTGGCCGTGCTC 
CAG Oligo 1: TGAGGAAGCTGAGGAGTGGAAGGACTTG 
CAG Oligo 2: TGAGGAAGCTGAGGAGGGAAGGACTTG 
CAG Oligo 3: TGAGGAAGCTGAGGATGGAAGGACTTG 
CAG Oligo 4: TGAGGAAGCTGAGGAGGAAGGACTTG 
CAG Oligo 5: TGAGGAAGCTGAGGAGCTGGAAGGACTTG 
CAG Oligo 6: TGAGGAAGCTGAGGAGGTGGAAGGACTTG 
CAG Oligo 7: TGAGGAAGCTGAGGAGGCTGGAAGGACTTG 
CAG Oligo Scrambled: ATAGTGCGTGGAGGAATGAGGGAGGTAC 
 
Cell-free translation systems: Wheat germ extract and Rabbit reticulocyte lysate 
(Promega) were used to generate active luciferase for quantitation of translation. 
Reactions were run in 15 µL volumes using 300 ng/well firefly luciferase RNA (various 
clones) as well as 0.3 ng/well renilla luciferase RNA (unmodified). For oligonucleotide or 
compound incubations, RNA and drug were pre-incubated in a total volume of 3 µL. The 
concentrations assayed are that seen by the RNA in this 3 µL volume, but after a 15 min 
incubation at 37°C, the cell free extract was added to a total volume of 15 µL. This 
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reaction was incubated for a further 45 mins, and then was frozen at -20°C before 
assaying in a Dual Luciferase System (Promega).  
 
Luciferase quantification: All firefly data was internally normalized to the renilla value 
from that same well. 10 µL of the cell free translation reaction was added to each well of 
a white-bottom plate compatible with the Varioskan Flash (Thermo Scientific) 96-well 
luminometer. Reading time was 8 seconds after a 2 second lag time following reagent 
injection, and samples were read at room temperature. For screening, all plates 
contained at least 6 no drug (water) control wells, 3 Strong Hairpin wells, and 3 wells 
containing the exon 1 (Q47) construct as well as 10 fold excess inhibitory oligo. Plates 
were re-run if all positive controls were not at least 4 standard deviations below the 
mean of the no drug controls, and all drug wells were reported as a percentage of 
luciferase seen in the averaged no drug wells. Data was analyzed in Microsoft Excel. 
 
Results 
The 5’ Region of HTT is Highly Structured 
 mFOLD RNA structure prediction software (21) was used to investigate any 
potential secondary structure present in exon 1 of HTT, a region whose expression is 
sufficient for toxicity when expressed in mice (22). In doing so, the first 160 bases of the 
transcript present three highly structured and stable predicted hairpins (Figure 1A). This 
region of HTT is highly conserved between humans, chimpanzees, mice, and rats 
(Figure 1B), including the non-coding sequences, suggesting potential function that 
could exist on a structural level. The first such hairpin contains the start codon for an 
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upstream open reading frame (uORF), whose expression levels modulate downstream 
HTT levels (20). However, the third hairpin contains the HTT start codon, and is 
predicted to be the most stable of the three. Hence, we reasoned that this hairpin in 
particular could be amenable to small molecule or oligonucleotide targeting, as there 
are three bulges or loops into which a small molecule could potentially insert and 
stabilize the structure, on top of the base pairing apparent that could be altered through 
an agent that intercalates or rests in the major groove. This region was subcloned into 
luciferase vectors and transcribed in vitro for further study in cell-free translation 
systems, so as to screen for an ability to inhibit translation exogenously. Cell-free 
translation systems were favored for these studies in order to separate the activities of 
transcription and translation, ensuring that any activities observed are on the post-
transcriptional level. Additionally, this provides the practical advantages of using 
compounds with poor cell penetrance in primary screening.  
 
Genetic Modulation of the Start Codon-containing Hairpin has Strong Effects on 
the Translation Rate. 
 Before attempting to target the secondary structure of HTT exon 1 
pharmacologically, I needed to establish that altering the strength of this hairpin would, 
in fact, impact translation rates. Hence, the first 160 bases of HTT (from the 
transcription start site through the first 5 codons of HTT, pictured in Figure 1) were 
cloned upstream of firefly luciferase, while additional clones were modified to either 
strengthen or weaken the hairpin containing the start codon (Figure 2A). Originally with 
a free energy of -31.33 kcal/mol, five sites were mutated to strengthen this hairpin, 
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producing a new “Strong hairpin” with 50% increased stability (-47.23 kcal/mol). 
Encouragingly, the features whose alteration contributed most strongly to the predicted 
stability, the bulges, are those that may serve as the most attractive targets for 
drugging. Reciprocal alterations were made by creating a construct with extremely weak 
structure through similar mutations. Whereas the wild type hairpin shown (Figure 2A) is 
always present in mFOLD prediction permutations, the structure for this weakened 
structure (“Weak hairpin”) is predicted to be highly variable; the most stable such 
prediction was shown. 
 These constructs, plus two more that mutated the two start codons present (the 
uORF start codon, and that of HTT), were tested for translation rates by first in vitro 
transcribing the construct and then adding a set concentration of the purified transcript 
into cell free translation systems. In both systems (wheat germ extract and rabbit 
reticulocyte lysate), the strong hairpin reduced translation rates by >95%, almost as 
strongly as the construct with the mutated start codon. In addition, the weakened hairpin 
had a three to four fold increase of translation. An increase was also seen by removing 
uORF translation, indicating that both the secondary structure of the start codon-
containing UTR hairpin and uORF usage may be relevant regulatory cis elements in the 
HTT transcript. This is plausible considering the strong conservation of this sequence 
(both coding and non-coding) in humans, chimpanzee, mice, and rats (Figure 1B). 
 
Targeted Impairment of HTT Transcript Expression 
 The above results encouraged further analysis of HTT RNA structure as a 
therapeutic target. Looking more broadly at the HTT transcript, specifically the exon 1 
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region (Figure 3A), it is apparent that the poly(CAG) repeat, encoding polyglutamine, 
also has substantial potential structure. This is not surprising; a poly(CUG) repeat forms 
hairpins in DM1 (1), while there is evidence that expanded poly(CAG) androgen 
receptor and poly(CAG) HTT can form RNA foci in nuclei of fibroblasts (23). Hence, 
there are two potential hairpins in the 5’ region of HTT that may be amenable to 
stabilization with small molecules or oligonucleotides (Figure 3B). To identify such 
molecules, two approaches are reasonable. Targeted design requires substantial 
computational predictive ability for the 3D structure of the resulting hairpin, but such 
approaches have been fruitful for identifying first generation compounds to target the 
poly(CUG) repeat of DMPK in DM1 (6), and may be potentially useful for the poly(CAG) 
repeat of HTT. Oligonucleotide approaches, on the other hand, may be initiated with 
only knowledge of the base pairs to which we want them to anneal, “locking” the base of 
the hairpin and possibly stabilizing it to mimic the effects demonstrated genetically. 
 Figure 4 demonstrates my testing with several oligonucleotides (oligos), 
designed against the base of the UTR hairpin (Figure 4A-B) or the base of the 
poly(CAG) hairpin (Figure 4C-D) in the context of cell-free extracts translating luciferase 
constructs with the appropriate sequence upstream. Two details are apparent. First, 
several such oligos have substantial efficacy, capable of reducing luciferase by >60% in 
many cases or even as much as 80%. Second, the effects are blunted in rabbit 
reticulocyte lysate versus wheat germ extract. That plant and mammalian cell free 
systems have differences in oligo interaction is not surprising, but there are two 
particularly intriguing possibilities for how this difference could be seen. If steric 
hindrance by “locking” the hairpin is the mechanism of action, there may be differences 
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in the kinds or activities of helicases between the two preps. On the other hand, if 
RNase H is mediating the reduction by degrading mRNA found in RNA-DNA hybrids, 
this could be seen if the two systems have different RNase H activity. I am unaware of 
any detailed studies on the differing helicase activities of the two systems, but RNase H 
is much more active in wheat germ extract than in rabbit reticulocyte lysate (24). The 
actual mechanism of action of these oligomers, whether steric hindrance or nuclease 
engagement, is currently under investigation in our group. 
 
Screening a Small Molecule Library for Inhibitors of mHTT Translation 
 Other than rationally designed approaches for identifying translation inhibitors, 
unbiased compound library screens can be attempted. As a proof of principle for this, I 
acquired a library of ~1800 natural compounds from the laboratory of Jerry Pelletier at 
McGill University and attempted to identify compounds within that naturally suppress 
luciferase translation in a manner specific to mHTT sequence elements. From extensive 
tests of the values produced by negative controls (HTT exon 1 (Q47) – Firefly fusion) 
and positive controls (Strong Hairpin – Firefly fusion), I determined that the screen has 
an appropriate variance and dynamic range to facilitate screens (Z-score = 0.55). 
Hence, singlet tests using 20 µM of each compound were conducted to identify those 
that reduced luciferase levels (Figure 5A). Several such compounds were identified, 
which were validated in triplicate. However, because the compounds were not removed 
from solution prior to luciferase activity testing, it is likely that many of them are simply 
inhibitors of luciferase rather than suppressors of translation. Hence, these 34 positive 
compounds were further tested for an ability to suppress luminescence when pre-
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incubated with a luciferase transcript with no HTT sequences (Figure 5B). Many 
remained effective in this setting (suggesting an activity related to luciferase enzymatic 
activity), but others were ineffective, and hence appear to have inhibitory effects that 
were HTT sequence-specific. Four such compounds (isobavachalcone, gancaonin G, 
alpinumisoflavone, and glyasperin H) inhibited luciferase with exon 1 (Q47) upstream by 
>40% but were at least 1.5-fold less effective at inhibiting luciferase alone. All are highly 
aromatic, which may lend itself to intercalation. Isobavachalcone, in particular, was 4.4 
fold more effective at inhibiting activity of the exon 1 (Q47) transcript than that of 
luciferase alone. There is evidence of anti-inflammatory and anti-tumorigenic activity of 
this compound (25,26), but interestingly for us, it has also been directly demonstrated to 
relax supercoiled DNA (27), demonstrating a potential ability to interact with double 
stranded nucleic acids. 
  
Discussion 
 Inhibiting HTT translation is amongst the most promising therapeutic options for 
HD, because while there are several pathways downstream of mHTT that contain 
pharmaceutical targets (such as creatine for mitochondrial defects or BDNF cell and 
gene therapy for trophic factor starvation), an ideal solution that would resolve all of the 
varied toxicities would be reducing the amount of mHTT present in neurons. Efforts 
aimed at directly removing mHTT are ongoing and promising (11,13), but prevention of 
translation may reduce protein levels with the fewest side effects. The aromatic small 
molecules identified from preliminary screening efforts may be specific to the HTT 
transcript, but it is more likely that they simply interact with double stranded RNA. 
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However, this kind of screening could be generally used to inform us about secondary 
structures in RNA and what kinds of compounds efficiently interact with them. Additional 
structured RNA sequences can be cloned into luciferase, and similar screens for 
prevention of translation can be attempted. Perhaps more powerfully, small molecule 
microarrays could rapidly assess direct binding to transcripts in a sequence-specific 
manner, and hit compounds could be rapidly validated in cell free systems and in tissue 
culture for translation inhibition. Sequence specificity may not be easily ascertained, but 
learning what kinds of compounds interact with what kinds of structures could allow for 
better rational drug design, such as scaffolding approaches (28). 
 The predicted secondary structures in HTT RNA require tremendous work for 
validation and further screening efforts to identify interactors, but there is also potential 
here for avoiding off target effects present in standard knockdown approaches. 
Targeting HTT transcripts with RNAi engaging small RNAs, such as AAV-delivered 
shRNA transgenes (14-16,29), presents the risk for off target toxicity due to the nature 
of the RISC complex, as the 6-base seed sequence mediates much of the specificity. 
Promiscuous sequences can result in the reduction of many unintended targets, often 
with toxic consequences (30). However, if either oligo or small molecule approaches 
identify compounds that require a particular secondary structure for their inhibitory 
effects, it would provide additional specificity in the form of structure in addition to 
sequence. In the case of the UTR hairpin, there is preliminary data from our group to 
suggest that oligo binding to the sequence immediately upstream of the hairpin is 
sufficient for inhibitory effects. Furthermore, not only is the effect likely RNase H 
mediated, but importantly, it may be dependent on an intact RNA hairpin downstream of 
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the binding site. If validated, this could provide a suitable binding site within the HTT 
transcript for oligonucleotide therapeutic approaches, but one for which off-target effects 
would be blunted in those transcripts without sufficient adjacent secondary structure. 
 Testing for therapeutic efficacy requires a demonstration of improvement in 
neuropathology and behavior. The oligos identified here may have more immediate 
therapeutic potential than the aromatic compound hits, and there have been recent 
strides in oligonucleotide therapeutics for mouse models of HD (18). We have 
preliminary data that backbone modifications to protect the oligos from nuclease 
degradation do not impair its efficacy, and delivery to tissue culture for knockdown 
validation is ongoing. For testing in vivo, it my D2GFP assay could be used in mouse 
models of HD to evaluate oligos, primarily because of its sensitivity. This allows small 
cohorts to give conclusive results, and because oligos can be modified in many ways, 
multiple iterations may need to be tested in vivo to demonstrate a substantial protective 
effect before it becomes worthwhile to invest in larger behavioral studies. 
 In all, this work is at early stages but demonstrates that, on top of sequence 
specificity, structure specificity might be leveraged to make prevention of HTT 
translation as safe as possible from off target effects. Further studies, in vitro and in 
vivo, are in progress, but my small cohort D2GFP dysregulation assay would be an 
ideal test for efficacy given the modular and rapidly modifiable nature of such oligos. 
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Figure 1: The 5’ HTT mRNA sequence is predicted to contain significant 
secondary structure. (A) mFOLD structure prediction was applied to the 5’ HTT mRNA 
sequence, from the transcription start site to through the 5th codon of HTT. An upstream 
open reading frame is present, with a start codon (1) and stop codon (2) within 
structured regions. The strongest structured region (4) contains the HTT start codon (3). 
(B) There is significant homology of this region in human, chimpanzee, mouse, and rat 
huntingtin (labeled HsHTT, PtHTT, MmHtt, and RnHtt, respectively), even among the 
noncoding sequences. The blue shaded region is the upstream open reading frame, 
while the red shaded region is the beginning of the HTT coding sequence. The green 






Figure 2: Modifying the start codon-containing hairpin structure impacts its 
translation rate. (A) The start codon in the wild type HTT transcript is within a hairpin 
with a predicted energy of -31.33 kCal/mol (“Wild type Hairpin”). Five sites (blue boxes) 
were mutagenized to raise the melting temperature (“Strong Hairpin”); the kCal/mol 
changes of each mutation are indicated in blue. Alternatively, a weakened version was 
made that abrogated most of the strong base pairing (“Weak Hairpin”). Neither the 
Strong nor the Weak hairpins have an altered protein coding sequence. (B) When 
placed upstream of firefly luciferase, translation rates were measured as luminescence 
from cell free extracts. WGE = wheat germ extract, RRL = rabbit reticulocyte lysate. 








Figure 3: Hairpins formed in the 5’UTR and by the CAG repeat may be targetable 
by drugs or oligonucleotides. (A) Apart from the hairpin containing the start codon 
(Figures 1 and 2), another hairpin formed by the CAG repeat may serve as a target. The 
HTT transcript up to intron 1, when structure is predicted by mFOLD, has such a 
predicted hairpin, whose size only increases as the CAG repeat length increases 
without affecting the rest of the structure. (B) Strategies for targeting these secondary 
structures (UTR hairpin on the left, poly(CAG) on the right) could include finding an 
intercalating drug that stabilizes the annealed hairpin (1), or finding oligonucleotides that 
span the base of the structure to “lock” it in place (2). 
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Figure 4: Oligonucleotides targeting the base of the hairpins can suppress 
translation. (A) Oligonucleotides (oligos) versus the UTR hairpin were screened. The 
most effective one (Oligo 6) was tested for dose response (B) in both WGE and RRL. 
(C) A similar strategy was attempted for oligos targeting the base of the CAG repeat 
hairpin, with oligo 2 tested more thoroughly in WGE. (D). Interestingly, in WGE, there 
was no altered dose response in the exon 1 constructs with longer poly(CAG) tracts. 
The dosage curves in (B) and (D) were completed by adding oligo in the given fold 
excess, while the data in (A) and (C) used a 10 fold excess of oligo. Str HP = strong 
hairpin, Scr = scrambled. WGE = wheat germ extract, RRL = rabbit reticulocyte lysate. 
All luciferase data presented as firefly (HTT constructs) normalized to renilla 
(unmodified), and all oligos were pre-incubated with target transcripts prior to addition of 







Figure 5: The exon 1-luciferase fusion transcript can be screened for compounds 
that specifically inhibit the translation of exon 1. (A) A small molecule library of 
~1800 compounds was screened for an ability to inhibit luminescence produced by in 
vitro transcription of the HTT exon 1 (Q47) – luciferase construct. Compounds were 
tested further if they resulted in lower luciferase activity than all of the water controls 
(pink shaded region). (B) When tested against a transcript encoding firefly luciferase 
alone, many of the hits from the primary screen (34 of which also re-validated in 
triplicate) failed to inhibit luciferase activity when the transcript lacked HTT exon 1 
sequences, suggesting sequence specificity to inhibiting HTT translation. Four such 
compounds were isobavachalcone (1), gancaonin G (2), alpinumisoflavone (3), and 
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